

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 9

September 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 9
September 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

BOCA PHARMACAL INC
(BOCA PHARMA)

BOCA PHARMACAL LLC
(BOCA PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408	15472	
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)	2502 (16.2%)	
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)	12970 (83.8%)	
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)	12827 (82.9%)	
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)	143 (0.9%)	
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)	
NEW MOLECULAR ENTITIES APPROVED	17	9	5	8	
NUMBER OF APPLICANTS	835	844	841	832	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET; ORAL						
ABACAVIR SULFATE						
AB	HETERO LABS LTD III EQ 300MG BASE		A091560	001	Sep 13, 2013	Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL						
ACAMPROSATE CALCIUM						
AB	GLENMARK GENERICS 333MG		A202229	001	Jul 16, 2013	Jul NEWA
CAMPRAL						
AB	+ FOREST LABS 333MG		N021431	001	Jul 29, 2004	Jul CFTG

ACARBOSE

TABLET; ORAL						
ACARBOSE						
>A> AB	VIRTUS PHARM 25MG		A091343	001	Oct 17, 2013	Sep NEWA
>A> AB	50MG		A091343	002	Oct 17, 2013	Sep NEWA
>A> AB	100MG		A091343	003	Oct 17, 2013	Sep NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	@ WEST WARD 500MG; 50MG; 40MG		A040261	001	Oct 28, 1998	Jul DISC
ESGIC-PLUS						
+	MIKART 500MG; 50MG; 40MG		A040085	001	Mar 28, 1996	Jul CTEC
TABLET; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	@ MIRROR PHARMS LLC 500MG; 50MG; 40MG		A040883	001	Dec 23, 2008	Feb DISC
	@ WEST WARD 500MG; 50MG; 40MG		A040336	001	Aug 18, 1999	Aug DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL						
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	@ MIKART 356.4MG; 30MG; 16MG		A040109	001	Aug 26, 1997	Feb DISC
	@ WRASER PHARMS LLC 356.4MG; 30MG; 16MG		A040688	001	Apr 03, 2007	Jun DISC
TABLET; ORAL						
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	@ BOCA PHARMA 712.8MG; 60MG; 32MG		A040701	001	Apr 03, 2007	Jun DISC
	@ MIKART 712.8MG; 60MG; 32MG		A040316	001	Apr 28, 1999	Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	AUROLIFE PHARMA LLC 300MG; 15MG		A202800	001	Apr 15, 2013	Apr NEWA
AA	300MG; 30MG		A202800	002	Apr 15, 2013	Apr NEWA
AA	300MG; 60MG		A202800	003	Apr 15, 2013	Apr NEWA
	@ MIKART 300MG; 30MG		A089238	001	Feb 25, 1986	Jun DISC
	@ 650MG; 30MG		A089231	001	Mar 03, 1986	Feb DISC
	@ 650MG; 60MG		A089363	001	Sep 09, 1991	Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@ MIKART 500MG; 5MG		A081067	001	Nov 30, 1989	Feb DISC
	@ 500MG; 5MG		A089008	001	Feb 21, 1986	Jun DISC
SOLUTION; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	PAI 325MG/15ML; 7.5MG/15ML		A040838	001	May 10, 2013	Apr NEWA
TABLET; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	CARACO 325MG; 5MG		A090118	001	Dec 23, 2008	May CAHN
AA	325MG; 7.5MG		A090118	002	Dec 23, 2008	May CAHN
AA	325MG; 10MG		A090118	003	Dec 23, 2008	May CAHN
AA	500MG; 5MG		A090265	001	Dec 23, 2008	May CAHN
AA	500MG; 7.5MG		A090265	002	Dec 23, 2008	May CAHN
AA	500MG; 10MG		A090265	003	Dec 23, 2008	May CAHN
AA	650MG; 7.5MG		A090380	001	Dec 23, 2008	Jun CAHN
AA	650MG; 10MG		A090380	002	Dec 23, 2008	Jun CAHN
AA	660MG; 10MG		A090380	003	Dec 23, 2008	Jun CAHN

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		750MG; 7.5MG	A090380	004	Dec 23, 2008	Jun CAHN
	+	MIKART	A040846	001	Jun 09, 2010	Jul CRLD
	@	500MG; 2.5MG	A089698	001	Aug 25, 1989	Feb DISC
	@	650MG; 5MG	A040849	001	Jun 09, 2010	Feb DISC
AA	TRIS PHARMA INC	325MG; 5MG	A202214	001	Mar 27, 2013	Mar NEWA
AA		325MG; 7.5MG	A202214	002	Mar 27, 2013	Mar NEWA
AA		325MG; 10MG	A202214	003	Mar 27, 2013	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS ELIZABETH	325MG; 2.5MG	A201447	001	Apr 12, 2013	Apr NEWA
AA		325MG; 5MG	A201447	002	Apr 12, 2013	Apr NEWA
AA		325MG; 7.5MG	A201447	003	Apr 12, 2013	Apr NEWA
AA		325MG; 10MG	A201447	004	Apr 12, 2013	Apr NEWA
AA	AUROLIFE PHARMA LLC	325MG; 2.5MG	A201972	001	Jul 15, 2013	Jul NEWA
AA		325MG; 5MG	A201972	002	Jul 15, 2013	Jul NEWA
AA		325MG; 7.5MG	A201972	003	Jul 15, 2013	Jul NEWA
AA		325MG; 10MG	A201972	004	Jul 15, 2013	Jul NEWA
	@ MIKART	400MG; 2.5MG	A040679	001	May 16, 2006	Jul DISC
AA	VINTAGE PHARMS	325MG; 2.5MG	A090733	001	Jul 11, 2013	Jul NEWA
AA		325MG; 7.5MG	A090734	001	Jul 11, 2013	Jul NEWA
AA		325MG; 10MG	A090734	002	Jul 11, 2013	Jul NEWA
	ROXICET 5/500					
	@ ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989	Aug DISC

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

@	WATSON LABS	250MG	A088882	001	Oct 22, 1985	Jan DISC
---	-------------	-------	---------	-----	--------------	----------

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT AGILA	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Jan CAHN
----	--------------	--------------------	---------	-----	--------------	----------

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB	BARR LABS INC	10MG	A091455	001	Apr 04, 2013	Mar NEWA
AB		25MG	A091455	002	Apr 04, 2013	Mar NEWA
AB	TEVA PHARMS USA	17.5MG	A202897	001	Apr 04, 2013	Mar NEWA
AB		22.5MG	A202897	002	Apr 04, 2013	Mar NEWA
	SORIATANE					
AB	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Mar CFTG
AB		17.5MG	N019821	003	Aug 06, 2009	Mar CFTG
AB		22.5MG	N019821	004	Aug 06, 2009	Mar CFTG
AB	+	25MG	N019821	002	Oct 28, 1996	Mar CFTG

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+	ACTIENT PHARMS	8MG; 60MG	N019806	001	Mar 25, 1994	May CAHN
---	----------------	-----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>D>	AB	@ MYLAN	200MG	A074977	001	Apr 13, 1998	Aug DISC
>A>		WATSON LABS	200MG	A075101	001	Apr 15, 1998	Sep DISC
		@	200MG	A075101	001	Apr 15, 1998	Sep DISC

CREAM;TOPICAL

ZOVIRAX

+	VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002	Jul CAHN
---	-----------------	----	---------	-----	--------------	----------

OINTMENT;TOPICAL

ACYCLOVIR

AB	MYLAN PHARMS INC	5%	A202459	001	Apr 03, 2013	Mar NEWA
	ZOVIRAX					
AB	+ VALEANT BERMUDA	5%	N018604	001	Mar 29, 1982	May CAHN
AB	+ VALEANT INTL	5%	N018604	001	Mar 29, 1982	Mar CFTG
	SUSPENSION;ORAL					

		SUSPENSION; ORAL							
		ZOVIRAX							
AB	+	DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jun	CAHN	
>D>		TABLET; BUCCAL							
>D>		SITAVIG							
>D>	+	BIOALLIANCE PHARMA	50MG	N203791	001	Apr 12, 2013	Sep	DISC	
>A>	@		50MG	N203791	001	Apr 12, 2013	Sep	DISC	
	+		50MG	N203791	001	Apr 12, 2013	Apr	NEWA	
		TABLET; ORAL							
		ACYCLOVIR							
	@	MYLAN	400MG	A074976	001	Apr 13, 1998	Aug	DISC	
	@		800MG	A074976	002	Apr 13, 1998	Aug	DISC	
<u>ACYCLOVIR SODIUM</u>									
		INJECTABLE; INJECTION							
		ACYCLOVIR SODIUM							
>A>	AP	AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701	001	Oct 11, 2013	Sep	NEWA	
<u>ACYCLOVIR; HYDROCORTISONE</u>									
		CREAM; TOPICAL							
		XERESE							
	+	VALEANT BERMUDA	5%; 1%	N022436	001	Jul 31, 2009	Apr	CAHN	
<u>ADEFOVIR DIPIVOXIL</u>									
		TABLET; ORAL							
		ADEFOVIR DIPIVOXIL							
AB		SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Aug	NEWA	
		HEPSERA							
AB	+	GILEAD	10MG	N021449	001	Sep 20, 2002	Aug	CFTG	
<u>ADENOSINE</u>									
		INJECTABLE; INJECTION							
		ADENOSCAN							
AP	+	ASTELLAS	3MG/ML	N020059	001	May 18, 1995	Aug	CTEC	
		ADENOSINE							
	@	TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004	Apr	CAHN	
AP			3MG/ML	A077425	001	Aug 29, 2013	Aug	NEWA	
	@		3MG/ML	A078676	001	Jul 31, 2008	Apr	CAHN	
<u>AFATINIB DIMALEATE</u>									
		TABLET; ORAL							
		GILOTRIF							
		BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul	NEWA	
			EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul	NEWA	
	+		EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul	NEWA	
<u>ALBENDAZOLE</u>									
		TABLET; ORAL							
		ALBENZA							
	+	AMEDRA PHARMS	200MG	N020666	001	Jun 11, 1996	Feb	CAHN	
<u>ALBUTEROL SULFATE</u>									
		AEROSOL, METERED; INHALATION							
		PROAIR HFA							
BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Apr	CAHN	
		VENTOLIN HFA							
BX	+	GLAXO GRP LTD	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	May	CAHN	
		SOLUTION; INHALATION							
		ALBUTEROL SULFATE							
	@	APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010	Apr	DISC	
	@		EQ 0.042% BASE	A078623	002	Apr 05, 2010	Apr	DISC	
	@		EQ 0.083% BASE	A075717	001	Feb 02, 2007	Apr	DISC	
	@		EQ 0.5% BASE	A076391	001	Apr 01, 2003	Apr	DISC	
AN	+	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jan	CAHN	
	@	WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999	Mar	DISC	
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>									
		SOLUTION; INHALATION							
		ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
	@	APOTEX INC	EQ 0.083% BASE; 0.017%	A077117	001	Dec 31, 2007	Apr	DISC	
AN		CIPLA LTD	EQ 0.083% BASE; 0.017%	A077559	001	Dec 31, 2007	Aug	CAHN	

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA	ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Feb NEWA
	FOSAMAX					
AA	+ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Feb CFTG
	TABLET; ORAL					
	ALENDRONATE SODIUM					
AB	CIPLA LTD	EQ 5MG BASE	A076768	001	Aug 04, 2008	Jul CAHN
AB		EQ 10MG BASE	A076768	002	Aug 04, 2008	Jul CAHN
AB		EQ 35MG BASE	A076768	003	Aug 04, 2008	Jul CAHN
AB		EQ 40MG BASE	A076768	004	Aug 04, 2008	Jul CAHN
AB		EQ 70MG BASE	A076768	005	Aug 04, 2008	Jul CAHN
	@ MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Aug DISC
	@	EQ 70MG BASE	A078638	002	Aug 04, 2008	Aug DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

AB	+ COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Apr CAHN
----	---------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013	Apr NEWA
AB		300MG	A203154	002	May 06, 2013	Apr NEWA

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE	N022271	002	Jan 25, 2013	Jan NEWA
	+	EQ 25MG BASE	N022271	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE; 1GM	N203414	002	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE; 500MG	N203414	001	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSINI

	TAKEDA PHARMS USA	EQ 12.5MG BASE; 15MG	N022426	004	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE; 30MG	N022426	005	Jan 25, 2013	Jan NEWA
		EQ 12.5MG BASE; 45MG	N022426	006	Jan 25, 2013	Jan NEWA
		EQ 25MG BASE; 15MG	N022426	001	Jan 25, 2013	Jan NEWA
		EQ 25MG BASE; 30MG	N022426	002	Jan 25, 2013	Jan NEWA
+		EQ 25MG BASE; 45MG	N022426	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSINI

	TAKEDA PHARMS USA	EQ 12.5MG BASE; EQ 15MG BASE	N022426	004	Jan 25, 2013	Feb CAIN
		EQ 12.5MG BASE; EQ 30MG BASE	N022426	005	Jan 25, 2013	Feb CAIN
		EQ 12.5MG BASE; EQ 45MG BASE	N022426	006	Jan 25, 2013	Feb CAIN
		EQ 25MG BASE; EQ 15MG BASE	N022426	001	Jan 25, 2013	Feb CAIN
		EQ 25MG BASE; EQ 30MG BASE	N022426	002	Jan 25, 2013	Feb CAIN
+		EQ 25MG BASE; EQ 45MG BASE	N022426	003	Jan 25, 2013	Feb CAIN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ TEVA PHARMS USA

@

@

@

@

0.5MG

1MG

2MG

3MG

A077979	001	Feb 28, 2007	Jun DISC
A077979	002	Feb 28, 2007	Jun DISC
A077979	003	Feb 28, 2007	Jun DISC
A077979	004	Feb 28, 2007	Jun DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

INJECTABLE; INJECTION							
ALPROSTADIL							
AP	TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999	Apr	CAHN
<u>AMIKACIN SULFATE</u>							
INJECTABLE; INJECTION							
AMIKACIN SULFATE							
	@ HOSPIRA	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994	Mar	DISC
	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Jun	CAHN
AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Jun	CAHN
<u>AMINOPHYLLINE</u>							
INJECTABLE; INJECTION							
AMINOPHYLLINE							
	@ INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982	Jun	DISC
	@ PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983	Jun	DISC
TABLET; ORAL							
AMINOPHYLLINE							
	@ WEST WARD	100MG	A084540	001		Jul	DISC
	@	200MG	A085003	001		Jul	DISC
<u>AMIODARONE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
AMIODARONE HYDROCHLORIDE							
	@ AGILA SPECLTS	50MG/ML	A076394	001	Apr 25, 2003	Aug	CAHN
	@ APOTEX INC	50MG/ML	A076394	001	Apr 25, 2003	Apr	DISC
AP	+ MYLAN INSTITUTIONAL	50MG/ML	A076217	001	Oct 15, 2002	Apr	CAHN
	@ TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003	Apr	CAHN
<u>AMLEXANOX</u>							
PASTE; DENTAL							
APHTHASOL							
	@ ULURU	5%	N020511	001	Dec 17, 1996	Jun	DISC
<u>AMLODIPINE BESYLATE</u>							
TABLET; ORAL							
AMLODIPINE BESYLATE							
AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013	Apr	NEWA
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013	Apr	NEWA
AB	CIPLA LTD	EQ 2.5MG BASE	A077073	001	Sep 26, 2007	Aug	CAHN
AB		EQ 5MG BASE	A077073	002	Sep 26, 2007	Aug	CAHN
AB		EQ 10MG BASE	A077073	003	Sep 26, 2007	Aug	CAHN
<u>AMLODIPINE BESYLATE; VALSARTAN</u>							
TABLET; ORAL							
AMLODIPINE BESYLATE AND VALSARTAN							
AB	PAR PHARM INC	EQ 5MG BASE; 160MG	A090011	001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE; 320MG	A090144	001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE; 160MG	A090011	002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE; 320MG	A090011	004	Mar 28, 2013	Mar	NEWA
EXFORGE							
AB	NOVARTIS	EQ 5MG BASE; 160MG	N021990	002	Jun 20, 2007	Mar	CFTG
AB		EQ 5MG BASE; 320MG	N021990	004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE; 160MG	N021990	003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE; 320MG	N021990	005	Jun 20, 2007	Mar	CFTG
<u>AMMONIA N-13</u>							
INJECTABLE; INTRAVENOUS							
AMMONIA N 13							
AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700	001	Feb 25, 2013	Feb	NEWA
AP	+ FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007	Feb	CFTG
AP	MCPHF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321	001	Feb 25, 2013	Feb	NEWA
AP	UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812	001	Jun 27, 2013	Jun	NEWA
<u>AMOXICILLIN</u>							
FOR SUSPENSION; ORAL							
AMOXICILLIN							
	@ RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	Feb	DISC
	@	400MG/5ML	A065113	002	Nov 29, 2002	Feb	DISC
TABLET; ORAL							
AMOXICILLIN							

TABLET;ORAL

AMOXICILLIN

@ DAVA PHARMS INC 875MG

A065344 001 Jan 15, 2009 Jun DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

@ DAVA PHARMS INC 125MG

A064139 001 Jan 29, 1996 Mar DISC

@ 250MG

A064139 002 Jan 29, 1996 Mar DISC

@ RANBAXY 200MG

A065060 001 Nov 29, 2000 Feb DISC

@ 400MG

A065060 002 Nov 29, 2000 Feb DISC

AMOXIL

@ DR REDDYS LABS INC 200MG

N050761 001 Apr 15, 1999 Feb DISC

@ 400MG

N050761 002 Apr 15, 1999 Feb DISC

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

@ AUROBINDO PHARMA LTD 200MG

A065324 001 Jan 17, 2007 Jan DISC

@ 400MG

A065324 002 Jan 17, 2007 Jan DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB TEVA PHARMS USA 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG

A200218 001 Aug 30, 2013 Aug NEWA

PREVPAC

AB + TAKEDA PHARMS USA 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG

N050757 001 Dec 02, 1997 Aug CFTG

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ APOTEX INC 250MG;EQ 125MG BASE

A065333 001 Feb 24, 2009 Apr DISC

@ 500MG;EQ 125MG BASE

A065333 002 Feb 24, 2009 Apr DISC

@ 875MG;EQ 125MG BASE

A065317 003 Oct 20, 2008 Apr DISC

@ RANBAXY LABS 500MG;EQ 125MG BASE

A065109 001 Nov 04, 2002 Apr DISC

AB TEVA PHARMS USA 875MG;EQ 125MG BASE

A065096 001 Oct 29, 2002 Apr CRLD

AUGMENTIN '250'

AB + DR REDDYS LABS INC 250MG;EQ 125MG BASE

N050564 001 Aug 06, 1984 Apr CRLD

AUGMENTIN '500'

AB + DR REDDYS LABS INC 500MG;EQ 125MG BASE

N050564 002 Aug 06, 1984 Apr CRLD

AUGMENTIN '875'

AB + DR REDDYS LABS INC 875MG;EQ 125MG BASE

N050720 001 Feb 13, 1996 Apr CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB TEVA 1.25MG;1.25MG;1.25MG;1.25MG

A077488 001 Apr 29, 2013 Apr NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG

A077488 002 Apr 29, 2013 Apr NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG

A077488 003 Apr 29, 2013 Apr NEWA

AB 5MG;5MG;5MG;5MG

A077488 004 Apr 29, 2013 Apr NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG

A077488 005 Apr 29, 2013 Apr NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG

A077488 006 Apr 29, 2013 Apr NEWA

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB BARR LABS INC 1.25MG;1.25MG;1.25MG;1.25MG

A076536 001 Feb 12, 2013 Jan NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG

A076536 002 Feb 12, 2013 Jan NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG

A076536 003 Feb 12, 2013 Jan NEWA

AB 5MG;5MG;5MG;5MG

A076536 004 Feb 12, 2013 Jan NEWA

AB 6.25MG;6.25MG;6.25MG;6.25MG

A076536 005 Feb 12, 2013 Jan NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG

A076536 006 Feb 12, 2013 Jan NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D> @ MALLINCKRODT INC 1.25MG;1.25MG;1.25MG;1.25MG

A040440 001 Oct 07, 2003 Sep CMFD

>A> AB 1.25MG;1.25MG;1.25MG;1.25MG

A040440 001 Oct 07, 2003 Sep CMFD

>D> @ 1.875MG;1.875MG;1.875MG;1.875MG

A040440 002 Oct 07, 2003 Sep CMFD

>A> AB 1.875MG;1.875MG;1.875MG;1.875MG

A040440 002 Oct 07, 2003 Sep CMFD

>D> @ 2.5MG;2.5MG;2.5MG;2.5MG

A040440 003 Oct 07, 2003 Sep CMFD

>A> AB 2.5MG;2.5MG;2.5MG;2.5MG

A040440 003 Oct 07, 2003 Sep CMFD

>D> @ 3.125MG;3.125MG;3.125MG;3.125MG

A040440 004 Oct 07, 2003 Sep CMFD

>A> AB 3.125MG;3.125MG;3.125MG;3.125MG

A040440 004 Oct 07, 2003 Sep CMFD

>D> @ 3.75MG;3.75MG;3.75MG;3.75MG

A040440 005 Oct 07, 2003 Sep CMFD

>A> AB 3.75MG;3.75MG;3.75MG;3.75MG

A040440 005 Oct 07, 2003 Sep CMFD

>D> @ 5MG;5MG;5MG;5MG

A040440 006 Oct 07, 2003 Sep CMFD

>A> AB 5MG;5MG;5MG;5MG

A040440 006 Oct 07, 2003 Sep CMFD

>D> @ 7.5MG;7.5MG;7.5MG;7.5MG

A040440 007 Oct 07, 2003 Sep CMFD

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Sep CMFD
	@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003	Jan DISC
	@		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003	Jan DISC
	@		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003	Jan DISC
	@		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003	Jan DISC

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013	Mar NEWA
AP			EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013	Mar NEWA
AP			EQ 10GM BASE/VIAL	A090889	001	Apr 03, 2013	Mar NEWA
AP			EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013	Mar NEWA
	@	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Jun DISC
	@		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Jun DISC
	@		EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Jun DISC
	@		EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Jun DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

UNASYN

AP	+	PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901	002	Feb 27, 1992	Jul NEWA
AP	+		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901	001	Nov 23, 1988	Jul CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

>D>	AB		EQ 0.5MG BASE	A076417	001	Apr 18, 2005	Sep DISC
>A>	@		EQ 0.5MG BASE	A076417	001	Apr 18, 2005	Sep DISC
>D>	AB		EQ 1MG BASE	A076417	002	Apr 18, 2005	Sep DISC
>A>	@		EQ 1MG BASE	A076417	002	Apr 18, 2005	Sep DISC

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB		ACCORD HLTHCARE	1MG	A090568	001	Jun 28, 2010	Apr CAHN
	@	KUDCO IRELAND	1MG	A091331	001	Jan 05, 2011	Feb DISC

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

		OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Feb NEWA
	+		400MG/VIAL	N202971	002	Feb 28, 2013	Feb NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

	@	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug DISC
	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881	001	Aug 02, 2006	Aug CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC

	@	PRINSTON INC	385MG;30MG;25MG	A075141	001	May 29, 1998	Apr CAHN
		ORPHENGESIC FORTE					
	@	PRINSTON INC	770MG;60MG;50MG	A075141	002	May 29, 1998	Apr CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

	@	MYLAN	25MG	A074126	003	Aug 26, 1998	Aug DISC
	@		50MG	A074126	001	Mar 23, 1994	Aug DISC
	@		100MG	A074126	002	Mar 23, 1994	Aug DISC
	@	WATSON LABS	50MG	A073352	001	Dec 27, 1991	Mar DISC
	@		100MG	A073353	001	Dec 27, 1991	Mar DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	KUDCO IRELAND	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	NEWA
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	NEWA
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	NEWA
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

MERCK SHARP DOHME

		EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May	NEWA
		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May	NEWA
		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May	NEWA
+		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May	NEWA

AZACITIDINE

INJECTABLE;IV-SC

AZACITIDINE

AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Aug	NEWA
	VIDAZA						
AP	+ CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Aug	CFTG

AZELAIC ACID

GEL;TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun	CAHN
---	----------------	-----	---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

>A>	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Sep	CAHN
>A>	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Sep	CAHN
>D>	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Sep	CAHN
>D>	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Sep	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

>A>	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Sep	CAHN
>A>	+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Sep	CAHN
>D>	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Sep	CAHN
>D>	+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Sep	CAHN

AZITHROMYCIN

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Aug	CAHN
---	-------------	-----------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

AZITHROMYCIN

AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	Mar	NEWA
----	--------------------	--------------------	---------	-----	--------------	-----	------

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Jun	CAHN
---	----------------------	--------------	---------	-----	--	-----	------

POWDER;FOR RX COMPOUNDING

BACI-RX

@	X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001		Mar	DISC
---	--------------	---------------------	---------	-----	--	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM	A060764	002		Jun	CAHN
----	----------------------	--	---------	-----	--	-----	------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	PERRIGO CO TENNESSEE	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jun	CAHN
----	----------------------	------------------------------	---------	-----	--------------	-----	------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG	A062166	002			Jun	CAHN
		BASE;10,000 UNITS/GM						

BACLOFEN

INJECTABLE;INTRATHECAL

GABLOFEN

AP	MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010	May	CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	May	CAHN
		1MG/ML	N022462	004	Jun 22, 2012	May	CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	May	CAHN

BENDAMUSTINE HYDROCHLORIDE

>A> SOLUTION;IV (INFUSION)

>A> TREANDA

>A>	+	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Oct 13, 2013	Sep	NEWA
>A>	+		180MG/2ML (90MG/ML)	N022249	004	Oct 13, 2013	Sep	NEWA

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	CARACO	100MG	A040587	001	Mar 19, 2008	May	CAHN
AA		200MG	A040587	002	Mar 19, 2008	May	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

+	DOW PHARM	2.5%;1.2%	N050819	001	Oct 23, 2008	Apr	CAHN
	BENZACLIN						

AB	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN
BT	+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

BENZAMYCIN PAK

+	VALEANT LUXEMBOURG	5%;3%	N050769	001	Nov 27, 2000	Jun	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

@	COREPHARMA	50MG	A040714	001	Oct 29, 2007	Feb	DISC
---	------------	------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

AP	NAVINTA LLC	1MG/ML	A091525	001	Feb 05, 2013	Jan	NEWA
----	-------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

BENZTROPINE MESYLATE

@	PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Mar	DISC
@		1MG	A040705	001	Feb 14, 2008	Mar	DISC
@		2MG	A040706	001	Feb 14, 2008	Mar	DISC

BETAMETHASONE

SYRUP;ORAL

CELESTONE

@	MERCK SHARP DOHME	0.6MG/5ML	N014215	002		Apr	CAHN
---	-------------------	-----------	---------	-----	--	-----	------

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

CELESTONE SOLUSPAN

AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML	N014602	001		Apr	CAHN
----	---	-------------------	-----------------------	---------	-----	--	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

SUSPENSION;TOPICAL

TACLONEX

>D>	+	LEO PHARM	0.064%;0.005%	N022185	001	May 09, 2008	Sep	CAHN
>A>	+	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Sep	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

	AB		PERRIGO	0.12%	A078337	001	Nov 26, 2012	Apr	CPOT
			LUXIQ						
>A>	AB	+	DELCOR ASSET	0.12%	N020934	001	Feb 28, 1999	Sep	CAHN
>A>	AB	+		0.12%	N020934	001	Feb 28, 1999	Sep	CAHN
>D>	AB	+	STIEFEL	0.12%	N020934	001	Feb 28, 1999	Sep	CAHN
	AB	+		0.12%	N020934	001	Feb 28, 1999	Apr	CPOT

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ APOTEX INC

EQ 0.5% BASE

A075446 001 Sep 28, 2000 Apr DISC

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA		CARACO	5MG	A040897	001	Apr 22, 2009	Jun CAHN
AA			10MG	A040897	002	Apr 22, 2009	Jun CAHN
AA			25MG	A040897	003	Apr 22, 2009	Jun CAHN
AA			50MG	A040897	004	Apr 22, 2009	Jun CAHN
		@ LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Jun DISC
		@	50MG	A040677	001	Mar 27, 2008	Jun DISC

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

	+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CAHN
		GEL; TOPICAL					
		TARGRETIN					
	+	VALEANT LUXEMBOURG	1%	N021056	001	Jun 28, 2000	Jun CAHN
	+	VALEANT PHARMS INC	1%	N021056	001	Jun 28, 2000	Feb CAHN

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009	Apr CAHN
>D>	AB	SYNTHON PHARMS	50MG	A077973	001	Jul 06, 2009	Sep DISC
>A>		@	50MG	A077973	001	Jul 06, 2009	Sep DISC

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@ PHARMACHEMIE BV

EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007 Feb DISC

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

>A>	+	GALDERMA LABS LP	0.33%	N204708	001	Aug 23, 2013	Sep CAHN
>D>	+	GALDERMA R AND D	0.33%	N204708	001	Aug 23, 2013	Sep CAHN
	+		0.33%	N204708	001	Aug 23, 2013	Aug NEWA

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

	+	ALCON RES LTD	0.2%; 1%	N204251	001	Apr 19, 2013	Apr NEWA
--	---	---------------	----------	---------	-----	--------------	----------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CPOT
		BROMFENAC SODIUM					
AT		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Apr CPOT
AT		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Apr CPOT
AT			0.09%	A202030	001	Jan 09, 2013	Feb CAHN
		PROLENSA					
	+	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013	Apr NEWA
		XIBROM					
		@ ISTA PHARMS INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CPOT

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

		@ APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr DISC
		@	0.5MG/2ML	A078202	002	Mar 30, 2009	Apr DISC
>A>	AN	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Sep NEWA
>A>	AN		0.5MG/2ML	A201966	002	Sep 27, 2013	Sep NEWA
>A>	AN		1MG/2ML	A201966	001	Sep 27, 2013	Sep NEWA
		PULMICORT RESPULES					
>D>	+	ASTRAZENECA	1MG/2ML	N020929	003	Aug 08, 2000	Sep CTEC
>A>	AN	+	1MG/2ML	N020929	003	Aug 08, 2000	Sep CTEC
		TABLET, EXTENDED RELEASE; ORAL					
		UCERIS					
	+	SANTARUS	9MG	N203634	001	Jan 14, 2013	Jan NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

		@ INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002	Jun DISC
		@	0.5%	A076012	002	Jan 09, 2002	Jun DISC
		@	0.75%	A076012	003	Jan 09, 2002	Jun DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

		PURDUE PHARMA LP	15MCG/HR	N021306	004	Jul 25, 2013	Aug NEWA
--	--	------------------	----------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 8MG BASE; EQ 2MG BASE	N022410	002	Aug 30, 2010	Jul CRLD
	+		EQ 12MG BASE; EQ 3MG BASE	N022410	004	Aug 10, 2012	Jul CRLD

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE; EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Jul CTNA
AB	+		EQ 8MG BASE; EQ 2MG BASE	A091422	002	Feb 22, 2013	Jul CTNA
AB		AMNEAL PHARMS	EQ 8MG BASE; EQ 2MG BASE	A203136	002	Feb 22, 2013	Aug CTNA
		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
AB		AMNEAL PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Aug CTNA
		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE					
AB		ACTAVIS ELIZABETH	EQ 2MG BASE; EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Feb NEWA
AB	+		EQ 8MG BASE; EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr CRLD
AB			EQ 8MG BASE; EQ 2MG BASE	A091422	002	Feb 22, 2013	Feb NEWA
AB		AMNEAL PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Feb NEWA
AB			EQ 8MG BASE; EQ 2MG BASE	A203136	002	Feb 22, 2013	Feb NEWA

SUBOXONE

		@ RECKITT BENCKISER	EQ 2MG BASE; EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Mar DISC
AB			EQ 2MG BASE; EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Feb CFTG
		@	EQ 8MG BASE; EQ 2MG BASE	N020733	002	Oct 08, 2002	Mar DISC
AB	+		EQ 8MG BASE; EQ 2MG BASE	N020733	002	Oct 08, 2002	Feb CFTG

ZUBSOLV

		OREXO AB	EQ 1.4MG BASE; EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul NEWA
	+		EQ 5.7MG BASE; EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

		VALEANT BERMUDA	174MG	N022108	001	Apr 23, 2008	Apr CAHN
	+		348MG	N022108	002	Apr 23, 2008	Apr CAHN
			522MG	N022108	003	Apr 23, 2008	Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

		@ TEVA	75MG	A075310	001	Nov 29, 1999	Feb CDJR
		@	100MG	A075310	002	Nov 29, 1999	Feb DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

		@ IMPAX LABS	300MG	A077415	002	Dec 15, 2006	Apr DISC
>A>	AB1	JUBILANT LIFE	100MG	A202774	001	Oct 11, 2013	Sep NEWA
>A>	AB1		150MG	A202774	002	Oct 11, 2013	Sep NEWA

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>A>	AB2	150MG	A202775	001	Oct 11, 2013	Sep	NEWA
>A>	AB1	200MG	A202774	003	Oct 11, 2013	Sep	NEWA
>D>	AB3	WATSON LABS 300MG	A077715	002	Jun 13, 2007	Sep	CTEC
>A>	BX	300MG	A077715	002	Jun 13, 2007	Sep	CTEC
	AB1	WATSON LABS INC 100MG	A077455	001	Jul 19, 2010	Apr	CAHN
	AB3	150MG	A077285	001	Nov 26, 2008	Apr	CAHN
	AB1	150MG	A077455	002	Mar 12, 2008	Apr	CAHN
	AB1	200MG	A077455	003	Jul 19, 2010	Apr	CAHN
	AB3	300MG	A077285	002	Aug 15, 2008	Apr	CAHN

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Mar	CRLD
	GYNAZOLE-1						
@	KV PHARM	2%	N019881	001	Feb 07, 1997	Mar	DISC

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC 2MG/ML
BUTORPHANOL TARTRATE PRESERVATIVE FREE

A075697 001 Oct 23, 2001 Apr DISC

@ APOTEX INC 1MG/ML
@ 2MG/ML

A075695 001 Oct 23, 2001 Apr DISC

A075695 002 Oct 23, 2001 Apr DISC

STADOL

@ APOTHECON 2MG/ML

N017857 004 Jun DISC

STADOL PRESERVATIVE FREE

@ APOTHECON 1MG/ML

N017857 001 Jun DISC

@ 2MG/ML

N017857 002 Jun DISC

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Feb	NEWA
----	-------------	-------	---------	-----	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA	MIKART	100MG;1MG	A040590	001	Sep 16, 2005	Mar	CMFD
	@	100MG;1MG	A040590	001	Sep 16, 2005	Jan	DISC

CALCIPOTRIENE

OINTMENT;TOPICAL

DOVONEX

>D>	@ LEO PHARM	0.005%	N020273	001	Dec 29, 1993	Sep	CAHN
>A>	@ LEO PHARMA AS	0.005%	N020273	001	Dec 29, 1993	Sep	CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	BANNER PHARMACAPS	0.25MCG	A091174	001	May 24, 2013	May	NEWA
AB		0.5MCG	A091174	002	May 24, 2013	May	NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A203135	001	Feb 07, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A202420	001	Feb 05, 2013	Jan	NEWA
----	----------------	------------------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74 MG/100ML;640MG/100ML;500MG/100ML;7 4MG/100ML	N019867	001	Dec 20, 1993	Mar	DISC
---	---------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	001	Jun 13, 1994	Feb DISC
-------------	---	---------	-----	--------------	----------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	002	Jun 13, 1994	Feb DISC
-------------	---	---------	-----	--------------	----------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	003	Jun 13, 1994	Feb DISC
-------------	---	---------	-----	--------------	----------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	004	Jun 13, 1994	Feb DISC
-------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

+ LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996	Jun CAHN
----------------------	--	---------	-----	--------------	----------

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr CAHN
+	300MG	N204042	002	Mar 29, 2013	Apr CAHN
JANSSEN RES AND DEV	100MG	N204042	001	Mar 29, 2013	Mar NEWA
+	300MG	N204042	002	Mar 29, 2013	Mar NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998	Apr CFTG
AB		8MG	N020838	002	Jun 04, 1998	Apr CFTG
AB		16MG	N020838	003	Jun 04, 1998	Apr CFTG
AB	+	32MG	N020838	004	Jun 04, 1998	Apr CFTG
	CANDESARTAN CILEXETIL					
AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr NEWA
AB		8MG	A078702	002	May 03, 2013	Apr NEWA
AB		16MG	A078702	003	May 03, 2013	Apr NEWA
AB		32MG	A078702	004	May 03, 2013	Apr NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG;25MG	A202884	003	Jun 03, 2013	May NEWA
AB	DR REDDYS LABS LTD	16MG;12.5MG	A202965	001	Jun 03, 2013	May NEWA
AB		32MG;12.5MG	A202965	002	Jun 03, 2013	May NEWA
AB		32MG;25MG	A202965	003	Jun 03, 2013	May NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	TEVA PHARMS USA	150MG	A091649	001	Sep 16, 2013	Aug NEWA
AB		500MG	A091649	002	Sep 16, 2013	Aug NEWA
	XELODA					
AB	HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998	Aug CFTG
AB	+	500MG	N020896	002	Apr 30, 1998	Aug CFTG

CAPSAICIN

PATCH;TOPICAL

QUTENZA

+	ACORDA	8%	N022395	001	Nov 16, 2009	Jul CAHN
---	--------	----	---------	-----	--------------	----------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jun DISC
@	25MG	A074477	002	Feb 13, 1996	Jun DISC
@	50MG	A074477	003	Feb 13, 1996	Jun DISC
@	100MG	A074477	004	Feb 13, 1996	Jun DISC

TABLET; ORAL							
CAPTOPRIL							
	@ TEVA	12.5MG	A074483	001	Feb 13, 1996	Jun	DISC
	@	25MG	A074483	002	Feb 13, 1996	Jun	DISC
	@	50MG	A074483	003	Feb 13, 1996	Jun	DISC
	@	100MG	A074483	004	Feb 13, 1996	Jun	DISC
<u>CARBAMAZEPINE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
CARBAMAZEPINE							
AB	TARO	100MG	A201106	001	Jun 21, 2013	Jun	NEWA
AB		200MG	A201106	002	Jun 21, 2013	Jun	NEWA
AB		300MG	A201106	003	Jun 21, 2013	Jun	NEWA
<u>CARBIDOPA; LEVODOPA</u>							
TABLET, EXTENDED RELEASE; ORAL							
CARBIDOPA AND LEVODOPA							
AB	ACCORD HLTHCARE	25MG; 100MG	A202323	001	Feb 08, 2013	Jan	NEWA
AB		50MG; 200MG	A202323	002	Feb 08, 2013	Jan	NEWA
<u>CARBINOXAMINE MALEATE</u>							
SUSPENSION, EXTENDED RELEASE; ORAL							
KARBINAL ER							
+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013	Mar	NEWA
<u>CARBOPLATIN</u>							
INJECTABLE; INJECTION							
CARBOPLATIN							
	@ PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004	Feb	DISC
	@	150MG/VIAL	A076602	002	Nov 16, 2004	Feb	DISC
	@	450MG/VIAL	A076602	003	Nov 16, 2004	Feb	DISC
INJECTABLE; IV (INFUSION)							
CARBOPLATIN							
	@ FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	DISC
	@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	DISC
	@ PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Apr	DISC
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Apr	DISC
	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Apr	DISC
PARAPLATIN							
	@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CAHN
	@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CAHN
	@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CAHN
	@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CAHN
<u>CARISOPRODOL</u>							
TABLET; ORAL							
CARISOPRODOL							
AA	ACCEL RX LABS	350MG	A040576	001	Jun 07, 2005	May	CAHN
	@ COREPHARMA	350MG	A040397	001	Sep 21, 2000	Feb	DISC
	@ PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Jun	DISC
<u>CARMUSTINE</u>							
IMPLANT; INTRACRANIAL							
GLIADEL							
+	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996	Mar	CAHN
INJECTABLE; INJECTION							
BICNU							
+	EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Jan	CAHN
<u>CARTEOLOL HYDROCHLORIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
CARTEOLOL HYDROCHLORIDE							
	@ APOTEX INC	1%	A076097	001	Feb 06, 2002	Apr	DISC
<u>CARVEDILOL</u>							
TABLET; ORAL							
CARVEDILOL							
AB	CIPLA LTD	3.125MG	A077474	001	Sep 05, 2007	Aug	CAHN
AB		6.25MG	A077474	002	Sep 05, 2007	Aug	CAHN
AB		12.5MG	A077474	003	Sep 05, 2007	Aug	CAHN
AB		25MG	A077474	004	Sep 05, 2007	Aug	CAHN
	@ WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Feb	DISC

TABLET;ORAL
CARVEDILOL

@	6.25MG	A078786	002	Dec 22, 2009	Feb DISC
@	12.5MG	A078786	003	Dec 22, 2009	Feb DISC
@	25MG	A078786	004	Dec 22, 2009	Feb DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION;ORAL
CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349	001	Apr 25, 2013	Apr NEWA
AB		EQ 500MG BASE/5ML	A065349	002	Apr 25, 2013	Apr NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Mar DISC
	@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Mar DISC

CEFAZOLIN SODIUMINJECTABLE;INJECTION
CEFAZOLIN SODIUM

	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008	Aug DISC
	@	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008	Aug DISC
AP	+ HOSPIRA INC	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Feb CRLD
AP	+	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Feb CRLD
AP	+	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Feb CRLD
AP	+	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Feb CRLD
AP	+ STERI PHARMA	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul CRLD

CEFEPIME HYDROCHLORIDEINJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

@	SANDOZ	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Mar DISC
@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Mar DISC
@		EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Mar DISC

CEFIXIMEFOR SUSPENSION;ORAL
SUPRAX

+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Feb CDFR
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Feb CDFR
		200MG/5ML	A065355	001	Apr 10, 2007	Feb CDFR

CEFOTAXIME SODIUMINJECTABLE;INJECTION
CEFOTAXIME SODIUM

@	AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009	Aug DISC
@		EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009	Aug DISC
@		EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009	Aug DISC
@	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009	Jun DISC

CEFTAZIDIMEINJECTABLE;INJECTION
CEFTAZIDIME

@	AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010	Jun DISC
@		2GM/VIAL	A065481	003	May 28, 2010	Jun DISC
@		6GM/VIAL	A065482	001	May 28, 2010	Jun DISC
@		500MG/VIAL	A065481	001	May 28, 2010	Jun DISC

CEFTRIAXONE SODIUMINJECTABLE;IM-IV
CEFTRIAXONE

	@ AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008	May DISC
	@	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008	May DISC
	@	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008	May DISC
	@	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008	May DISC
>D> AP	STERI PHARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Sep DISC
>A>	@	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Sep DISC
>D> AP		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Sep DISC
>A>	@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Sep DISC
	@ TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006	Jul DISC
	@	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006	Jul DISC
AP	TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	May CAHN
AP		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	May CAHN
AP		EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	May CAHN
AP		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	May CAHN

INJECTABLE;INJECTION

CEFTRIAXONE

@ AUROBINDO PHARMA LTD EQ 10GM BASE/VIAL

A065504 001 Jul 31, 2008 May DISC

CEFUROXIME SODIUM

INJECTABLE;IM-IV

CEFUROXIME SODIUM

@ TEVA PHARMS EQ 1.5GM BASE/VIAL

A064192 001 Apr 16, 1998 Jul DISC

@ EQ 750MG BASE/VIAL

A064192 002 Apr 16, 1998 Jul DISC

INJECTABLE;INJECTION

CEFUROXIME SODIUM IN PLASTIC CONTAINER

@ SAMSON MEDCL EQ 75GM BASE/VIAL

A065251 001 Dec 30, 2009 Aug DISC

@ EQ 225GM BASE/VIAL

A065251 002 Dec 30, 2009 Aug DISC

ZINACEF IN PLASTIC CONTAINER

@ COVIS PHARMA SARL EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jun DISC

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

ALKEM LABS LTD EQ 333MG BASE

A090836 003 Mar 29, 2013 Mar NEWA

AB EQ 750MG BASE

A090836 004 Mar 29, 2013 Mar NEWA

KEFLEX

AB + SHIONOGI INC EQ 750MG BASE

N050405 005 May 12, 2006 Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

@ APOTEX INC 5MG/5ML

A078412 001 Jun 18, 2008 Apr DISC

@ AUROBINDO PHARMA LTD 5MG/5ML

A090751 001 Dec 16, 2009 Feb DISC

AA BIO PHARM INC 5MG/5ML

A078870 001 Apr 27, 2009 May CAHN

>A> AA BRECKENRIDGE PHARM 5MG/5ML

A078488 001 Oct 06, 2008 Sep CAHN

AA CARACO 5MG/5ML

A090191 001 Nov 12, 2009 Jun CAHN

>D> AA CYPRESS PHARM 5MG/5ML

A078488 001 Oct 06, 2008 Sep CAHN

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

@ EMD SERONO INC EQ 3MG BASE/ML

N021197 002 Aug 11, 2000 Jun DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB ROXANE 30MG

A091591 001 Jul 08, 2013 Jun NEWA

EVOXAC

>A> AB + DAIICHI SANKYO 30MG

N020989 002 Jan 11, 2000 Sep CAHN

>D> AB + DAIICHI SANKYO CO 30MG

N020989 002 Jan 11, 2000 Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

@ APOTEX INC 0.12%

A075561 001 Nov 14, 2000 Apr DISC

PAROEX

AT SUNSTAR AMERICAS 0.12%

A076434 001 Nov 29, 2005 Apr CTNA

CHLOROTHIAZIDE

TABLET;ORAL

CHLOROTHIAZIDE

+ MYLAN 250MG

A084388 001 Jul CTEC

500MG

A084217 001 Jul CTEC

@ WEST WARD 250MG

A086028 001 Jul 14, 1982 Jul DISC

@

500MG

A087736 001 Jul 14, 1982 Jul DISC

DIURIL

@ OAK PHARMS AKORN 250MG

N011145 004 Jan CAHN

@ 500MG

N011145 002 Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP LUITPOLD EQ 500MG BASE/VIAL

A202561 001 Apr 22, 2013 Jun CAHN

AP PHARMAFORCE EQ 500MG BASE/VIAL

A202561 001 Apr 22, 2013 Apr NEWA

DIURIL

INJECTABLE;INJECTION
DIURIL

AP + OAK PHARMS AKORN EQ 500MG BASE/VIAL N011145 005 Jan CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL
VITUZ

+ CYPRESS PHARM 4MG/5ML;5MG/5ML N204307 001 Feb 20, 2013 Feb NEWA

CHLORPROPAMIDE

TABLET;ORAL
CHLORPROPAMIDE

@ WATSON LABS INC 100MG A088852 001 Sep 26, 1984 Jan DISC
@ 250MG A088826 001 Sep 26, 1984 Jan DISC

CHLORTHALIDONE

TABLET;ORAL
CHLORTHALIDONE

>A> @ BARR LABS INC 25MG A088902 001 Sep 19, 1985 Sep DISC
>A> AB 25MG A088902 001 Sep 19, 1985 Sep CAHN
>A> @ 50MG A088903 001 Sep 19, 1985 Sep DISC
>A> AB 50MG A088903 001 Sep 19, 1985 Sep CAHN
>D> AB MYLAN 25MG A086831 002 Sep CTEC
>D> AB 25MG A086831 002 Sep CTEC
>D> AB + 50MG A086831 001 Sep CTEC
>A> + 50MG A086831 001 Sep CTEC
>D> AB PLIVA 25MG A088902 001 Sep 19, 1985 Sep CAHN
>D> AB 50MG A088903 001 Sep 19, 1985 Sep CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB ANCHEN PHARMS EQ 45MG FENOFIBRIC ACID A201573 002 Jul 18, 2013 Jul NEWA
AB EQ 135MG FENOFIBRIC ACID A201573 001 Jul 18, 2013 Jul NEWA
AB MYLAN PHARMS INC EQ 45MG FENOFIBRIC ACID A200913 001 Mar 25, 2013 Mar NEWA
AB EQ 135MG FENOFIBRIC ACID A200913 002 Mar 25, 2013 Mar NEWA
AB TRILIPIX
AB ABBVIE EQ 45MG FENOFIBRIC ACID N022224 001 Dec 15, 2008 Mar CFTG
AB + EQ 135MG FENOFIBRIC ACID N022224 002 Dec 15, 2008 Mar CFTG

CICLOPIROX

CREAM;TOPICAL
LOPROX

>D> AB + MEDICIS 0.77% N018748 001 Dec 30, 1982 Sep CAHN
>A> AB + MEDIMETRIKS PHARMS 0.77% N018748 001 Dec 30, 1982 Sep CAHN

SOLUTION;TOPICAL
CICLOPIROX

@ APOTEX INC 8% A078172 001 Sep 18, 2007 Apr DISC
AT CIPLA LTD 8% A078124 001 Sep 18, 2007 Aug CAHN
@ TEVA PHARMS 8% A078079 001 Sep 18, 2007 Jan DISC
PENLAC
AT + VALEANT BERMUDA 8% N021022 001 Dec 17, 1999 May CAHN
AT + VALEANT INTL 8% N021022 001 Dec 17, 1999 Feb CAHN

CIMETIDINE

TABLET;ORAL
CIMETIDINE

@ WATSON LABS INC 200MG A074349 001 Aug 30, 1996 May DISC
@ 300MG A074349 002 Aug 30, 1996 May DISC
@ 400MG A074349 003 Aug 30, 1996 May DISC
@ 800MG A074316 001 Feb 28, 1996 Jun DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

@ APOTEX INC EQ 300MG BASE/5ML A075560 001 Mar 15, 2000 Apr DISC

CIPROFLOXACIN

INJECTABLE;INJECTION
CIPROFLOXACIN

@ TEVA PHARMS USA 200MG/20ML (10MG/ML) A077782 001 Aug 28, 2006 Apr CAHN
@ 400MG/40ML (10MG/ML) A077782 002 Aug 28, 2006 Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

@ APOTEX INC EQ 0.3% BASE A075928 001 Jun 09, 2004 Apr DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CIPRO XR

@ BAYER HLTHCARE 212.6MG;EQ 287.5MG BASE N021473 001 Dec 13, 2002 May DISC

@ 425.2MG;EQ 574.9MG BASE N021473 002 Aug 28, 2003 May DISC

CIPROFLOXACIN EXTENDED RELEASE

@ DR REDDYS LABS LTD 212.6MG;EQ 287.5MG BASE A077701 002 Oct 31, 2007 Jun DISC

AB + MYLAN PHARMS INC 212.6MG;EQ 287.5MG BASE A078183 001 Mar 22, 2007 May CRLD

AB + 425.2MG;EQ 574.9MG BASE A078183 002 Mar 22, 2007 May CRLD

CISPLATIN

INJECTABLE;INJECTION
CISPLATIN

>D> @ TEVA PARENTERAL 1MG/ML A074814 001 May 16, 2000 Sep CAHN

>A> @ TEVA PHARMS USA 1MG/ML A074814 001 May 16, 2000 Sep CAHN

PLATINOL

@ HQ SPCLT PHARMA 10MG/VIAL N018057 001 Jan CAHN

@ 50MG/VIAL N018057 002 Jan CAHN

PLATINOL-AQ

@ HQ SPCLT PHARMA 0.5MG/ML N018057 003 Jul 18, 1984 Jan CAHN

@ 1MG/ML N018057 004 Nov 08, 1988 Jan CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL
CITALOPRAM HYDROBROMIDE

@ APOTEX INC EQ 10MG BASE/5ML A077601 001 Nov 15, 2005 Apr DISC

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB CIPLA LTD EQ 10MG BASE A077044 001 Nov 05, 2004 Aug CAHN

AB EQ 20MG BASE A077044 002 Nov 05, 2004 Aug CAHN

AB EQ 40MG BASE A077044 003 Nov 05, 2004 Aug CAHN

@ COREPHARMA EQ 10MG BASE A077036 001 Oct 28, 2004 Feb DISC

@ EQ 20MG BASE A077036 002 Oct 28, 2004 Feb DISC

@ EQ 40MG BASE A077036 003 Oct 28, 2004 Feb DISC

@ NATCO PHARMA LTD EQ 20MG BASE A077141 002 Apr 10, 2008 Jun DISC

@ EQ 40MG BASE A077141 001 Apr 10, 2008 Jun DISC

CLARITHROMYCIN

TABLET;ORAL
CLARITHROMYCIN

AB ALLIED PHARMA INC 250MG A202710 001 Jun 10, 2013 May NEWA

AB 500MG A202710 002 Jun 10, 2013 May NEWA

CLEMASTINE FUMARATE

SYRUP;ORAL
CLEMASTINE FUMARATE

@ APOTEX INC EQ 0.5MG BASE/5ML A075703 001 Nov 27, 2000 Apr DISC

@ SILARX EQ 0.5MG BASE/5ML A074884 001 Dec 17, 1997 Mar DISC

CLEVIDIPINE

EMULSION;INTRAVENOUS
CLEVIPREX

+ MEDICINES CO 25MG/50ML (0.5MG/ML) N022156 001 Aug 01, 2008 Feb CAIN

+ 50MG/100ML (0.5MG/ML) N022156 002 Aug 01, 2008 Feb CAIN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA AUROBINDO PHARMA LTD EQ 75MG BASE/5ML A202409 001 Apr 30, 2013 Apr NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL
EVOCLIN

>A> AT + DELCOR ASSET 1% N050801 001 Oct 22, 2004 Sep CAHN

>D> AT + STIEFEL LABS INC 1% N050801 001 Oct 22, 2004 Sep CAHN

INJECTABLE;INJECTION

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	AKORN INC	EQ 6MG BASE/ML	A203048	001	Apr 04, 2013	Mar NEWA
AP		EQ 12MG BASE/ML	A203048	002	Apr 04, 2013	Mar NEWA
AP		EQ 18MG BASE/ML	A203048	003	Apr 04, 2013	Mar NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

	@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	May CAHN
AT	PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Aug CMFD
	@	EQ 1% BASE	A064050	001	Nov 30, 1995	Feb DISC

CLOBAZAM

TABLET;ORAL

ONFI

	@ LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Jul DISC
--	----------------	-----	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

OLUX E

AB2	+ DELCOR ASSET	0.05%	N022013	001	Jan 12, 2007	Jun CAHN
-----	----------------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	@ TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994	Jun DISC
--	-------------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL

EMBELINE

AT	+ HI TECH PHARMA	0.05%	A074222	001	Dec 06, 1995	Jul CRLD
	TEMOVATE					
	@ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jul DISC

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	ACCORD HLTHCARE	0.5MG	A077147	001	May 02, 2005	Apr CAHN
AB		1MG	A077147	002	May 02, 2005	Apr CAHN
AB		2MG	A077147	003	May 02, 2005	Apr CAHN
	@ APOTEX INC	0.5MG	A075468	001	Oct 06, 2000	Feb DISC
	@	1MG	A075468	002	Oct 06, 2000	Feb DISC
	@	2MG	A075468	003	Oct 06, 2000	Feb DISC

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	CARLSBAD	0.1MG	A202297	001	Jun 13, 2013	May NEWA
AB		0.2MG	A202297	002	Jun 13, 2013	May NEWA
AB		0.3MG	A202297	003	Jun 13, 2013	May NEWA

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

>A>	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Sep NEWA
>A>	AB	0.2MG	A202984	002	Sep 30, 2013	Sep NEWA

JENLOGA

	@ CONCORDIA PHARMS INC	0.1MG	N022331	001	Sep 30, 2009	May CAHN
--	------------------------	-------	---------	-----	--------------	----------

	@	0.2MG	N022331	002	May 25, 2010	May CAHN
--	---	-------	---------	-----	--------------	----------

KAPVAY

>D>	+ CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Sep CFTG
>A>	AB	0.1MG	N022331	003	Sep 28, 2010	Sep CFTG
	+	0.1MG	N022331	003	Sep 28, 2010	May CAHN
>D>		0.2MG	N022331	004	Sep 28, 2010	Sep CFTG
>A>	AB	0.2MG	N022331	004	Sep 28, 2010	Sep CFTG
		0.2MG	N022331	004	Sep 28, 2010	May CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	Mar NEWA
AB		EQ 300MG BASE	A202925	002	Mar 27, 2013	Mar NEWA
AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	May NEWA
AB	MUTUAL PHARM	EQ 75MG BASE	A078133	001	Jun 10, 2013	May NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

TRANXENE

	@ RECORDATI RARE	3.75MG	N017105	001		May CAHN
--	------------------	--------	---------	-----	--	----------

CAPSULE; ORAL							
TRANXENE							
	@	7.5MG		N017105	002		May CAHN
	@	15MG		N017105	003		May CAHN
TABLET; ORAL							
TRANXENE							
AB	RECORDATI RARE	3.75MG		N017105	006		May CAHN
AB		7.5MG		N017105	007		May CAHN
AB	+	15MG		N017105	008		May CAHN
TRANXENE SD							
	@ RECORDATI RARE	11.25MG		N017105	005		May CAHN
	@	22.5MG		N017105	004		May CAHN
<u>CLOTTRIMAZOLE</u>							
CREAM; TOPICAL							
MYCELEX							
>A>	@ BAYER	1%		N018183	001		Sep CAHN
>D>	@ BAYER PHARMS	1%		N018183	001		Sep CAHN
<u>CLOZAPINE</u>							
SUSPENSION; ORAL							
VERSACLOZ							
+	DOUGLAS PHARMS	50MG/ML		N203479	001	Feb 06, 2013	Feb NEWA
+	JAZZ PHARMS III	50MG/ML		N203479	001	Feb 06, 2013	Mar CAHN
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>							
SYRUP; ORAL							
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
AA	AMNEAL PHARMS	10MG/5ML; 6.25MG/5ML		A200894	001	Apr 24, 2013	Apr NEWA
AA	CARACO	10MG/5ML; 6.25MG/5ML		A090180	001	Mar 17, 2010	May CAHN
	@ PHARM ASSOC	10MG/5ML; 6.25MG/5ML		A089647	001	Dec 22, 1988	Aug DISC
<u>COSYNTROPIN</u>							
INJECTABLE; INJECTION							
COSYNTROPIN							
AP	MYLAN LLC	0.25MG/VIAL		A090574	001	Dec 17, 2009	Feb CAHN
<u>CRIZOTINIB</u>							
CAPSULE; ORAL							
XALKORI							
>A>	PF PRISM CV	200MG		N202570	001	Aug 26, 2011	Sep CAHN
>A>	+	250MG		N202570	002	Aug 26, 2011	Sep CAHN
>D>	PFIZER	200MG		N202570	001	Aug 26, 2011	Sep CAHN
>D>	+	250MG		N202570	002	Aug 26, 2011	Sep CAHN
<u>CROMOLYN SODIUM</u>							
CONCENTRATE; ORAL							
CROMOLYN SODIUM							
AA	MICRO LABS LTD INDIA	100MG/5ML		A202745	001	Apr 04, 2013	Mar NEWA
SOLUTION; INHALATION							
CROMOLYN SODIUM							
	@ APOTEX INC	10MG/ML		A075333	001	Apr 30, 2002	Apr DISC
SOLUTION/DROPS; OPHTHALMIC							
CROMOLYN SODIUM							
	@ APOTEX INC	4%		A075615	001	Jan 26, 2001	Apr DISC
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
AMRIX							
AB	IVAX INTL	15MG		N021777	001	Feb 01, 2007	Jan CAHN
AB	+	30MG		N021777	002	Feb 01, 2007	Jan CAHN
CYCLOBENZAPRINE HYDROCHLORIDE							
AB	TWI PHARMS INC	15MG		A091281	001	Jan 31, 2013	Jan NEWA
AB		30MG		A091281	002	Jan 31, 2013	Jan NEWA
TABLET; ORAL							
CYCLOBENZAPRINE HYDROCHLORIDE							
AB	MYLAN PHARMS INC	7.5MG		A073144	003	Mar 25, 2013	Mar NEWA
	@ PROSAM LABS	5MG		A077291	001	Feb 03, 2006	Mar DISC
	@ SANDOZ	5MG		A072854	002	Feb 03, 2006	Apr DISC
	@	10MG		A072854	001	Nov 19, 1991	Apr DISC

CYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
AKPENTOLATE

@ AKORN 2%

A040165 001 Jan 13, 1997 Mar DISC

CYCLOGYL

+ ALCON LABS INC 2%

A084108 001 Mar CTEC

CYCLOPHOSPHAMIDE

>A> CAPSULE;ORAL

>A> CYCLOPHOSPHAMIDE

>A> ROXANE 25MG

N203856 001 Sep 16, 2013 Sep NEWA

>A> + 50MG

N203856 002 Sep 16, 2013 Sep NEWA

INJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

AP + BAXTER HLTHCARE 1GM/VIAL

N012142 004 Aug 30, 1982 Mar CTNA

@ 1GM/VIAL

N012142 010 Sep 24, 1985 Jan CTNA

AP + 2GM/VIAL

N012142 005 Aug 30, 1982 Mar CTNA

@ 2GM/VIAL

N012142 009 Dec 10, 1985 Jan CTNA

AP + 500MG/VIAL

N012142 003 Mar CTNA

@ 500MG/VIAL

N012142 008 Jan 04, 1984 Jan CTNA

CYCLOSPORINESOLUTION;ORAL
CYCLOSPORINE

@ APOTEX INC 100MG/ML

A065167 001 Jan 05, 2005 Apr DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA PHARM ASSOC 2MG/5ML

A091295 001 Mar 28, 2013 Mar NEWA

CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE;ORAL
PROCYSBI

RAPTOR PHARMS EQ 25MG BASE

N203389 001 Apr 30, 2013 Apr NEWA

+ EQ 75MG BASE

N203389 002 Apr 30, 2013 Apr NEWA

CYTARABINEINJECTABLE;INJECTION
CYTOSAR-U

AP + TEVA PHARMS USA 1GM/VIAL

A075206 004 Dec 30, 1998 Jun CAHN

AP + 2GM/VIAL

A075206 003 Dec 30, 1998 Jun CAHN

AP 100MG/VIAL

A075206 001 Dec 30, 1998 Jun CAHN

AP + 500MG/VIAL

A075206 002 Dec 30, 1998 Jun CAHN

DABRAFENIB MESYLATECAPSULE;ORAL
TAFINLAR

GLAXOSMITHKLINE EQ 50MG BASE

N202806 001 May 29, 2013 May NEWA

+ EQ 75MG BASE

N202806 002 May 29, 2013 May NEWA

DACARBAZINEINJECTABLE;INJECTION
DACARBAZINE

AP TEVA PHARMS USA 200MG/VIAL

A075259 002 Aug 27, 1998 Apr CAHN

AP + 500MG/VIAL

A075259 001 Sep 22, 2000 Apr CAHN

DACTINOMYCININJECTABLE;INJECTION
COSMEGEN

AP + RECORDATI RARE 0.5MG/VIAL

N050682 001 May CAHN

DACTINOMYCIN

AP PHARMAFORCE 0.5MG/VIAL

A202562 001 Aug 23, 2013 Aug NEWA

DALTEPARIN SODIUMINJECTABLE;SUBCUTANEOUS
FRAGMIN

@ EISAI INC 10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007 Jun DISC

@ 95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002 Jun DISC

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul	CMFD
AB		50MG	A076686	002	Oct 24, 2005	Jul	CMFD
AB		100MG	A076686	003	Oct 24, 2005	Jul	CMFD

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DAUNORUBICIN HYDROCHLORIDE

AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Apr	CAHN
----	-----------------	----------------	---------	-----	--------------	-----	------

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	+ EISAI INC	50MG/VIAL	N021790	001	May 02, 2006	Jul	CFTG
AP	DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013	Jul	NEWA

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE

AP	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan	NEWA
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	0.15MG,N/A;0.02MG,0.01MG	A202296	001	Aug 30, 2013	Aug	NEWA
AB	NOVAST LABS LTD	0.15MG;0.03MG	A091234	001	Jul 12, 2013	Jul	NEWA
	ENSKYCE						
AB	LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013	Feb	NEWA
	PIMTREA						
AB	NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247	001	Aug 01, 2013	Jul	NEWA

DESONIDE

GEL;TOPICAL

DESONATE

	+ BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Jun	CAHN
--	------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

>A> AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Sep	NEWA
	SPRAY;TOPICAL						
	TOPICORT						
	+ TARO	0.25%	N204141	001	Apr 11, 2013	Apr	NEWA

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

BC	+ ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Jul	CTEC
	+	50MG	N204150	001	Mar 04, 2013	Apr	CRLD
		50MG	N204150	001	Mar 04, 2013	Mar	NEWA
BC	+	100MG	N204150	002	Mar 04, 2013	Jul	CTEC
	+	100MG	N204150	002	Mar 04, 2013	Mar	NEWA
	KHEDEZLA						
BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	Jul	NEWA
BC		100MG	N204683	002	Jul 10, 2013	Jul	NEWA

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May	CRLD
----	----------------------	-----------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun	CAHN
	SUSPENSION/DROPS;OPHTHALMIC						

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

@ ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721	001	Nov 17, 1986	Jan DISC
--------------------	---------------------------------------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar NEWA
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MYLAN PHARMS INC	30MG	A202580	001	Aug 28, 2013	Aug NEWA
	FOCALIN XR					
AB	NOVARTIS	30MG	N021802	005	Oct 23, 2009	Aug CFTG

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

TOTECT

+	BIOCODEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	May CAHN
---	--------------	--------------------	---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May CFTG
AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		AUROLIFE PHARMA LLC	5MG	A202893	001	Jul 31, 2013	Jul NEWA
AA			10MG	A202893	002	Jul 31, 2013	Jul NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982	Jan DISC
-----------	-----------------------	---------	-----	--------------	----------

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986	Jun DISC
---------------	--------	---------	-----	--------------	----------

DIAZOXIDE

SUSPENSION;ORAL

PROGLYCEM

+	TEVA BRANDED PHARM	50MG/ML	N017453	001		Apr CAHN
---	--------------------	---------	---------	-----	--	----------

DICLOFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

@ APOTEX INC	0.1%	A077600	001	Nov 13, 2008	Apr DISC
--------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	SANDOZ	50MG;0.2MG	A200158	001	May 09, 2013	Apr NEWA
AB		75MG;0.2MG	A200158	002	May 09, 2013	Apr NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

@ WEST WARD	10MG	A040204	001	Feb 28, 1997	Jul DISC
-------------	------	---------	-----	--------------	----------

DIDANOSINE

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

	AUROBINDO	100MG	A077275	001	Aug 14, 2012	Apr CDFR
		150MG	A077275	002	Aug 14, 2012	Apr CDFR
+		200MG	A077275	003	Aug 14, 2012	Apr CDFR

DIFLORASONE DIACETATE

CREAM; TOPICAL							
DIFLORASONE DIACETATE							
BX	+	@ FOUGERA PHARMS	0.05%	A075187	001	Mar 30, 1998	May DISC
		TARO	0.05%	A075508	001	Apr 24, 2000	May CRLD
		PSORCON					
		@ TARO PHARMS NORTH	0.05%	N020205	001	Nov 20, 1992	Jun CAHN

DIGOXIN

TABLET; ORAL							
DIGOXIN							
		@ CARACO	0.125MG	A076363	001	Jan 31, 2003	Jun DISC
		@	0.25MG	A076363	002	Jan 31, 2003	Jun DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
DILTIAZEM HYDROCHLORIDE							
AB3		PAR PHARM	120MG	A074984	001	Dec 20, 1999	Jan CAHN
AB3			180MG	A074984	002	Dec 20, 1999	Jan CAHN
AB3			240MG	A074984	003	Dec 20, 1999	Jan CAHN
AB3			300MG	A074984	004	Dec 20, 1999	Jan CAHN
AB4		SANDOZ	120MG	A091022	001	Sep 28, 2012	Feb CAHN
AB4			180MG	A091022	002	Sep 28, 2012	Feb CAHN
AB4			240MG	A091022	003	Sep 28, 2012	Feb CAHN
AB4			300MG	A091022	004	Sep 28, 2012	Feb CAHN
AB4			360MG	A091022	005	Sep 28, 2012	Feb CAHN
AB4			420MG	A091022	006	Sep 28, 2012	Feb CAHN
INJECTABLE; INJECTION							
DILTIAZEM HYDROCHLORIDE							
AP		AKORN INC	5MG/ML	A075086	001	Apr 09, 1998	Jul CAHN
		@ APOTEX INC	5MG/ML	A075375	001	Sep 30, 1999	Apr DISC
		@ TEVA PHARMS USA	5MG/ML	A074894	001	Aug 26, 1997	Apr CAHN
	+		10MG/ML	A074894	002	Apr 19, 2002	Apr CAHN
TABLET; ORAL							
DILTIAZEM HYDROCHLORIDE							
		@ DAVA PHARMS INC	30MG	A074093	001	Nov 05, 1992	Jan DISC
		@	60MG	A074093	002	Nov 05, 1992	Jan DISC
		@	90MG	A074093	003	Nov 05, 1992	Jan DISC
		@	120MG	A074093	004	Nov 05, 1992	Jan DISC

DIMENHYDRINATE

INJECTABLE; INJECTION							
DIMENHYDRINATE							
	+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004	Apr CRLD
		@ WATSON LABS	50MG/ML	A080615	001		Apr DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL							
TECFIDERA							
		BIAGEN IDEC INC	120MG	N204063	001	Mar 27, 2013	Mar NEWA
	+		240MG	N204063	002	Mar 27, 2013	Mar NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION							
DIPHENHYDRAMINE HYDROCHLORIDE							
		@ WATSON LABS INC	10MG/ML	A080873	001		Mar DISC
		@	50MG/ML	A080873	002		Mar DISC
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE							
AP		BD RX	50MG/ML	A091526	001	Mar 26, 2013	Mar NEWA
		@ WATSON LABS INC	50MG/ML	A080873	003		Mar DISC

DIPYRIDAMOLE

INJECTABLE; INJECTION							
DIPYRIDAMOLE							
		@ AGILA SPECLTS	5MG/ML	A075769	001	Nov 27, 2002	Aug CAHN
		@ APOTEX INC	5MG/ML	A075769	001	Nov 27, 2002	Apr DISC
		@ TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997	May CAHN
TABLET; ORAL							
DIPYRIDAMOLE							
		@ PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Jun DISC
		@	50MG	A040542	002	Apr 21, 2006	Jun DISC

TABLET;ORAL
DIPYRIDAMOLE
@

75MG

A040542 003 Apr 21, 2006 Jun DISC

DISULFIRAM

TABLET;ORAL
DISULFIRAM

AB ALVOGEN PINE BROOK 250MG

A091681 001 Aug 08, 2013 Jul NEWA

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

@ MYLAN EQ 125MG VALPROIC ACID
@ EQ 250MG VALPROIC ACID
@ EQ 500MG VALPROIC ACID

A077254 001 Jul 29, 2008 Aug DISC
A077254 002 Jul 29, 2008 Aug DISC
A077254 003 Jul 29, 2008 Aug DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

@ TEVA PHARMS USA EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009 Mar DISC

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP ACCORD HLTHCARE 160MG/8ML (20MG/ML)

N201195 005 Apr 20, 2012 Aug CTEC

AP ACTAVIS INC 20MG/ML (20MG/ML)

N203551 001 Apr 12, 2013 Apr NEWA

AP 80MG/4ML (20MG/ML)

N203551 002 Apr 12, 2013 Apr NEWA

140MG/7ML (20MG/ML)

N203551 003 Apr 12, 2013 Apr NEWA

@ APOTEX INC 20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012 May DISC

@ 80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012 May DISC

TAXOTERE

AP + SANOFI AVENTIS US 160MG/8ML (20MG/ML)

N020449 005 Apr 13, 2012 Aug NEWA

DOLUTEGRAVIR SODIUM

TABLET;ORAL
TIVICAY

+ VIIIV HLTHCARE EQ 50MG BASE

N204790 001 Aug 12, 2013 Aug NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
ARICEPT

AB + EISAI INC 23MG

N022568 001 Jul 23, 2010 Jul CTEC

DONEPEZIL HYDROCHLORIDE

@ ACCORD HLTHCARE 5MG

A201335 001 Aug 29, 2011 Jan DISC

@ 10MG

A201335 002 Aug 29, 2011 Jan DISC

AB ACTAVIS GRP PTC 5MG

A090551 001 May 31, 2011 Apr CAHN

AB 10MG

A090551 002 May 31, 2011 Apr CAHN

AB ALEMBIC PHARMS LTD 5MG

A201724 001 Feb 25, 2013 Feb NEWA

AB 10MG

A201724 002 Feb 25, 2013 Feb NEWA

>D> AB ALVOGEN PINE BROOK 5MG

A202114 001 Jul 05, 2013 Sep CAHN

AB 5MG

A202114 001 Jul 05, 2013 Jun NEWA

>D> AB 10MG

A202114 002 Jul 05, 2013 Sep CAHN

AB 10MG

A202114 002 Jul 05, 2013 Jun NEWA

>A> AB CSPC OUYI PHARM CO 5MG

A202114 001 Jul 05, 2013 Sep CAHN

>A> AB 10MG

A202114 002 Jul 05, 2013 Sep CAHN

AB DR REDDYS LABS LTD 23MG

A202723 001 Jul 24, 2013 Jul NEWA

AB PAR PHARM 23MG

A202542 001 Jul 24, 2013 Jul NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

@ APOTEX INC EQ 2% BASE

A078395 001 Oct 28, 2008 Apr DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ APOTEX INC EQ 2% BASE;EQ 0.5% BASE

A078201 001 Oct 28, 2008 Apr DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION
DOPRAM

AP + HIKMA MAPLE 20MG/ML

N014879 001 Jul CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000	Jan	DISC
@		EQ 2MG BASE	A075426	002	Oct 18, 2000	Jan	DISC
@		EQ 4MG BASE	A075426	003	Oct 18, 2000	Jan	DISC
@		EQ 8MG BASE	A075426	004	Oct 18, 2000	Jan	DISC

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 10MG BASE	A070791	002	May 13, 1986	Jun	CRLD
AB		EQ 10MG BASE	A070791	002	May 13, 1986	May	CRLD
AB	+	EQ 25MG BASE	A070791	003	May 13, 1986	Jun	CRLD
	@ PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	May	DISC
	@	EQ 25MG BASE	A071437	001	Nov 09, 1987	May	DISC
	@	EQ 50MG BASE	A071595	001	Nov 09, 1987	May	DISC
	@	EQ 75MG BASE	A071608	001	Nov 09, 1987	May	DISC
	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	May	DISC
	@ WATSON LABS	EQ 10MG BASE	A071485	001	Apr 30, 1987	May	DISC
	@	EQ 25MG BASE	A071486	001	Apr 30, 1987	May	DISC
	@	EQ 50MG BASE	A071238	001	Apr 30, 1987	May	DISC
	@	EQ 75MG BASE	A071326	001	Apr 30, 1987	May	DISC
	@	EQ 100MG BASE	A071239	001	Apr 30, 1987	May	DISC

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

@	PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004	Mar	DISC
---	-------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jul	NEWA
AB		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jul	NEWA
	SILENOR						
AB	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jul	CFTG
		EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
AB	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jul	CFTG
	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP		INNOPHARMA INC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Aug	NEWA
		HECTOROL						
AP	+	GENZYME CORP	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug	CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	SAGENT PHARMS	2MG/ML	A091495	001	Mar 18, 2013	Mar	NEWA
AP	TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995	Jun	CAHN
AP		200MG/100ML	A064140	002	Jul 28, 1995	Jun	CAHN

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan	CFTG
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan	CFTG

DOXIL (LIPOSOMAL)

AB		JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jun	CRLD
AB	+		20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Apr	CTNA
AB			50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jun	CRLD
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Apr	CTNA

DOXORUBICIN HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jan	NEWA
AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jan	NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	+	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jun	CRLD
AB	+		20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Apr	CTNA
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jun	CRLD
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Apr	CTNA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

FOR SUSPENSION;ORAL

DOXYCYCLINE

>A>	AB	CHARTWELL LIFE SCI	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Sep CAHN
>D>	AB	IVAX SUB TEVA PHARMS	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Sep CAHN
	AB	LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Mar NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

>A>	AB	CHARTWELL LIFE SCI	EQ 50MG BASE	A062500	001	Sep 11, 1984	Sep CAHN
>A>	AB		EQ 100MG BASE	A062500	002	Sep 11, 1984	Sep CAHN
	AB	HIKMA PHARMS	EQ 50MG BASE	A062396	002	Nov 07, 1984	May CAHN
	AB		EQ 100MG BASE	A062396	001	May 07, 1984	May CAHN
>D>	AB	IVAX SUB TEVA PHARMS	EQ 50MG BASE	A062500	001	Sep 11, 1984	Sep CAHN
>D>	AB		EQ 100MG BASE	A062500	002	Sep 11, 1984	Sep CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

		@ BLU CARIBE INC	EQ 50MG BASE	A062269	003		Mar CAHN
		@	EQ 100MG BASE	A062269	002	Nov 08, 1982	Mar CAHN
AB		CHARTWELL LIFE SCI	EQ 100MG BASE	A062505	001	Sep 11, 1984	Jul CAHN
AB	+	HIKMA PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	May CAHN

TABLET, DELAYED RELEASE;ORAL

DORYX

		MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr NEWA
			EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr NEWA

DOXYCYCLINE HYCLATE

AB		HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr NEWA
AB			EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr NEWA
AB			EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

+	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr NEWA
---	-----------	-----------	---------	-----	--------------	----------

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB		BANNER PHARMACAPS	0.5MG	A200899	001	May 30, 2013	May NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar CAHN
----	--	--------------	----	---------	-----	--------------	----------

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

AP	+	VALEANT PHARMS	10MG/ML	N007959	001		Jul CAHN
		TENSILON PRESERVATIVE FREE					
AP	+	VALEANT PHARMS	10MG/ML	N007959	002		Jul CAHN

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Aug NEWA
---	-------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ENALAPRIL MALEATE

@	MYLAN	2.5MG	A075472	001	Aug 22, 2000	Aug DISC
@		5MG	A075472	002	Aug 22, 2000	Aug DISC
@		10MG	A075472	003	Aug 22, 2000	Aug DISC
@		20MG	A075472	004	Aug 22, 2000	Aug DISC

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP		TEVA PHARMS USA	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
----	--	-----------------	-----------	---------	-----	--------------	----------

ENTACAPONE

TABLET;ORAL

ENTACAPONE

TABLET;ORAL
ENTACAPONE

AB MYLAN PHARMS INC 200MG A202394 001 May 13, 2013 Apr NEWA

EPINEPHRINE

INJECTABLE;IM-SC
EPIPEN

>D> BX + MERIDIAN MEDCL TECHN 0.3MG/DELIVERY N019430 001 Dec 22, 1987 Sep CAHN
 BX + 0.3MG/DELIVERY N019430 001 Dec 22, 1987 Jul CDFR
 >A> BX + MYLAN SPECLT 0.3MG/DELIVERY N019430 001 Dec 22, 1987 Sep CAHN
 EPIPEN JR.
 >D> BX + MERIDIAN MEDCL TECHN 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Sep CAHN
 BX + 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Jul CDFR
 >A> BX + MYLAN SPECLT 0.15MG/DELIVERY N019430 002 Dec 22, 1987 Sep CAHN

INJECTABLE;INTRAMUSCULAR
EPI E Z PEN JR

>D> @ MERIDIAN MEDCL TECHN 0.15MG/DELIVERY N019430 004 Aug 03, 1995 Sep CAHN
 >A> @ MYLAN SPECLT 0.15MG/DELIVERY N019430 004 Aug 03, 1995 Sep CAHN
 EPIPEN E Z PEN
 >D> @ MERIDIAN MEDCL TECHN 0.3MG/DELIVERY N019430 003 Aug 03, 1995 Sep CAHN
 >A> @ MYLAN SPECLT 0.3MG/DELIVERY N019430 003 Aug 03, 1995 Sep CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

@ MYLAN LLC 50MG/25ML (2MG/ML) A065371 001 Nov 28, 2007 Feb DISC
 @ 200MG/100ML (2MG/ML) A065371 002 Nov 28, 2007 Feb DISC
 AP TEVA PHARMS USA 50MG/25ML (2MG/ML) A065331 001 Aug 09, 2007 Apr CAHN
 AP 200MG/100ML (2MG/ML) A065331 002 Aug 09, 2007 Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION
EPOPROSTENOL SODIUM

AP TEVA PHARMS USA EQ 0.5MG BASE/VIAL A078396 001 Apr 23, 2008 Apr CAHN
 AP EQ 1.5MG BASE/VIAL A078396 002 Apr 23, 2008 Apr CAHN

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)
INVANZ

+ MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001 Jun CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL
ERYC

AB + MAYNE PHARMA 250MG N050536 001 Mar CAHN
 @ WARNER CHILCOTT LLC 250MG A062338 001 Apr DISC

GEL;TOPICAL
ERYGEL

AT + DELCOR ASSET CORP 2% N050617 001 Oct 21, 1987 Jul CAHN

OINTMENT;OPHTHALMIC
ERYTHROMYCIN

AT + PERRIGO CO TENNESSEE 0.5% A062447 001 Sep 26, 1983 Jun CAHN

SOLUTION;TOPICAL
SANSAC

@ DOW PHARM 2% A062522 001 Jan 24, 1985 Apr CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL
ESCITALOPRAM OXALATE

AA SILARX PHARMS INC EQ 5MG BASE/5ML A090477 001 Jun 12, 2013 May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

>A> NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

>A> AB DR REDDYS LABS LTD EQ 20MG BASE;375MG A202461 001 Sep 27, 2013 Sep NEWA

>A> AB EQ 20MG BASE;500MG A202461 002 Sep 27, 2013 Sep NEWA

VIMOVO

>D> ASTRAZENECA LP EQ 20MG BASE;375MG N022511 002 Apr 30, 2010 Sep CFTG

>A> AB EQ 20MG BASE;375MG N022511 002 Apr 30, 2010 Sep CFTG

>D> + EQ 20MG BASE;500MG N022511 001 Apr 30, 2010 Sep CFTG

>A> AB + EQ 20MG BASE;500MG N022511 001 Apr 30, 2010 Sep CFTG

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar NEWA
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar NEWA
	NEXIUM IV					
AP	+ ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Mar CFTG
AP	+	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Mar CFTG

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

>A>	HANMI PHARM CO LTD	EQ 20MG BASE	N202342	001	Aug 06, 2013	Sep CAHN
>A>	+	EQ 40MG BASE	N202342	002	Aug 06, 2013	Sep CAHN
>D>	HANMI USA	EQ 20MG BASE	N202342	001	Aug 06, 2013	Sep CAHN
		EQ 20MG BASE	N202342	001	Aug 06, 2013	Aug NEWA
>D>	+	EQ 40MG BASE	N202342	002	Aug 06, 2013	Sep CAHN
	+	EQ 40MG BASE	N202342	002	Aug 06, 2013	Aug NEWA

ESTRADIOL VALERATEINJECTABLE;INJECTION
ESTRADIOL VALERATE

@ WATSON LABS	40MG/ML	A083714	001			Jun DISC
@ WATSON LABS INC	20MG/ML	A083547	001			Jun DISC

ESTROGENS, CONJUGATED SYNTHETIC A

>D>	CREAM;VAGINAL					
>D>	SYNTHETIC CONJUGATED ESTROGENS A					
>D>	+ TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008	Sep DISC
>A>	@	0.625MG/GM	N021788	001	Nov 28, 2008	Sep DISC

ESTRONEINJECTABLE;INJECTION
ESTRONE

@ WATSON LABS	5MG/ML	A085239	001			Jun DISC
---------------	--------	---------	-----	--	--	----------

ESTROPIPATETABLET;ORAL
ORTHO-EST

@ CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr DISC
@	1.5MG	A089582	001	Jul 17, 1991	Apr DISC

ESZOPICLONETABLET;ORAL
ESZOPICLONE

AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar NEWA
AB		2MG	A091151	002	Mar 26, 2013	Mar NEWA
AB		3MG	A091151	003	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar NEWA
AB		2MG	A091103	002	Apr 03, 2013	Mar NEWA
AB		3MG	A091103	003	Apr 03, 2013	Mar NEWA
	LUNESTA					
AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar CTEC
AB		2MG	N021476	002	Dec 15, 2004	Mar CTEC
AB	+	3MG	N021476	003	Dec 15, 2004	Mar CTEC

ETHAMBUTOL HYDROCHLORIDETABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE

	@ WEST WARD	100MG	A075095	001	Nov 30, 1999	Jul DISC
	@	400MG	A075095	002	Nov 30, 1999	Jul DISC
	MYAMBUTOL					
AB	+ STI PHARMA LLC	400MG	N016320	003		Jul CRLD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET;ORAL
DAYSEE

AB	LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467	001	Apr 10, 2013	Mar NEWA
	QUARTETTE					
+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar NEWA

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB1	FAMY CARE LTD	0.02MG;0.1MG	A200245	001	Oct 09, 2013	Sep NEWA
	AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

	AB	FAMY CARE LTD	0.05MG;1MG	A203006	001	Aug 05, 2013	Jul NEWA
		OVCON-50					
	AB	+ WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jul CFTG
		PIRMELLA 1/35					
	AB	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Apr NEWA
		PIRMELLA 7/7/7					
	AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75	A201510	001	Apr 24, 2013	Apr NEWA
			MG,1MG				
>A>		VYFEMLA					
>A>	AB	LUPIN LTD	0.035MG;0.4MG	A201886	001	Sep 26, 2013	Sep NEWA
		TABLET, CHEWABLE;ORAL					
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
>A>	AB	AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	Sep CAHN
>D>	AB	WATSON LABS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	Sep CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

MINASTRIN 24 FE

	+	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr NEWA
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
		@ WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	May DISC
		TABLET;ORAL					
		FEMHRT					
		@ WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan DISC
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Jan CRLD
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
>A>	AB	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Sep CAHN
>D>	AB	WATSON LABS	0.02MG;1MG	A078267	001	Sep 01, 2009	Sep CAHN

TABLET;ORAL-28

LARIN FE 1.5/30

	AB	NOVAST LABS LTD	0.03MG;1.5MG	A091453	001	Aug 23, 2013	Aug NEWA
		LARIN FE 1/20					
	AB	NOVAST LABS LTD	0.02MG;1MG	A091454	001	Aug 26, 2013	Aug NEWA
		TABLET, CHEWABLE;ORAL					
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2003	May NEWA
		TABLET, CHEWABLE, TABLET;ORAL					
		LO MINASTRIN FE					
	+	WARNER CHILCOTT	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jul NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

	AB	SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Jan NEWA
		TRI LO SPRINTC					
		@ BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A076784	001	Jun 29, 2009	Apr DISC
			15MG,0.25MG				
		TRI-ESTARYLLA					
	AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A090793	001	Jan 30, 2013	Jan NEWA
			15MG,0.25MG				

ETHOTOIN

TABLET;ORAL

PEGANONE

	+	RECORDATI RARE	250MG	N010841	001		May CAHN
--	---	----------------	-------	---------	-----	--	----------

ETODOLAC

TABLET;ORAL

ETODOLAC

		@ PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar DISC
		@	500MG	A074819	002	Apr 28, 1998	Mar DISC

ETOPOSIDEINJECTABLE; INJECTION
ETOPOSIDE

AP	ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr CAHN
	@ PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr DISC
AP	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May CAHN
AP		20MG/ML	A074529	001	Jul 24, 1996	Apr CAHN

FAMCICLOVIRTABLET; ORAL
FAMCICLOVIR

AB	CIPLA LTD	125MG	A078278	001	Mar 21, 2011	Jul CAHN
AB		250MG	A078278	002	Mar 21, 2011	Jul CAHN
AB		500MG	A078278	003	Mar 21, 2011	Jul CAHN

FAMOTIDINEINJECTABLE; INJECTION
FAMOTIDINE

	@ APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr DISC
	FAMOTIDINE PRESERVATIVE FREE					
AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Mar CAHN
	@ APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr DISC
	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Mar CAHN
	@ APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr DISC
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
	@ MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr CAHN
	TABLET; ORAL					
	FAMOTIDINE					
>D> AB	WATSON LABS	20MG	A075062	002	Apr 16, 2001	Sep DISC
>A>	@	20MG	A075062	002	Apr 16, 2001	Sep DISC
>D> AB		40MG	A075062	001	Apr 16, 2001	Sep DISC
>A>	@	40MG	A075062	001	Apr 16, 2001	Sep DISC

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB	APOTEX INC	43MG	A202252	001	Jul 26, 2013	Jul NEWA
AB		130MG	A202252	002	Jul 26, 2013	Jul NEWA

FENOFIBRIC ACIDTABLET; ORAL
FIBRICOR

	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Feb CAHN
+		105MG	N022418	002	Aug 14, 2009	Feb CAHN

FENOPROFEN CALCIUMTABLET; ORAL
FENOPROFEN CALCIUM

	@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar DISC
+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar CTEC

FENTANYLSPRAY; SUBLINGUAL
SUBSYS

	INSYS THERAP	1.2MG	N202788	006	Aug 30, 2012	Aug NEWA
		1.6MG	N202788	007	Aug 30, 2012	Aug NEWA

FENTANYL CITRATEFILM; BUCCAL
ONSOLIS

	@ MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May DISC
	@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May DISC
	@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May DISC
	@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May DISC
	@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	May DISC

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	HIKMA MAPLE	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jul CAHN
		SPRAY, METERED; NASAL					
		LAZANDA					

SPRAY, METERED;NASAL
LAZANDA

>D>	ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep CAHN
>D>	+	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep CAHN
>A>	DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep CAHN
>A>	+	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep CAHN

TABLET;BUCCAL, SUBLINGUAL
FENTORA

AB	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb CDfR
AB		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb CDfR
	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb CDfR
AB	+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb CDfR
AB		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb CDfR
AB		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb CDfR

TABLET;SUBLINGUAL
ABSTRAL

	GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May CAHN
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May CAHN
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May CAHN
	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May CAHN
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May CAHN
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May CAHN

FERRIC CARBOXYMALTOSE

INJECTABLE;IV
INJECTAFER

+	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jul NEWA
---	----------	--------------------------------	---------	-----	--------------	----------

FERUMOXFIL

SUSPENSION;ORAL
GASTROMARK

@	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996	Feb DISC
---	-----------------	--------------------	---------	-----	--------------	----------

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr CAHN
AB	HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013	Jun NEWA
AB		5MG	A090061	001	Jun 07, 2010	Apr CAHN
AB	SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013	Jun NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

	@ APOTEX INC	50MG	A079164	001	Jul 09, 2009	Apr DISC
	@	100MG	A079164	002	Jul 09, 2009	Apr DISC
	@	150MG	A079164	003	Jul 09, 2009	Apr DISC
AB	+	ROXANE	A076278	003	Jan 14, 2003	May CRLD
	TAMBOCOR					
	@ MEDICIS	50MG	N018830	004	Aug 23, 1988	May DISC
	@	100MG	N018830	001	Oct 31, 1985	May DISC
	@	150MG	N018830	003	Jun 03, 1988	May DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

@	TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006	Mar DISC
@		200MG/5ML	A076918	002	Dec 18, 2006	Mar DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug CAHN
@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug CAHN
@	APOTEX INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr DISC
@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May CAHN
AP		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug CAHN
@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug CAHN
@	APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr DISC
@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr DISC

TABLET;ORAL

FLUCONAZOLE

>D>	AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Sep	DISC
>A>	@		50MG	A078423	001	Mar 07, 2011	Sep	DISC
>D>	AB		100MG	A078423	002	Mar 07, 2011	Sep	DISC
>A>	@		100MG	A078423	002	Mar 07, 2011	Sep	DISC
>D>	AB		150MG	A078423	003	Mar 07, 2011	Sep	DISC
>A>	@		150MG	A078423	003	Mar 07, 2011	Sep	DISC
>D>	AB		200MG	A078423	004	Mar 07, 2011	Sep	DISC
>A>	@		200MG	A078423	004	Mar 07, 2011	Sep	DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	+	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan	CRLD
AP		TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan	CRLD
AP		TEVA PHARMS USA	50MG/VIAL	A076349	001	Aug 28, 2003	Apr	CAHN
AP			50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Apr	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

+	HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013	Jun	CRLD
+		20-500mCi/ML	A203665	001	Feb 14, 2013	Jan	NEWA
	MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013	Jul	NEWA
+	UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Jun	NEWA

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

	@	APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	DISC	
	@		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	DISC	
	@	TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Apr	CAHN	
	@		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Apr	CAHN	
>D>		ROMAZICON							
>D>	AP	+	HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML)	N020073	001	Dec 20, 1991	Sep	DISC
>A>	@		1MG/10ML (0.1MG/ML)	N020073	001	Dec 20, 1991	Sep	DISC	
>D>	AP		0.5MG/5ML (0.1MG/ML)	N020073	002	Dec 20, 1991	Sep	DISC	
>A>	@		0.5MG/5ML (0.1MG/ML)	N020073	002	Dec 20, 1991	Sep	DISC	

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROBID

>D>								
>D>	+	ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984	Sep	DISC
>A>	@		0.25MG/INH	N018340	001	Aug 17, 1984	Sep	DISC

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT		PERRIGO ISRAEL	0.01%	A202847	001	Aug 09, 2013	Jul	NEWA
AT			0.01%	A202848	001	Aug 09, 2013	Jul	NEWA

FLUOCINONIDE

CREAM;TOPICAL

LIDEX

@ CNTY LINE PHARMS

LIDEX-E

@ CNTY LINE PHARMS

GEL;TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A074935	001	Jul 29, 1997	Jan	CRLD
----	---	------	-------	---------	-----	--------------	-----	------

LIDEX

@ CNTY LINE PHARMS

OINTMENT;TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A075008	001	Jun 30, 1999	Jan	CRLD
----	---	------	-------	---------	-----	--------------	-----	------

LIDEX

@ CNTY LINE PHARMS

SOLUTION;TOPICAL

FLUOCINONIDE

AT		ACTAVIS MID ATLANTIC	0.05%	A071535	001	Dec 02, 1988	May	CAHN
AT	+	TARO	0.05%	A074799	001	Dec 31, 1996	Jan	CRLD

SOLUTION; TOPICAL

LIDEX

@ CNTY LINE PHARMS
@ MEDICIS

0.05%
0.05%

N018849 001 Apr 06, 1984 May CAHN
N018849 001 Apr 06, 1984 Jan DISC

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP + MYLAN LLC 1GM/20ML (50MG/ML)
AP + 500MG/10ML (50MG/ML)
AP + TEVA PHARMS USA 2.5GM/50ML (50MG/ML)
AP + 5GM/100ML (50MG/ML)
AP + 500MG/10ML (50MG/ML)

A040743 001 Apr 26, 2007 Feb CAHN
A040743 002 Apr 26, 2007 Feb CAHN
A040334 001 Feb 25, 2000 May CAHN
A040334 002 Feb 25, 2000 May CAHN
A040333 001 Jan 27, 2000 May CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1 @ CARLSBAD EQ 10MG BASE
@ EQ 20MG BASE
@ CR DOUBLE CRANE EQ 10MG BASE
AB1 EQ 10MG BASE
@ EQ 20MG BASE
AB1 EQ 20MG BASE
>D> AB1 DR REDDYS LABS INC EQ 10MG BASE
>D> AB1 EQ 20MG BASE
>D> AB EQ 40MG BASE
>A> AB1 DR REDDYS LABS LTD EQ 10MG BASE
>A> AB1 EQ 20MG BASE
>A> AB EQ 40MG BASE
AB1 TEVA PHARMS USA EQ 10MG BASE
AB1 EQ 20MG BASE
@ WOCKHARDT LTD EQ 10MG BASE
@ EQ 20MG BASE
@ EQ 40MG BASE

A076022 001 Jan 30, 2002 Mar DISC
A076022 002 Jan 30, 2002 Mar DISC
A076165 001 Feb 01, 2002 Apr DISC
A076165 001 Feb 01, 2002 Mar CAHN
A076165 002 Feb 01, 2002 Apr DISC
A076165 002 Feb 01, 2002 Mar CAHN
A075465 001 Jan 29, 2002 Sep CAHN
A075465 002 Jan 29, 2002 Sep CAHN
A075465 003 Aug 02, 2001 Sep CAHN
A075465 001 Jan 29, 2002 Sep CAHN
A075465 002 Jan 29, 2002 Sep CAHN
A075465 003 Aug 02, 2001 Sep CAHN
A076001 001 Jan 29, 2002 Jul CAHN
A076001 002 Jan 29, 2002 Jul CAHN
A078143 001 Jan 16, 2008 Feb DISC
A078143 002 Jan 16, 2008 Feb DISC
A078143 003 Jan 16, 2008 Feb DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ APOTEX INC EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002 Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB TEVA PHARMS EQ 25MG BASE; EQ 3MG BASE

A202074 001 Mar 25, 2013 Mar NEWA

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ AGILA SPECLTS 25MG/ML
@ APOTEX INC 25MG/ML

A075918 001 Aug 17, 2001 Aug CAHN
A075918 001 Aug 17, 2001 Apr DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@ WEST WARD 15MG
@ 30MG

A071107 001 Dec 08, 1986 Jul DISC
A071108 001 Dec 08, 1986 Jul DISC

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+ GLAXO GRP LTD 0.1MG/INH; EQ 0.025MG BASE/INH

N204275 001 May 10, 2013 May NEWA

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

@ FOUGERA PHARMS 0.05%

N019958 001 Dec 18, 1990 Aug DISC

LOTION; TOPICAL

FLUTICASONE PROPIONATE

AB PERRIGO ISRAEL 0.05%

A091553 001 Jul 30, 2013 Jul NEWA

POWDER; INHALATION

FLOVENT DISKUS 100

+ GLAXO GRP LTD 0.1MG/INH

N020833 002 Sep 29, 2000 May CAHN

FLOVENT DISKUS 250

+ GLAXO GRP LTD 0.25MG/INH

N020833 003 Sep 29, 2000 May CAHN

POWDER; INHALATION

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May CAHN
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May CAHN
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May CAHN

POWDER; INHALATION

ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May CAHN
---	---------------	------------------------------	---------	-----	--------------	----------

ADVAIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May CAHN
---	---------------	-------------------------------	---------	-----	--------------	----------

ADVAIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May CAHN
---	---------------	------------------------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013	Apr NEWA
AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar NEWA
AB		150MG	A091476	002	Mar 13, 2013	Mar NEWA

LUVOX CR

AB	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Mar CFTG
----	-------------	-------	---------	-----	--------------	----------

AB	+	150MG	N022033	002	Feb 28, 2008	Mar CFTG
----	---	-------	---------	-----	--------------	----------

TABLET; ORAL

FLUVOXAMINE MALEATE

@	CARACO	25MG	A075900	001	Feb 23, 2006	Jun DISC
@		50MG	A075900	002	Feb 23, 2006	Jun DISC
@		100MG	A075900	003	Feb 23, 2006	Jun DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	BICON PHARM	1MG	A091145	001	Jul 12, 2013	Jul NEWA
----	-------------	-----	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

>D>	+	MERCK AND CO INC	EQ 115MG BASE/VIAL	N022023	001	Jan 25, 2008	Sep DISC
>A>	@		EQ 115MG BASE/VIAL	N022023	001	Jan 25, 2008	Sep DISC

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar DISC
@		20MG	A076987	002	Dec 23, 2004	Mar DISC
@		40MG	A076987	003	Dec 23, 2004	Mar DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006	Aug DISC
@		20MG;12.5MG	A077705	002	Aug 14, 2006	Aug DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	May CAHN
	@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007	Apr DISC
	@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	INTL MEDICATION	10MG/ML	N018025	001		Jan DISC
---	-----------------	---------	---------	-----	--	----------

TABLET; ORAL

FUROSEMIDE

@	DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982	Feb DISC
---	-----------------	------	---------	-----	--------------	----------

TABLET;ORAL							
FUROSEMIDE							
	@	40MG		N018415	002	Jul 27, 1982	Feb DISC
	@	80MG		N018415	003	Nov 26, 1984	Feb DISC
<u>GABAPENTIN</u>							
CAPSULE;ORAL							
GABAPENTIN							
AB	TARO	100MG		A077261	001	Aug 02, 2013	Jul NEWA
AB		300MG		A077261	002	Aug 02, 2013	Jul NEWA
AB		400MG		A077261	003	Aug 02, 2013	Jul NEWA
SOLUTION;ORAL							
GABAPENTIN							
AA	TARO	250MG/5ML		A076672	001	Jul 03, 2013	Jun NEWA
TABLET;ORAL							
GABAPENTIN							
AB	ALLIED PHARMA INC	600MG		A203244	002	Jul 12, 2013	Jul NEWA
AB		800MG		A203244	001	Jul 12, 2013	Jul NEWA
<u>GABAPENTIN ENACARBIL</u>							
TABLET, EXTENDED RELEASE;ORAL							
HORIZANT							
	XENOPORT INC	300MG		N022399	002	Dec 13, 2011	May CAHN
	+	600MG		N022399	001	Apr 06, 2011	May CAHN
<u>GADOTERATE MEGLUMINE</u>							
SOLUTION;INTRAVENOUS							
DOTAREM							
+	GUERBET	3.769GM/10ML (376.9MG/ML)		N204781	002	Mar 20, 2013	Mar NEWA
+		5.6535GM/15ML (376.9MG/ML)		N204781	003	Mar 20, 2013	Mar NEWA
+		7.538GM/20ML (376.9MG/ML)		N204781	004	Mar 20, 2013	Mar NEWA
+		37.69GM/100ML (376.9MG/ML)		N204781	001	Mar 20, 2013	Mar NEWA
<u>GADOXETATE DISODIUM</u>							
SOLUTION;INTRAVENOUS							
EOVIST							
	BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)		N022090	002	Feb 04, 2013	Feb NEWA
<u>GALLIUM NITRATE</u>							
INJECTABLE;INJECTION							
GANITE							
	@ CHAPTER 7 TRUSTEE	25MG/ML		N019961	002	Jan 17, 1991	Jul CAHN
	@ GENTA	25MG/ML		N019961	002	Jan 17, 1991	Jul DISC
<u>GANCICLOVIR</u>							
IMPLANT;IMPLANTATION							
VITRASERT							
	@ BAUSCH AND LOMB	4.5MG		N020569	001	Mar 04, 1996	May DISC
<u>GANCICLOVIR SODIUM</u>							
INJECTABLE;INJECTION							
GANCICLOVIR							
AP	PHARMAFORCE	EQ 500MG BASE/VIAL		A202624	001	Sep 18, 2013	Aug NEWA
<u>GANIRELIX ACETATE</u>							
INJECTABLE;INJECTION							
GANIRELIX ACETATE							
+	ORGANON USA INC	EQ 250MCG BASE/0.5ML		N021057	001	Jul 29, 1999	Aug CTNA
<u>GATIFLOXACIN</u>							
SOLUTION/DROPS;OPHTHALMIC							
GATIFLOXACIN							
	@ APOTEX INC	0.3%		A079084	001	Aug 19, 2011	Apr DISC
AT	LUPIN LTD	0.5%		A202653	001	Aug 28, 2013	Aug NEWA
ZYMEXID							
AT	+	ALLERGAN	0.5%	N022548	001	May 18, 2010	Aug CFTG
<u>GEMCITABINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
GEMCITABINE HYDROCHLORIDE							
AP	CIPLA LTD	EQ 1GM BASE/VIAL		A078759	002	Jul 25, 2011	Jul CAHN

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul CAHN
AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997	001	May 07, 2013	Apr NEWA
AP	JIANGSU HANSON PHARM	EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Apr NEWA
AP	LUITPOLD	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Aug CAHN
AP		EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Aug CAHN
AP	PHARMAFORCE	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Apr NEWA
AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Apr NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	CARACO	600MG	A079239	001	Dec 29, 2008	Jun CAHN
----	--------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982	Aug DISC
AP		EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Aug NEWA
	@	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982	Aug DISC
AP	+	EQ 40MG BASE/ML	A062366	001	Aug 04, 1983	Aug CRLD

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jun CAHN
----	----------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Jun CAHN
----	----------------------	--------------	---------	-----	--------------	----------

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

	@ TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996	Apr CAHN
--	-------------------	-----------	---------	-----	--------------	----------

INJECTABLE;SUBCUTANEOUS

COPAXONE

	+ TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Apr CAHN
--	-------------------	---------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

	@ COREPHARMA	1MG	A077274	001	Oct 06, 2005	Feb DISC
	@	2MG	A077274	002	Oct 06, 2005	Feb DISC
	@	4MG	A077274	003	Oct 06, 2005	Feb DISC
AB	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Jul NEWA
AB		2MG	A078952	002	Aug 01, 2013	Jul NEWA
AB		4MG	A078952	003	Aug 01, 2013	Jul NEWA
AB	INDOCO REMEDIES	1MG	A202112	001	Apr 17, 2013	Apr NEWA
AB		2MG	A202112	002	Apr 17, 2013	Apr NEWA
AB		4MG	A202112	003	Apr 17, 2013	Apr NEWA
AB	MICRO LABS LTD INDIA	1MG	A091220	001	Jun 29, 2012	Jul CAHN
AB		2MG	A091220	002	Jun 29, 2012	Jul CAHN
		3MG	A091220	003	Jun 29, 2012	Jul CAHN
AB		4MG	A091220	004	Jun 29, 2012	Jul CAHN
		6MG	A091220	005	Jun 29, 2012	Jul CAHN
AB		8MG	A091220	006	Jun 29, 2012	Jul CAHN
	@ MYLAN	1MG	A077486	001	Feb 10, 2006	Aug DISC
	@	2MG	A077486	002	Feb 10, 2006	Aug DISC
	@	4MG	A077486	003	Feb 10, 2006	Aug DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	Apr CAHN
AB		10MG	A074550	002	Sep 11, 1997	Apr CAHN
	@ BARR LABS INC	5MG	A074619	001	Apr 04, 1997	May CAHN
	@	10MG	A074619	002	Apr 04, 1997	May CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

>A> AB	PAR PHARM	5MG	A076159	002	Sep 20, 2013	Sep NEWA
--------	-----------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
GLIPIZIDE

>A> AB 10MG A076159 001 Sep 20, 2013 Sep NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL
RAVICTI

+ HYPERION THERAP INC 1.1GM/ML N203284 001 Feb 01, 2013 Feb NEWA

GLYCOPYRROLATE

INJECTABLE;INJECTION
ROBINUL

AP + HIKMA MAPLE 0.2MG/ML N017558 001 Apr CAHN

TABLET;ORAL

GLYCOPYRROLATE

AA AUROLIFE PHARMA LLC 1MG A202675 001 Apr 15, 2013 Apr NEWA
@ COREPHARMA 1MG A040568 001 Dec 22, 2004 Mar DISC
@ 2MG A040568 002 Dec 22, 2004 Mar DISC
@ WEST WARD 1MG A040836 001 Mar 05, 2009 Jul DISC
@ 2MG A040836 002 Mar 05, 2009 Jul DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

@ APOTEX INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078197 001 Dec 31, 2007 Apr DISC
@ EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078198 001 Jun 30, 2008 Apr DISC
@ EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078198 002 Jun 30, 2008 Apr DISC
@ EBEWE PHARMA EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078808 001 Apr 29, 2008 Feb DISC
AP + TEVA PHARMS USA EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078392 001 Dec 31, 2007 May CAHN
AP + EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077963 001 Jan 03, 2008 May CAHN
AP + EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077297 001 Jun 30, 2008 May CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
@ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077165 001 Dec 31, 2007 May CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL
GRIFULVIN V

AB + VALEANT LUXEMBOURG 125MG/5ML A062483 001 Jan 26, 1984 Apr CAHN

TABLET;ORAL

GRISEOFULVIN

SANDOZ 250MG A091592 001 Aug 07, 2013 Jul NEWA
AB 500MG A091592 002 Aug 07, 2013 Jul NEWA

GUANFACINE HYDROCHLORIDE

TABLET;ORAL
GUANFACINE HYDROCHLORIDE

@ EPIC PHARMA LLC EQ 1MG BASE A074673 001 Feb 28, 1997 Jun DISC
@ EQ 2MG BASE A074673 002 Feb 28, 1997 Jun DISC

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL
HALOBETASOL PROPIONATE

@ FOUGERA PHARMS 0.05% A076903 001 Dec 16, 2004 Apr DISC
@ G AND W LABS INC 0.05% A077109 001 Jun 14, 2005 Jun CAHN
@ TARO 0.05% A076994 001 Dec 16, 2004 Mar DISC

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

@ AGILA SPECLTS EQ 50MG BASE/ML A075440 001 Feb 28, 2000 Aug CAHN
@ EQ 100MG BASE/ML A075440 002 Feb 28, 2000 Aug CAHN
@ EQ 100MG BASE/ML A075440 002 Feb 28, 2000 Aug CAHN
@ APOTEX INC EQ 50MG BASE/ML A075440 001 Feb 28, 2000 Apr DISC
@ EQ 100MG BASE/ML A075440 002 Feb 28, 2000 Apr DISC
AO TEVA PHARMS USA EQ 50MG BASE/ML A075393 001 May 11, 1999 Jun CAHN
AO EQ 100MG BASE/ML A075393 002 May 11, 1999 Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

INJECTABLE; INJECTION
HALOPERIDOL

	@	APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr DISC
	@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr DISC
AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP	+	HIKMA MAPLE	1,000 UNITS/ML	N017037	001		Aug CAHN
AP	+		5,000 UNITS/ML	N017037	002		Aug CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Aug CAHN
AP	+		10,000 UNITS/ML	N017037	003		Aug CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

>D>	AB	NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011	Sep CTEC
>A>	AA		1.5MG; 5MG	A091528	001	Apr 20, 2011	Sep CTEC
		TUSSIGON					
>D>	AB	+ KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Sep CTEC
>A>	AA	+	1.5MG; 5MG	A088508	001	Jul 30, 1985	Sep CTEC

HYALURONIDASE

INJECTABLE; INJECTION
VITRASE

	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	May CAHN
	@		6,200 UNITS/VIAL	N021640	001	May 05, 2004	May CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP		NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar NEWA
----	--	-------------	---------	---------	-----	--------------	----------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr CAHN
AA			25MG	A091679	002	Mar 04, 2013	Apr CAHN
AA			50MG	A091679	003	Mar 04, 2013	Apr CAHN
AA			100MG	A091679	004	Mar 04, 2013	Apr CAHN
AA		ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Feb NEWA
AA			25MG	A091679	002	Mar 04, 2013	Feb NEWA
AA			50MG	A091679	003	Mar 04, 2013	Feb NEWA
AA			100MG	A091679	004	Mar 04, 2013	Feb NEWA
AA		ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr CTEC
AA			25MG	A200737	002	Dec 07, 2012	Apr CTEC
AA			50MG	A200737	003	Dec 07, 2012	Apr CTEC
AA			100MG	A200737	004	Dec 07, 2012	Apr CTEC
AA		HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr CAHN
AA			25MG	A040901	002	Sep 12, 2008	Apr CAHN
AA			50MG	A040901	003	Sep 12, 2008	Apr CAHN
AA			100MG	A040901	004	Sep 12, 2008	Apr CAHN
AA		STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr NEWA
AA			50MG	A200770	002	May 03, 2013	Apr NEWA
AA			100MG	A200770	003	May 03, 2013	Apr NEWA
	@	ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Jun DISC
	@		25MG	A040858	002	Feb 26, 2010	Jun DISC
	@		50MG	A040858	003	Feb 26, 2010	Jun DISC
	@		100MG	A040858	004	Feb 26, 2010	Jun DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar DISC
--	---	-------------	------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	12.5MG; 150MG	A203630	001	Feb 22, 2013	Feb NEWA
AB			12.5MG; 300MG	A203630	002	Feb 22, 2013	Feb NEWA
AB		LUPIN LTD	12.5MG; 150MG	A201524	001	Feb 27, 2013	Feb NEWA
AB			12.5MG; 300MG	A201524	002	Feb 27, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013	Feb NEWA
AB		12.5MG;100MG	A201682	002	Mar 01, 2013	Feb NEWA
AB		25MG;100MG	A201682	003	Mar 01, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	+ WYETH PHARMS INC	25MG;40MG	N018031	001		Jul CAHN
----	--------------------	-----------	---------	-----	--	----------

INDERIDE-80/25

@ WYETH PHARMS INC 25MG;80MG

N018031	002		Jul CAHN
---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D> AB	WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986	Sep DISC
>A>	@	25MG;40MG	A070301	001	Apr 18, 1986	Sep DISC
>D> AB		25MG;80MG	A070305	001	Apr 18, 1986	Sep DISC
>A>	@	25MG;80MG	A070305	001	Apr 18, 1986	Sep DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

AB	+ MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	May CAHN
----	--------------------	-----------	---------	-----	--------------	----------

MAXZIDE-25

AB	MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	May CAHN
----	------------------	-------------	---------	-----	--------------	----------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan DISC
---------------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A201662	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A201662	005	Mar 21, 2013	Mar NEWA
AB	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A203026	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A203026	005	Mar 21, 2013	Mar NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A202519	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A202519	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A202519	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A202519	005	Mar 21, 2013	Mar NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A078946	004	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A078946	001	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A078946	005	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A078946	002	Mar 21, 2013	Mar NEWA
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013	Apr NEWA
AB		12.5MG;160MG	A203145	002	Apr 19, 2013	Apr NEWA
AB		12.5MG;320MG	A203145	003	Apr 19, 2013	Apr NEWA
AB		25MG;160MG	A203145	004	Apr 19, 2013	Apr NEWA
AB		25MG;320MG	A203145	005	Apr 19, 2013	Apr NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A091519	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A091519	005	Mar 21, 2013	Mar NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May NEWA
AB		5MG;200MG	A091633	002	May 28, 2013	May NEWA
AB		7.5MG;200MG	A091633	003	May 28, 2013	May NEWA
AB		10MG;200MG	A091633	004	May 28, 2013	May NEWA
REPREXAIN						
AB	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May CFTG
AB		10MG;200MG	A076642	004	Oct 19, 2007	May CFTG

HYDROCORTISONE

LOTION;TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT;TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATE

PASTE;TOPICAL

ORABASE HCA

@ COLGATE

0.5%

A083205 001 Mar DISC

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL

CARMOL HC

@ FOUGERA PHARMS

1%;10%

A080505 001 Aug DISC

U-CORT

TARO

1%;10%

A089472 001 Jun 13, 1988 Aug CTEC

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE

>A>

AB

GLENMARK GENERICS

0.1%

A202145 001 Sep 27, 2013 Sep NEWA

LOCOID LIPOCREAM

>D>

+

PRECISION DERMAT

0.1%

N020769 001 Sep 08, 1997 Sep CTEC

>A>

AB

+

PRECISION DERMAT

0.1%

N020769 001 Sep 08, 1997 Sep CTEC

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

@ FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001 Feb DISC

+

TARO

0.2%

A075043 001 Aug 25, 1998 Feb CRLD

WESTCORT

@ RANBAXY

0.2%

N018726 001 Aug 08, 1983 Feb DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EXALGO

MALLINCKRODT INC

16MG

N021217 003 Mar 01, 2010 Jan CRLD

+

32MG

N021217 004 Aug 24, 2012 Jan CRLD

HYDROXYUREA

CAPSULE;ORAL

HYDROXYUREA

@ BARR LABS INC

250MG

A075020 002 Jun 26, 2000 Jun CAHN

@

500MG

A075020 001 Jul 30, 1998 Jun CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA

SILARX PHARMS INC

10MG/5ML

A201674 001 Aug 21, 2013 Jul NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB

CARACO

10MG

A040899 001 Jun 10, 2008 Jun CAHN

AB

25MG

A040899 002 Jun 10, 2008 Jun CAHN

AB

50MG

A040899 003 Jun 10, 2008 Jun CAHN

AB

HETERO LABS LTD III

10MG

A040805 001 May 29, 2008 Apr CAHN

AB

25MG

A040805 002 May 29, 2008 Apr CAHN

AB

50MG

A040805 003 May 29, 2008 Apr CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL							
HYDROXYZINE PAMOATE							
AB	EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	May	NEWA
AB		50MG	A201507	002	Jun 03, 2013	May	NEWA

IBUPROFEN

SOLUTION; INTRAVENOUS							
CALDOLOR							
	@ CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	May	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS							
NEOPROFEN							
+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	May	CAHN

ICOSAPENT ETHYL

CAPSULE; ORAL							
VASCEPA							
+	AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	Jun	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION							
IDARUBICIN HYDROCHLORIDE PFS							
AP	TEVA PHARMS USA	1MG/ML	A065036	001	May 01, 2002	Apr	CAHN

IFOSFAMIDE

		INJECTABLE; INJECTION											
		IFOSFAMIDE											
AP	+	TEVA PHARMS USA	1GM/20ML (50MG/ML)			A076657	001	Apr 04, 2007	May	CAHN			
AP	+		3GM/60ML (50MG/ML)			A076657	002	Apr 04, 2007	May	CAHN			

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS							
IFOSFAMIDE/MESNA KIT							
+	TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002	May	CAHN
+		3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002	May	CAHN

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL							
IMIPRAMINE HYDROCHLORIDE							
	@ PROSAM LABS	10MG	A040753	001	Feb 28, 2008	Mar	DISC
	@	25MG	A040752	001	Feb 28, 2008	Mar	DISC
	@	50MG	A040751	001	Feb 28, 2008	Mar	DISC

IMIPRAMINE PAMOATE

CAPSULE; ORAL							
IMIPRAMINE PAMOATE							
AB	MYLAN PHARMS INC	EQ 75MG HCL	A202338	001	Jun 28, 2013	Jun	NEWA
AB		EQ 100MG HCL	A202338	002	Jun 28, 2013	Jun	NEWA
AB		EQ 125MG HCL	A202338	003	Jun 28, 2013	Jun	NEWA
AB		EQ 150MG HCL	A202338	004	Jun 28, 2013	Jun	NEWA

INDINAVIR SULFATE

CAPSULE; ORAL							
CRIXIVAN							
	@ MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000	Jun	DISC

INDOMETHACIN

CAPSULE; ORAL							
INDOCIN							
	@ ICEUTICA OPERATIONS	25MG	N016059	001		Mar	CAHN
	@	50MG	N016059	002		Mar	CAHN
INDOMETHACIN							
AB	CARACO	25MG	A091401	001	Mar 28, 2013	Jun	CAHN
AB		50MG	A091401	002	Mar 28, 2013	Jun	CAHN
AB	HETERO LABS LTD III	25MG	A091240	001	Apr 12, 2011	Apr	CAHN
AB		50MG	A091240	002	Apr 12, 2011	Apr	CAHN
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Mar	NEWA

CAPSULE;ORAL							
INDOMETHACIN							
AB		50MG		A091401	002	Mar 28, 2013	Mar NEWA
<u>INDOMETHACIN SODIUM</u>							
INJECTABLE;INJECTION							
INDOCIN							
AP	+	RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	May CAHN
<u>INSULIN GLARGINE RECOMBINANT</u>							
INJECTABLE;INJECTION							
LANTUS SOLOSTAR							
+		SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081	002	Apr 27, 2007	Aug NEWA
<u>IPRATROPIUM BROMIDE</u>							
SOLUTION;INHALATION							
IPRATROPIUM BROMIDE							
	@	APOTEX INC	0.02%	A075441	001	Mar 28, 2001	Apr DISC
	@	TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000	Mar DISC
SPRAY, METERED;NASAL							
IPRATROPIUM BROMIDE							
	@	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Apr DISC
	@		0.042MG/SPRAY	A076155	001	Apr 18, 2003	Apr DISC
<u>IRINOTECAN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
IRINOTECAN HYDROCHLORIDE							
>D>	AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Sep CAHN
>D>	AP		100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Sep CAHN
>D>	AP		500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Sep CAHN
>A>	AP	TEVA PHARMS USA	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Sep CAHN
>A>	AP		100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Sep CAHN
>A>	AP		500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Sep CAHN
<u>IRON SUCROSE</u>							
INJECTABLE;INTRAVENOUS							
VENOFER							
>D>		LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Sep DISC
>A>		@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Sep DISC
			EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Mar NEWA
<u>ISONIAZID</u>							
TABLET;ORAL							
ISONIAZID							
	@	MIKART	100MG	A040090	001	Jun 26, 1997	Aug DISC
	@		300MG	A040090	002	Jun 26, 1997	Aug DISC
	@	WATSON LABS	300MG	A080521	001		Jun DISC
<u>ISONIAZID; RIFAMPIN</u>							
CAPSULE;ORAL							
RIFAMATE							
+		SANOFI AVENTIS US	150MG;300MG	A061884	001		Apr CTEC
RIFAMPIN AND ISONIAZID							
	@	WEST WARD PHARM CORP	150MG;300MG	A065221	001	Jul 29, 2005	Apr DISC
<u>ISOPROTERENOL HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
ISOPROTERENOL HYDROCHLORIDE							
	@	INTL MEDICATION	0.2MG/ML	A083724	001		Mar DISC
ISUPREL							
+		HOSPIRA	0.2MG/ML	N010515	001		Mar CTEC
<u>ISOSORBIDE DINITRATE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
DILATRATE-SR							
+		ACTIENT PHARMS	40MG	N019790	001	Sep 02, 1988	May CAHN
TABLET;ORAL							
ISORDIL							
AB		VALEANT BERMUDA	5MG	N012093	007	Jul 29, 1988	Apr CAHN

TABLET;ORAL							
ISORDIL							
AB		10MG	N012093	002	Jul 29, 1988	Apr	CAHN
AB		20MG	N012093	006	Jul 29, 1988	Apr	CAHN
AB	+	30MG	N012093	005	Jul 29, 1988	Apr	CAHN
	+	40MG	N012093	001	Jul 29, 1988	Apr	CAHN
AB	VALEANT PHARM NORTH	5MG	N012093	007	Jul 29, 1988	Mar	CAHN
AB		10MG	N012093	002	Jul 29, 1988	Mar	CAHN
AB		20MG	N012093	006	Jul 29, 1988	Mar	CAHN
AB	+	30MG	N012093	005	Jul 29, 1988	Mar	CAHN
	+	40MG	N012093	001	Jul 29, 1988	Mar	CAHN
ISOSORBIDE DINITRATE							
AB	PAR PHARM	5MG	A086923	001	Mar 12, 1987	Apr	CMFD
	@	5MG	A086923	001	Mar 12, 1987	Feb	DISC
	@ WATSON LABS	5MG	A086034	001	Jan 06, 1988	Apr	DISC
	@	10MG	A086032	001	Jan 07, 1988	Apr	DISC
TABLET;SUBLINGUAL							
ISOSORBIDE DINITRATE							
	@ WATSON LABS	2.5MG	A086033	001	Feb 26, 1988	Jun	DISC
	@	5MG	A086031	001	Sep 29, 1987	Jun	DISC
	@ WEST WARD	2.5MG	A086054	001	Oct 29, 1987	Aug	DISC
	@ WEST WARD PHARM CORP	5MG	A086055	001	Nov 02, 1987	Aug	DISC
AB	+	5MG	A086055	001	Nov 02, 1987	Jun	CRLD
<u>ISOTRETINOIN</u>							
CAPSULE;ORAL							
ABSORICA							
BX	RANBAXY	10MG	N021951	001	May 25, 2012	Feb	CAHN
BX		20MG	N021951	002	May 25, 2012	Feb	CAHN
BX		30MG	N021951	003	May 25, 2012	Feb	CAHN
BX	+	40MG	N021951	004	May 25, 2012	Aug	CRLD
BX		40MG	N021951	004	May 25, 2012	Feb	CAHN
AMNESTEEM							
AB	MYLAN PHARMS INC	20MG	A075945	002	Nov 08, 2002	Apr	CRLD
CLARAVIS							
AB	TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	May	CAHN
AB		30MG	A076135	003	May 11, 2006	Apr	CRLD
AB	+	40MG	A076135	001	Apr 11, 2003	Apr	CRLD
ZENATANE							
AB	DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar	NEWA
AB		20MG	A202099	002	Mar 25, 2013	Mar	NEWA
AB		40MG	A202099	003	Mar 25, 2013	Mar	NEWA
<u>ISRADIPINE</u>							
TABLET, EXTENDED RELEASE;ORAL							
DYNACIRC CR							
	@ GLAXOSMITHKLINE LLC	5MG	N020336	001	Jun 01, 1994	Jun	DISC
	@	10MG	N020336	002	Jun 01, 1994	Jun	DISC
<u>KETOROLAC TROMETHAMINE</u>							
INJECTABLE;INJECTION							
KETOROLAC TROMETHAMINE							
	@ APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001	Apr	DISC
	@	30MG/ML	A075626	001	Jul 24, 2001	Apr	DISC
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr	DISC
	@	30MG/ML	A077201	001	Oct 14, 2005	Apr	DISC
	@ LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008	Jun	DISC
	@	30MG/ML	A078145	002	Jan 14, 2008	Jun	DISC
SOLUTION/DROPS;OPHTHALMIC							
ACULAR PRESERVATIVE FREE							
	@ ALLERGAN	0.5%	N020811	001	Nov 03, 1997	May	DISC
<u>LABETALOL HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
LABETALOL HYDROCHLORIDE							
AP	AKORN INC	5MG/ML	A075431	001	Nov 29, 1999	Jul	CAHN
AP		5MG/ML	A075524	001	Nov 29, 1999	Jul	CAHN
	@ APOTEX INC	5MG/ML	A076051	001	Jul 05, 2002	Apr	DISC
TABLET;ORAL							
LABETALOL HYDROCHLORIDE							
AB	+	200MG	A075113	002	Aug 04, 1998	Jan	CRLD
TRANDATE							

TABLET;ORAL							
TRANDATE							
@ PROMETHEUS LABS		100MG	N018716	001	May 24, 1985	Jan	DISC
@		200MG	N018716	002	Aug 01, 1984	Jan	DISC
<u>LACTULOSE</u>							
SOLUTION;ORAL							
LACTULOSE							
@ APOTEX INC		10GM/15ML	A075911	001	Feb 21, 2002	Apr	DISC
SOLUTION;ORAL, RECTAL							
LACTULOSE							
@ APOTEX INC		10GM/15ML	A076645	001	Jul 28, 2003	Apr	DISC
<u>LAMOTRIGINE</u>							
TABLET;ORAL							
LAMICTAL							
AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Mar CAHN
	@		50MG	N020241	006	Dec 27, 1994	Mar CAHN
AB			100MG	N020241	001	Dec 27, 1994	Mar CAHN
AB			150MG	N020241	002	Dec 27, 1994	Mar CAHN
AB			200MG	N020241	003	Dec 27, 1994	Mar CAHN
	@		250MG	N020241	004	Dec 27, 1994	Mar CAHN
LAMOTRIGINE							
AB		ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013	Jun NEWA
AB			100MG	A200694	002	Jun 14, 2013	Jun NEWA
AB			150MG	A200694	003	Jun 14, 2013	Jun NEWA
AB			200MG	A200694	004	Jun 14, 2013	Jun NEWA
AB		CIPLA LTD	25MG	A077783	001	Nov 01, 2010	Aug CAHN
AB			100MG	A077783	002	Nov 01, 2010	Aug CAHN
AB			150MG	A077783	003	Nov 01, 2010	Aug CAHN
AB			200MG	A077783	004	Nov 01, 2010	Aug CAHN
TABLET, CHEWABLE;ORAL							
LAMICTAL CD							
AB		GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Mar CAHN
AB			5MG	N020764	001	Aug 24, 1998	Mar CAHN
AB	+		25MG	N020764	002	Aug 24, 1998	Mar CAHN
	@		100MG	N020764	003	Aug 24, 1998	Mar CAHN
TABLET, EXTENDED RELEASE;ORAL							
LAMICTAL XR							
AB		GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29, 2009	Mar CAHN
AB	+		50MG	N022115	002	May 29, 2009	Mar CAHN
AB			100MG	N022115	003	May 29, 2009	Mar CAHN
AB			200MG	N022115	004	May 29, 2009	Mar CAHN
AB			250MG	N022115	006	Jun 21, 2011	Mar CAHN
AB			300MG	N022115	005	Apr 14, 2010	Mar CAHN
LAMOTRIGINE							
AB		DR REDDYS LABS LTD	25MG	A202383	001	Jun 19, 2013	Jun NEWA
AB			50MG	A202383	002	Jun 19, 2013	Jun NEWA
AB			100MG	A202383	003	Jun 19, 2013	Jun NEWA
AB			200MG	A202383	004	Jun 19, 2013	Jun NEWA
AB			300MG	A202383	005	Jun 19, 2013	Jun NEWA
AB		PAR PHARM	25MG	A201791	001	Jan 18, 2013	Jan NEWA
AB			50MG	A201791	002	Jan 18, 2013	Jan NEWA
AB			100MG	A201791	003	Jan 18, 2013	Jan NEWA
AB			200MG	A201791	004	Jan 18, 2013	Jan NEWA
AB			250MG	A201791	005	Jan 18, 2013	Jan NEWA
AB			300MG	A201791	006	Jan 18, 2013	Jan NEWA
AB		WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013	Jun NEWA
AB			50MG	A202887	002	Jun 17, 2013	Jun NEWA
AB			100MG	A202887	003	Jun 17, 2013	Jun NEWA
AB			200MG	A202887	004	Jun 17, 2013	Jun NEWA
TABLET, ORALLY DISINTEGRATING;ORAL							
LAMICTAL ODT							
AB		GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009	Jul CFTG
			25MG	N022251	001	May 08, 2009	Mar CAHN
AB	+		50MG	N022251	002	May 08, 2009	Jul CFTG
	+		50MG	N022251	002	May 08, 2009	Mar CAHN
AB			100MG	N022251	003	May 08, 2009	Jul CFTG
			100MG	N022251	003	May 08, 2009	Mar CAHN
AB			200MG	N022251	004	May 08, 2009	Jul CFTG
			200MG	N022251	004	May 08, 2009	Mar CAHN
LAMOTRIGINE							

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB	WATSON LABS INC	25MG	A200828	001	Jul 15, 2013	Jul NEWA
AB		50MG	A200828	002	Jul 15, 2013	Jul NEWA
AB		100MG	A200828	003	Jul 15, 2013	Jul NEWA
AB		200MG	A200828	004	Jul 15, 2013	Jul NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	SUN PHARMA GLOBAL	15MG	A202637	001	Sep 13, 2013	Aug NEWA
AB		30MG	A091509	001	Sep 13, 2013	Aug NEWA
AB	ZYDUS HLTHCARE	15MG	A202366	001	Aug 19, 2013	Jul NEWA
AB		30MG	A202366	002	Aug 19, 2013	Jul NEWA
	LANSOPRAZOLE					
AB	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Aug NEWA
AB		30MG	A091212	002	Sep 16, 2013	Aug NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

	@ APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr DISC
AT	DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Jan NEWA

LENALIDOMIDE

CAPSULE;ORAL
REVLIMID

	CELGENE	20MG	N021880	006	Jun 05, 2013	Jun NEWA
--	---------	------	---------	-----	--------------	----------

LEPIRUDIN RECOMBINANT

INJECTABLE;INJECTION
REFLUDAN

	@ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998	Jun DISC
--	------------------	-----------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL
LETROZOLE

AB	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	Apr NEWA
----	---------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993	Mar CAHN
AP		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997	Mar CAHN
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	@ LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001	Jun DISC

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar CAHN
	LUPRON					
	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CAHN
	LUPRON DEPOT					
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul CAHN
+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jul CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jul CAHN
	LUPRON DEPOT-PED					
	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul CAHN
	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul CAHN
+		7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
+		11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
+		11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN
+		15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
+		30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar NEWA
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar NEWA
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar NEWA
AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr NEWA
AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr NEWA
AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun NEWA
----	---------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

>A>	AA	@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr DISC
>D>	AA	BRECKENRIDGE PHARM	100MG/ML	A079120	001	Jan 16, 2009	Sep CAHN
	AA	CYPRESS PHARM	100MG/ML	A079120	001	Jan 16, 2009	Sep CAHN
	AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb NEWA
	AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr CAHN
	AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr NEWA

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	1GM	A090515	004	Oct 08, 2010	Apr CAHN
AB		250MG	A090515	001	Oct 08, 2010	Apr CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr CAHN
AB	PRINSTON INC	1GM	A078106	004	Feb 10, 2009	Apr CAHN
AB		250MG	A078106	001	Feb 10, 2009	Apr CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@	SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar DISC
	@		750MG	A091668	002	Nov 01, 2012	Mar DISC
AB		SUN PHARMA GLOBAL	500MG	A203059	001	Sep 09, 2013	Aug NEWA
AB			750MG	A203059	002	Sep 09, 2013	Aug NEWA
AB		VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan NEWA
AB			750MG	A202533	002	Jul 20, 2012	Jan NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	TARO PHARM INDS	2.5MG/5ML	A202673	001	Jul 26, 2013	Jul NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Aug NEWA
AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan NEWA
AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS LIFESCIENCES	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Jul NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Jul NEWA

INJECTABLE;INJECTION							
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Jul	NEWA
AP	FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013	Jun	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013	Jun	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013	Jun	NEWA
SOLUTION/DROPS;OPHTHALMIC							
LEVOFLOXACIN							
	@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr	DISC
<u>LEVOMILNACIPRAN HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
FETZIMA							
	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jul	NEWA
		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jul	NEWA
		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jul	NEWA
+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jul	NEWA
<u>LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN							
	@ NOVOCOL	0.05MG/ML;2%	A084697	001		Jun	DISC
	SCANDONEST L						
+	DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984	Jun	CRLD
<u>LEVONORGESTREL</u>							
INTRAUTERINE DEVICE;INTRAUTERINE							
SKYLA							
+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jan	NEWA
TABLET;ORAL							
LEVONORGESTREL							
AB	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan	NEWA
AB	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb	NEWA
<u>LEVOTHYROXINE SODIUM **</u>							
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium							
TABLET;ORAL							
LEVOTHYROXINE SODIUM							
	@ MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005	Jul	DISC
	@	0.05MG	A076752	002	Jun 16, 2005	Jul	DISC
	@	0.075MG	A076752	003	Jun 16, 2005	Jul	DISC
	@	0.088MG	A076752	004	Jun 16, 2005	Jul	DISC
	@	0.1MG	A076752	005	Jun 16, 2005	Jul	DISC
	@	0.112MG	A076752	006	Jun 16, 2005	Jul	DISC
	@	0.125MG	A076752	007	Jun 16, 2005	Jul	DISC
	@	0.15MG	A076752	008	Jun 16, 2005	Jul	DISC
	@	0.175MG	A076752	009	Jun 16, 2005	Jul	DISC
	@	0.2MG	A076752	010	Jun 16, 2005	Jul	DISC
	@	0.3MG	A076752	011	Jun 16, 2005	Jul	DISC
LEVOXYL							
AB1,	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.05MG	N021301	002	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.075MG	N021301	003	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.088MG	N021301	004	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.1MG	N021301	005	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.112MG	N021301	006	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.125MG	N021301	007	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.137MG	N021301	008	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.15MG	N021301	009	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.175MG	N021301	010	May 25, 2001	Mar	CAHN
AB3							
AB1, +		0.2MG	N021301	011	May 25, 2001	Mar	CAHN
AB3							
	@	0.3MG	N021301	012	May 25, 2001	Mar	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	@ INTL MEDICATION	1%	A083173	001		Sep	CMFD
>A> AP		1%	A083173	001		Sep	CMFD
>D>	@	2%	A083173	002		Sep	CMFD
>A> AP		2%	A083173	002		Sep	CMFD
	@ LUITPOLD	2%	A083198	001		Mar	DISC

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar	NEWA
AP		1%	A203082	001	Mar 14, 2013	Mar	NEWA
AP		2%	A203040	002	Mar 14, 2013	Mar	NEWA
AP		2%	A203082	002	Mar 14, 2013	Mar	NEWA

JELLY; TOPICAL

ANESTACON

@ POLYMEDICA

LIDOCAINE HYDROCHLORIDE

@ TEVA PHARMS USA

A080429	001		May	DISC
---------	-----	--	-----	------

A081318	001	Apr 29, 1993	Jun	DISC
---------	-----	--------------	-----	------

LIDOCAINE; TETRACAINE

PATCH; TOPICAL

SYNERA

+	GALEN SPECIALTY	70MG; 70MG	N021623	001	Jun 23, 2005	Aug	CAHN
---	-----------------	------------	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB		EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	Jul	NEWA
AB		5MG	A202554	002	Jul 30, 2013	Jul	NEWA
AB		10MG	A202554	003	Jul 30, 2013	Jul	NEWA
AB		20MG	A202554	004	Jul 30, 2013	Jul	NEWA
AB		30MG	A202554	005	Jul 30, 2013	Jul	NEWA
AB		40MG	A202554	006	Jul 30, 2013	Jul	NEWA
	@ SANDOZ	2.5MG	A075903	001	Jul 01, 2002	Aug	DISC
	@	2.5MG	A075999	001	Jul 01, 2002	Jan	CAHN
	@	5MG	A075903	002	Jul 01, 2002	Aug	DISC
	@	5MG	A075999	002	Jul 01, 2002	Jan	CAHN
	@	10MG	A075903	003	Jul 01, 2002	Aug	DISC
	@	10MG	A075999	003	Jul 01, 2002	Jan	CAHN
	@	20MG	A075903	004	Jul 01, 2002	Aug	DISC
	@	20MG	A075999	004	Jul 01, 2002	Jan	CAHN
	@	30MG	A075903	005	Jul 01, 2002	Aug	DISC
	@	30MG	A075999	005	Jul 01, 2002	Jan	CAHN
	@	40MG	A075903	006	Jul 01, 2002	Aug	DISC
	@	40MG	A075999	006	Jul 01, 2002	Jan	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

@ APOTEX INC

		300MG	A076795	001	Nov 22, 2004	Feb	DISC
AB	HETERO LABS LTD III	150MG	A090702	001	Sep 25, 2009	Apr	CAHN
AB		300MG	A090702	002	Sep 25, 2009	Apr	CAHN
AB		600MG	A090702	003	Sep 25, 2009	Apr	CAHN

TABLET; ORAL

LITHIUM CARBONATE

@ WEST WARD

A078715	001	Dec 28, 2010	Aug	DISC
---------	-----	--------------	-----	------

LOMUSTINE

CAPSULE; ORAL

CEENU

CORDEN PHARMA

		10MG	N017588	001		Apr	CAHN
		40MG	N017588	002		Apr	CAHN
+		100MG	N017588	003		Apr	CAHN

LORAZEPAMCONCENTRATE; ORAL
LORAZEPAM

AA	LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013	Feb NEWA
	INJECTABLE; INJECTION					
	LORAZEPAM					

AP	AKORN	2MG/ML	A075025	001	Jul 23, 1998	Jul CAHN
>D> AP	WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994	Sep DISC
>A>	@	2MG/ML	A074276	001	Apr 15, 1994	Sep DISC
>D> AP		4MG/ML	A074276	002	Apr 15, 1994	Sep DISC
>A>	@	4MG/ML	A074276	002	Apr 15, 1994	Sep DISC
	TABLET; ORAL					
	LORAZEPAM					
	@ SANDOZ	0.5MG	A071193	001	Apr 15, 1988	Apr DISC
	@	1MG	A071194	001	Apr 15, 1988	Apr DISC
	@	2MG	A071195	001	Apr 15, 1988	Apr DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ACTAVIS GRP PTC	25MG	A090382	001	Oct 06, 2010	Mar CAHN
AB		50MG	A090382	002	Oct 06, 2010	Mar CAHN
AB		100MG	A090382	003	Oct 06, 2010	Mar CAHN
AB	IPCA LABS LTD	25MG	A200290	001	Aug 30, 2013	Aug NEWA
AB		50MG	A200290	002	Aug 30, 2013	Aug NEWA
AB		100MG	A200290	003	Aug 30, 2013	Aug NEWA

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	+ CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb CRLD
	MEVACOR					
	@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb DISC
	@	40MG	N019643	004	Dec 14, 1988	Feb DISC

LOXAPINEPOWDER; INHALATION
ADASUVE

+	TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Jul CAHN
---	---------------------	------	---------	-----	--------------	----------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CMFD
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CMFD
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CMFD
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CMFD

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

SUNOVION PHARMS INC	60MG	N200603	005	Jul 12, 2013	Jul NEWA
---------------------	------	---------	-----	--------------	----------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLLON

+	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001		May CAHN
---	---------------------	-----------------	---------	-----	--	----------

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

AB	PAR FORM	5%	A201511	001	Feb 12, 2013	Jan NEWA
	SULFAMYLLON					
AB	+ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	May CAHN
AB	+ MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jan CFTG

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Jan NEWA
---	----------------	---	---------	-----	--------------	----------

MANNITOL

INJECTABLE; INJECTION
MANNITOL 20%

@ B BRAUN 20GM/100ML N014738 001 Jan DISC

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA 2.5MG A204054 001 Mar 19, 2013 Mar NEWA

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL
VALCHLOR

>A> + ACTELION PHARMS LTD 0.02% N202317 001 Aug 23, 2013 Sep CAHN
>D> + CEPTARIS THERAP 0.02% N202317 001 Aug 23, 2013 Sep CAHN
+ 0.02% N202317 001 Aug 23, 2013 Aug NEWA

INJECTABLE; INJECTION
MUSTARGEN

+ RECORDATI RARE 10MG/VIAL N006695 001 May CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

>D> AB MYLAN EQ 50MG BASE A071081 002 Sep 03, 1986 Sep CTEC
>A> EQ 50MG BASE A071081 002 Sep 03, 1986 Sep CTEC
>D> AB + EQ 100MG BASE A071081 001 Sep 03, 1986 Sep CTEC
>A> + EQ 100MG BASE A071081 001 Sep 03, 1986 Sep CTEC
>D> AB WATSON LABS EQ 50MG BASE A071468 001 Apr 15, 1987 Sep DISC
>A> @ EQ 50MG BASE A071468 001 Apr 15, 1987 Sep DISC
>D> AB EQ 100MG BASE A071469 001 Apr 15, 1987 Sep DISC
>A> @ EQ 100MG BASE A071469 001 Apr 15, 1987 Sep DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

@ TEVA PHARMS USA 150MG/ML A076552 001 Oct 27, 2004 May CAHN
AB 150MG/ML A076553 001 Jul 28, 2004 May CAHN

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

>A> AB BRECKENRIDGE PHARM 250MG A090359 001 Feb 05, 2013 Sep CAHN
>D> AB CYPRESS PHARM 250MG A090359 001 Feb 05, 2013 Sep CAHN
AB 250MG A090359 001 Feb 05, 2013 Jan NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL
MEFLOQUINE HYDROCHLORIDE

@ WEST WARD PHARM CORP 250MG A077699 001 Apr 21, 2010 Jun DISC

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

@ APOTEX INC 40MG/ML A077404 001 Feb 16, 2006 Apr DISC

MELOXICAM

TABLET; ORAL
MELOXICAM

AB CIPLA LTD 7.5MG A077929 001 Jul 19, 2006 Aug CAHN
AB 15MG A077929 002 Jul 19, 2006 Aug CAHN
@ COREPHARMA 7.5MG A077930 001 Jul 19, 2006 Feb DISC
@ 15MG A077930 002 Jul 19, 2006 Feb DISC
@ CR DOUBLE CRANE 7.5MG A078039 001 Dec 14, 2006 Apr DISC
AB 7.5MG A078039 001 Dec 14, 2006 Mar CAHN
@ 15MG A078039 002 Dec 14, 2006 Apr DISC
AB 15MG A078039 002 Dec 14, 2006 Mar CAHN
@ MYLAN 7.5MG A077934 001 Jul 20, 2006 Aug DISC
@ 15MG A077934 002 Jul 20, 2006 Aug DISC

MEPROBAMATE

TABLET; ORAL

TABLET;ORAL
MEPROBAMATE

@ TARO 200MG
@ 400MG

A200998 001 May 23, 2011 Jan DISC
A200998 002 May 23, 2011 Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL
DELZICOL

+ WARNER CHILCOTT LLC 400MG

N204412 001 Feb 01, 2013 Feb NEWA

SUPPOSITORY;RECTAL
CANASA

+ APTALIS PHARMA US 1GM

N021252 002 Nov 05, 2004 Feb CRLD

MESNA

INJECTABLE;INTRAVENOUS
MESNA

AP TEVA PHARMS USA 100MG/ML

A075764 001 Apr 27, 2001 May CAHN

METAPROTERENOL SULFATE

SOLUTION;INHALATION
METAPROTERENOL SULFATE

@ APOTEX INC 0.4%
@ 0.6%

A075402 001 Feb 28, 2001 Apr DISC
A075403 001 Feb 28, 2001 Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

@ APOTEX INC 10MG/5ML
@ NOVEX 10MG/5ML
+ SILARX 10MG/5ML

A075235 001 Jan 27, 2000 Apr DISC
A075235 001 Jan 27, 2000 Feb DISC
A073632 001 Jul 22, 1992 Feb CTEC

TABLET;ORAL

METAPROTERENOL SULFATE

PAR PHARM 10MG
+ 20MG
@ WATSON LABS 10MG
@ 20MG

A072024 001 Jun 28, 1988 Mar CTEC
A072025 001 Jun 28, 1988 Mar CTEC
A073013 001 Jan 31, 1991 Mar DISC
A072795 001 Jan 31, 1991 Mar DISC

METAXALONE

TABLET;ORAL
METAXALONE

AB AMNEAL PHARMS 800MG

A203399 001 Jun 21, 2013 Jun NEWA

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB CHARTWELL LIFE SCI 1GM
AB 500MG
625MG
750MG
AB 850MG
AB SANDOZ 1GM
@ 1GM
AB 500MG
@ 500MG
AB 850MG
@ 850MG
AB SCIEGEN PHARMS INC 500MG
AB 850MG
AB 1GM

A075972 003 Jan 24, 2002 Aug CAHN
A075972 001 Jan 24, 2002 Aug CAHN
A075972 005 Jan 24, 2002 Aug CAHN
A075972 004 Jan 24, 2002 Aug CAHN
A075972 002 Jan 24, 2002 Aug CAHN
A075965 003 Jan 25, 2002 May CMFD
A075965 003 Jan 25, 2002 Mar DISC
A075965 001 Jan 25, 2002 May CMFD
A075965 001 Jan 25, 2002 Mar DISC
A075965 002 Jan 25, 2002 May CMFD
A075965 002 Jan 25, 2002 Mar DISC
A203769 001 Sep 11, 2013 Aug NEWA
A203769 002 Sep 11, 2013 Aug NEWA
A203769 003 Sep 11, 2013 Aug NEWA

TABLET, EXTENDED RELEASE;ORAL
FORTAMET

AB2 + ANDRX LABS LLC 1GM
GLUMETZA

N021574 002 Apr 27, 2004 Jul CTEC

AB3 + SANTARUS 1GM
AB3 500MG

N021748 002 Jun 03, 2005 Jul CTEC
N021748 001 Jun 03, 2005 Jul CTEC

METFORMIN HYDROCHLORIDE

>D> AB1 ALVOGEN 500MG
>D> AB 750MG
>A> AB1 CSPC OUYI PHARM CO 500MG
>A> AB 750MG
AB2 LUPIN LTD 1GM
AB3 1GM
AB3 500MG
AB2 MYLAN PHARMS INC 1GM

A078321 001 Apr 17, 2008 Sep CAHN
A078321 002 Apr 17, 2008 Sep CAHN
A078321 001 Apr 17, 2008 Sep CAHN
A078321 002 Apr 17, 2008 Sep CAHN
A090692 002 Jun 29, 2011 Jul CTEC
A091664 002 Jul 19, 2013 Jul NEWA
A091664 001 Jul 19, 2013 Jul NEWA
A200690 002 Aug 01, 2012 Jul CTEC

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

@ TORRENT PHARMS LTD 750MG
@ WATSON LABS INC 500MG

A079226 001 Feb 18, 2010 Jun DISC
A076818 001 Dec 14, 2004 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB AUROBINDO PHARMA LTD 500MG;EQ 15MG BASE
AB 850MG;EQ 15MG BASE
AB SANDOZ 500MG;EQ 15MG BASE
AB 850MG;EQ 15MG BASE
AB TORRENT PHARMS LTD 500MG;EQ 15MG BASE
AB 850MG;EQ 15MG BASE

A200823 001 Feb 13, 2013 Jan NEWA
A200823 002 Feb 13, 2013 Jan NEWA
A091273 001 Apr 16, 2013 Apr NEWA
A091273 002 Apr 16, 2013 Apr NEWA
A202001 001 Feb 13, 2013 Jan NEWA
A202001 002 Feb 13, 2013 Jan NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA MALLINCKRODT INC 40MG
AA + ROXANE 40MG
AA SANDOZ 40MG
METHADOSE
AA MALLINCKRODT 40MG

A077142 001 Jul 12, 2005 Mar CDFR
N017058 001 Mar CDFR
A075082 001 Mar 25, 1998 Mar CDFR
A074184 001 Apr 29, 1993 Mar CDFR

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA + RECORDATI RARE 5MG

N005378 002 May CAHN

METHOCARBAMOL

INJECTABLE;INJECTION

METHOCARBAMOL

@ WATSON LABS 100MG/ML
ROBAXIN

A086459 001 Jul DISC

>D> + BAXTER HLTHCARE CORP 100MG/ML
+ 100MG/ML
>A> + HIKMA MAPLE 100MG/ML

N011790 001 Sep CAHN
N011790 001 Jul CTEC
N011790 001 Sep CAHN

TABLET;ORAL

METHOCARBAMOL

AA AUSTARPHARMA LLC 500MG
@ 500MG
AA 750MG
AA HETERO LABS LTD III 500MG
AA 750MG
AA PRINSTON INC 500MG
AA 750MG
AA @ SOLCO HLTHCARE 500MG

A200958 001 Oct 21, 2011 May CMFD
A200958 001 Oct 21, 2011 Jan DISC
A200958 002 Oct 21, 2011 May CMFD
A090200 001 Nov 06, 2009 Apr CAHN
A090200 002 Nov 06, 2009 Apr CAHN
A086989 001 Feb CMFD
A086988 001 Feb CAHN
A086989 001 Jan DISC

METHOXSALEN

CAPSULE;ORAL

OXSORALEN-ULTRA

+ DOW PHARM 10MG

N019600 001 Oct 30, 1986 Apr CAHN

METHYCLOTHIAZIDE

TABLET;ORAL

METHYCLOTHIAZIDE

+ MYLAN PHARMS INC 5MG
@ WATSON LABS 5MG

A087672 001 Aug 17, 1982 Jan CTEC
A088724 001 Sep 06, 1984 Jan DISC

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM;TOPICAL

METVIXIA

@ GALDERMA LABS LP EQ 16.8% BASE

N021415 001 Jul 27, 2004 Jun DISC

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ ACCORD HLTHCARE 125MG
AB 250MG
AB 500MG

A070070 003 Oct 15, 1985 Apr CAHN
A070084 001 Oct 15, 1985 Apr CAHN
A070085 001 Oct 15, 1985 Apr CAHN

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
METADATE CD

>D>	AB	UCB INC	10MG	N021259	003	May 27, 2003	Sep CTEC
>A>	AB2		10MG	N021259	003	May 27, 2003	Sep CTEC
>D>	AB		50MG	N021259	005	Feb 19, 2006	Sep CTEC
>A>	AB2		50MG	N021259	005	Feb 19, 2006	Sep CTEC
>D>	AB	+	60MG	N021259	006	Feb 19, 2006	Sep CTEC
>A>	AB2	+	60MG	N021259	006	Feb 19, 2006	Sep CTEC

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	TEVA PHARMS	10MG	A077707	001	Jul 19, 2012	Sep CTEC
>A>	AB2		10MG	A077707	001	Jul 19, 2012	Sep CTEC
>D>	AB		50MG	A078873	002	Jul 19, 2012	Sep CTEC
>A>	AB2		50MG	A078873	002	Jul 19, 2012	Sep CTEC
>D>	AB		60MG	A078873	003	Jul 19, 2012	Sep CTEC
>A>	AB2		60MG	A078873	003	Jul 19, 2012	Sep CTEC
	AB1	WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Apr CAHN
	AB1		30MG	A078458	002	Dec 01, 2011	Apr CAHN
	AB1		40MG	A078458	003	Dec 01, 2011	Apr CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CARACO	5MG	A090710	001	Mar 15, 2012	May CAHN
AB		10MG	A090710	002	Mar 15, 2012	May CAHN
AB		20MG	A090710	003	Mar 15, 2012	May CAHN

TABLET, EXTENDED RELEASE;ORAL
CONCERTA

AB	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Jun CTEC
	METHYLIN ER					
	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Feb CTEC
	METHYLPHENIDATE HYDROCHLORIDE					
AB	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013	Jun NEWA
AB		27MG	A091695	002	Jul 09, 2013	Jun NEWA
>A>	AB	36MG	A091695	003	Sep 23, 2013	Sep NEWA
>A>	AB	54MG	A091695	004	Sep 23, 2013	Sep NEWA

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	TEVA PHARMS USA	40MG/ML	A040557	001	Feb 23, 2005	May CAHN
AB		40MG/ML	A040620	001	Oct 27, 2006	May CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	May CAHN
AB		80MG/ML	A040620	002	Oct 27, 2006	May CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

AP	BD RX	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Apr NEWA
	@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Feb DISC
	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

METOZOLV ODT

+	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Jul CRLD
@		EQ 10MG BASE	N022246	002	Sep 04, 2009	Jul DISC

METOLAZONE

TABLET;ORAL

METOLAZONE

@	TEVA	2.5MG	A076600	001	Jan 06, 2004	Mar DISC
@		5MG	A076833	001	Mar 01, 2004	Jun DISC
@		10MG	A075543	003	Dec 24, 2003	May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@	NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Feb DISC
@		EQ 50MG TARTRATE	A077176	001	May 14, 2008	May DISC

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr NEWA
----	---------------------	--------	---------	-----	--------------	----------

INJECTABLE; INJECTION
METOPROLOL TARTRATE

	@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar	DISC
	TABLET; ORAL						
	METOPROLOL TARTRATE						
AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013	May	NEWA
AB		50MG	A202871	002	May 28, 2013	May	NEWA
AB		100MG	A202871	003	May 28, 2013	May	NEWA
	@ PRINSTON INC	50MG	A074453	001	Apr 27, 1995	Mar	CAHN
	@	100MG	A074453	002	Apr 27, 1995	Mar	CAHN

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984	Mar	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

METYSOSINE

CAPSULE; ORAL
DEMSEER

+	ATON PHARMA VPNA	250MG	N017871	001		Jun	CAHN
---	------------------	-------	---------	-----	--	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HYDROCHLORIDE

>D>	AB	TEVA	150MG	A074377	001	May 16, 1995	Sep	CTEC
>A>			150MG	A074377	001	May 16, 1995	Sep	CTEC
>D>	AB		200MG	A074377	002	May 16, 1995	Sep	CTEC
>A>			200MG	A074377	002	May 16, 1995	Sep	CTEC
>D>	AB	+	250MG	A074377	003	May 16, 1995	Sep	CTEC
>A>		+	250MG	A074377	003	May 16, 1995	Sep	CTEC
>D>	AB	WATSON LABS	150MG	A074711	001	Feb 26, 1997	Sep	DISC
>A>		@	150MG	A074711	001	Feb 26, 1997	Sep	DISC
>D>	AB		150MG	A074865	001	Apr 13, 1998	Sep	DISC
>A>		@	150MG	A074865	001	Apr 13, 1998	Sep	DISC
>D>	AB		200MG	A074711	002	Feb 26, 1997	Sep	DISC
>A>		@	200MG	A074711	002	Feb 26, 1997	Sep	DISC
>D>	AB		200MG	A074865	002	Apr 13, 1998	Sep	DISC
>A>		@	200MG	A074865	002	Apr 13, 1998	Sep	DISC
>D>	AB		250MG	A074711	003	Feb 26, 1997	Sep	DISC
>A>		@	250MG	A074711	003	Feb 26, 1997	Sep	DISC
>D>	AB		250MG	A074865	003	Apr 13, 1998	Sep	DISC
>A>		@	250MG	A074865	003	Apr 13, 1998	Sep	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul	CAHN
AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul	CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul	CAHN
	@ APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	DISC
	@ CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan	DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan	DISC
	@ INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005	Jun	DISC
	@	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005	Jun	DISC
	@ INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May	DISC
	@	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May	DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE
@ APOTEX INC

EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr	DISC
----------------	---------	-----	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

@ APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr	DISC
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
@ APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr	DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL								
MINOCYCLINE HYDROCHLORIDE								
AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr	NEWA	
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr	NEWA	
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr	NEWA	
CAPSULE, EXTENDED RELEASE;ORAL								
XIMINO								
	@ RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May	DISC	
	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May	DISC	
	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	May	DISC	
	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May	DISC	
	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	May	DISC	
TABLET, EXTENDED RELEASE;ORAL								
SOLODYN								
	@ MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr	DISC	
+		EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr	CRLD	
+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr	CRLD	
	@	EQ 135MG BASE	N050808	003	May 08, 2006	Apr	DISC	
<u>MIPOMERSEN SODIUM</u>								
SOLUTION;SUBCUTANEOUS								
KYNAMRO								
+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jan	NEWA	
<u>MIRTAZAPINE</u>								
TABLET, ORALLY DISINTEGRATING;ORAL								
MIRTAZAPINE								
	@ ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jun	DISC	
	@	30MG	A077959	002	Feb 14, 2011	Jun	DISC	
	@	45MG	A077959	003	Feb 14, 2011	Jun	DISC	
<u>MITOXANTRONE HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
MITOXANTRONE HYDROCHLORIDE								
AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAIN	
AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356	001	Apr 11, 2006	May	CAHN	
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356	002	Apr 11, 2006	May	CAHN	
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356	003	Apr 11, 2006	May	CAHN	
<u>MOMETASONE FUROATE</u>								
CREAM;TOPICAL								
ELOCON								
AB	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Apr	NEWA	
OINTMENT;TOPICAL								
MOMETASONE FUROATE								
	@ TARO	0.1%	A076624	001	Dec 03, 2004	May	DISC	
<u>MORPHINE SULFATE</u>								
CAPSULE, EXTENDED RELEASE;ORAL								
KADIAN								
AB1	+	WATSON LABS INC	10MG	N020616	008	Apr 20, 2007	May	CTEC
	+		10MG	N020616	008	Apr 20, 2007	Apr	CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Apr	CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Apr	CAHN
			40MG	N020616	009	Jul 09, 2012	Apr	CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Apr	CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Apr	CAHN
			70MG	N020616	010	Jul 09, 2012	Apr	CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Apr	CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Apr	CAHN
			130MG	N020616	011	Jul 09, 2012	Apr	CAHN
			150MG	N020616	012	Jul 09, 2012	Apr	CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	May	CTEC
	+		200MG	N020616	007	Feb 27, 2007	Apr	CAHN
MORPHINE SULFATE								
AB1	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Apr	CTEC	
AB1		30MG	A200812	002	Nov 10, 2011	Apr	CTEC	
AB1		50MG	A200812	003	Nov 10, 2011	Apr	CTEC	
AB1		60MG	A200812	004	Nov 10, 2011	Apr	CTEC	
AB1		80MG	A200812	005	Nov 10, 2011	Apr	CTEC	
AB1		100MG	A200812	006	Nov 10, 2011	Apr	CTEC	

CAPSULE, EXTENDED RELEASE;ORAL									
MORPHINE SULFATE									
AB1	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	May	NEWA		
AB1		20MG	A202104	002	Jun 03, 2013	May	NEWA		
AB1		30MG	A202104	003	Jun 03, 2013	May	NEWA		
AB1		50MG	A202104	004	Jun 03, 2013	May	NEWA		
AB1		60MG	A202104	005	Jun 03, 2013	May	NEWA		
AB1		80MG	A202104	006	Jun 03, 2013	May	NEWA		
AB1		100MG	A202104	007	Jun 03, 2013	May	NEWA		
SOLUTION;ORAL									
MORPHINE SULFATE									
	LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011	Jul	CPOT		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
EMBEDA									
+	ALPHARMA KING	60MG;2.4MG	N022321	004	Aug 13, 2009	Jul	CRLD		
		100MG;4MG	N022321	006	Aug 13, 2009	Jul	CRLD		
<u>MUPIROCIN CALCIUM</u>									
CREAM;TOPICAL									
BACTROBAN									
AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CFTG	
MUPIROCIN									
AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan	NEWA	
<u>MYCOPHENOLATE MOFETIL</u>									
CAPSULE;ORAL									
MYCOPHENOLATE MOFETIL									
AB	ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr	CAHN		
AB	ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013	Jun	NEWA		
<u>NABUMETONE</u>									
TABLET;ORAL									
NABUMETONE									
	@ DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008	Apr	DISC		
	@	750MG	A078420	002	Sep 24, 2008	Apr	DISC		
	@ PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Mar	DISC		
	@	750MG	A079093	002	Feb 27, 2009	Mar	DISC		
<u>NAFTIFINE HYDROCHLORIDE</u>									
GEL;TOPICAL									
NAFTIN									
+	MERZ PHARMS	2%	N204286	001	Jun 27, 2013	Jun	NEWA		
<u>NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE</u>									
TABLET;ORAL									
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE									
AB	GAVIS PHARMS	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Aug	CTNA		
AB	RANBAXY	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Aug	CTNA		
AB	+	WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736	001	Jan 21, 1997	Aug	CTNA	
<u>NALTREXONE HYDROCHLORIDE</u>									
TABLET;ORAL									
NALTREXONE HYDROCHLORIDE									
	@ SANDOZ	50MG	A075434	001	Mar 08, 2000	Apr	DISC		
REVIA									
AB	+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984	Jul	CAHN	
<u>NAPHAZOLINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
NAPHAZOLINE HYDROCHLORIDE									
AT	AKORN INC	0.1%	A083590	001		Jul	CAHN		
<u>NAPROXEN</u>									
TABLET;ORAL									
NAPROXEN									
AB	WEST WARD PHARM CORP	250MG	A076494	001	Jan 14, 2004	Apr	CAHN		
AB		375MG	A076494	002	Jan 14, 2004	Apr	CAHN		
AB		500MG	A076494	003	Jan 14, 2004	Apr	CAHN		

NARATRIPTAN HYDROCHLORIDETABLET; ORAL
AMERGE

AB	GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763	002	Feb 10, 1998	Mar CAHN
AB	+	EQ 2.5MG BASE	N020763	001	Feb 10, 1998	Mar CAHN

NELFINAVIR MESYLATEPOWDER; ORAL
VIRACEPT

@ AGOURON	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997	Jun DISC
-----------	-----------------------	---------	-----	--------------	----------

NEOMYCIN SULFATEPOWDER; FOR RX COMPOUNDING
NEO-RX

@ X GEN PHARMS	100%	A061579	001		Mar DISC
----------------	------	---------	-----	--	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATESUSPENSION/DROPS; OPHTHALMIC
POLY-PRED

@ ALLERGAN	EQ 0.35% BASE; 10,000 UNITS/ML; 0.5%	N050081	002		May DISC
------------	--------------------------------------	---------	-----	--	----------

NEOSTIGMINE METHYLSULFATESOLUTION; INTRAVENOUS
BLOXIVERZ

+	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	May NEWA
+		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	May NEWA

NEPAFENACSUSPENSION/DROPS; OPHTHALMIC
ILEVRO

+	ALCON RES LTD	0.3%	N203491	001	Oct 16, 2012	Aug CTNA
---	---------------	------	---------	-----	--------------	----------

NIACINTABLET, EXTENDED RELEASE; ORAL
NIACIN

AB	BARR	1GM	A076250	001	Apr 14, 2005	Aug CMFD
AB		500MG	A076378	001	Apr 26, 2005	Aug CMFD
AB		750MG	A076378	002	Apr 26, 2005	Aug CMFD

NIFEDIPINECAPSULE; ORAL
NIFEDIPINE

AB	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Apr CTEC
	@ CATALENT	10MG	A073250	001	Oct 08, 1991	Apr DISC
AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Apr NEWA
AB		20MG	A202644	002	Apr 25, 2013	Apr NEWA

NILUTAMIDETABLET; ORAL
NILANDRON

@ COVIS PHARMA SARL	50MG	N020169	001	Sep 19, 1996	Apr CAHN
+	150MG	N020169	002	Apr 30, 1999	Apr CAHN

NIMODIPINECAPSULE; ORAL
NIMODIPINE

AB	+	BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Jul CRLD
AB		SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Jul CRLD

SOLUTION; ORAL
NYMALIZE

+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May NEWA
---	------------------	-----------	---------	-----	--------------	----------

NISOLDIPINETABLET, EXTENDED RELEASE; ORAL
NISOLDIPINE

MYLAN	20MG	A079051	001	Jul 25, 2008	Jul CRLD
-------	------	---------	-----	--------------	----------

NITISINONECAPSULE; ORAL
ORFADIN

CAPSULE;ORAL

ORFADIN

SWEDISH ORPHAN

2MG

N021232 001 Jan 18, 2002 May CAHN

5MG

N021232 002 Jan 18, 2002 May CAHN

+

10MG

N021232 003 Jan 18, 2002 May CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

AB

CARACO

25MG/5ML

A201355 001 Aug 14, 2013 Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

ALVOGEN INC

25MG

N016620 003

Mar CTEC

AB

25MG

N016620 003

Feb CAHN

AB

50MG

N016620 001

Feb CAHN

AB

+

100MG

N016620 002

Feb CAHN

NITROFURANTOIN

@ WATSON LABS

25MG

A073696 001 Dec 31, 1992 Mar DISC

@

50MG

A073696 002 Dec 31, 1992 Mar DISC

@

100MG

A073696 003 Dec 31, 1992 Mar DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB

+

ALVOGEN INC

75MG;25MG

N020064 001 Dec 24, 1991 Mar CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

AB1

+

MERCK SHARP DOHME

0.1MG/HR

N020145 001 Apr 04, 1995 Mar CAHN

AB1

+

0.2MG/HR

N020145 002 Apr 04, 1995 Mar CAHN

+

0.3MG/HR

N020145 003 Apr 04, 1995 Mar CAHN

AB1

+

0.4MG/HR

N020145 004 Apr 04, 1995 Mar CAHN

AB1

+

0.6MG/HR

N020145 005 Apr 04, 1995 Mar CAHN

+

0.8MG/HR

N020145 006 Apr 04, 1995 Mar CAHN

INJECTABLE;INJECTION

NITROGLYCERIN

@ HOSPIRA

5MG/ML

N018531 001

Jul DISC

+

LUITPOLD

5MG/ML

A072034 001 May 24, 1988

Jul CTEC

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

>A>

AB

PERRIGO ISRAEL

0.4MG/SPRAY

A091496 001 Sep 20, 2013

Sep NEWA

NITROLINGUAL PUMPSPRAY

>D>

+

POHL BOSKAMP

0.4MG/SPRAY

N018705 002 Jan 10, 1997

Sep CFTG

>A>

AB

+

0.4MG/SPRAY

N018705 002 Jan 10, 1997

Sep CFTG

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

@ APOTEX INC

150MG

A076383 001 Jan 23, 2003

Feb DISC

@

300MG

A076383 002 Jan 23, 2003

Feb DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP

TEVA PHARMS USA

EQ 1MG BASE/ML

A040455 001 Mar 03, 2003

May CAHN

NORETHINDRONE

TABLET;ORAL

NORETHINDRONE

AB1

HAUPT PHARMA

0.35MG

A202260 001 Aug 01, 2013

Jul NEWA

TABLET;ORAL-28

JENCYCLA

AB2

LUPIN LTD

0.35MG

A091323 001 Mar 28, 2013

Apr CTEC

AB

0.35MG

A091323 001 Mar 28, 2013

Mar NEWA

NORETHINDRONE

AB2

FAMY CARE LTD

0.35MG

A200980 001 Jun 12, 2013

May NEWA

AB1

0.35MG

A201483 001 Jun 24, 2013

Jun NEWA

AB1

HAUPT PHARMA

0.35MG

A202260 001 Aug 01, 2013

Aug CDFR

AB2

NOVAST LABS

0.35MG

A200961 001 Sep 13, 2013

Aug NEWA

TABLET;ORAL-28

NORETHINDRONE

AB1	NOVAST LABS LTD	0.35MG	A202014	001	Sep 13, 2013	Aug NEWA
-----	-----------------	--------	---------	-----	--------------	----------

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

>D> AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012	Sep CTNA
--------	---------------	-----	---------	-----	--------------	----------

NORETHINDRONE ACETATE

>A> AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012	Sep CTNA
--------	---------------	-----	---------	-----	--------------	----------

NYSTATIN

SUSPENSION;ORAL

NILSTAT

@ GLENMARK GENERICS	100,000 UNITS/ML	N050299	001			Feb DISC
---------------------	------------------	---------	-----	--	--	----------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May CAHN
AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May CAHN
AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May CAHN
AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May CAHN
AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr NEWA
	@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr DISC

OMEPRazole; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRazole AND SODIUM BICARBONATE

AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr NEWA
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr NEWA
	ZEGERID					
AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CFTG
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr DISC
AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Jul CPOT
AP		2MG/ML	A078288	001	Feb 22, 2013	Feb NEWA
	@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar DISC
	@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb DISC
	ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
	@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan DISC
	@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr DISC
AP	BD RX	EQ 2MG BASE/ML	A202253	001	Jul 19, 2013	Jul NEWA
AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Jul CPOT
AP		2MG/ML	A078287	001	Feb 22, 2013	Feb NEWA
	@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>D> AB	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Sep DISC
>A>	@	EQ 4MG BASE	A077729	001	Mar 28, 2011	Sep DISC
>D> AB		EQ 8MG BASE	A077729	002	Mar 28, 2011	Sep DISC
>A>	@	EQ 8MG BASE	A077729	002	Mar 28, 2011	Sep DISC
>D> AB		EQ 24MG BASE	A077729	003	Mar 28, 2011	Sep DISC
>A>	@	EQ 24MG BASE	A077729	003	Mar 28, 2011	Sep DISC

OSPemifene

TABLET;ORAL

OSPheNA

+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb NEWA
---	--------------	------	---------	-----	--------------	----------

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan NEWA
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan NEWA
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan NEWA

OXAPROZINTABLET; ORAL
OXAPROZIN
@ CARACO

600MG

A075844 001 Jan 03, 2002 Jan DISC

OXAZEPAMCAPSULE; ORAL
OXAZEPAM

AB	+ ACTAVIS ELIZABETH	30MG	A072253	001	Apr 14, 1988	Jul CRLD
AB	IVAX SUB TEVA PHARMS	30MG	A070945	001	Aug 03, 1987	Jul CRLD

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

@ TEVA PHARMS USA
@
@150MG
300MG
600MGA078005 001 Dec 11, 2007 Mar DISC
A078005 002 Dec 11, 2007 Mar DISC
A078005 003 Dec 11, 2007 Mar DISCOXYBUTYNINGEL, METERED; TRANSDERMAL
GELNIQUE 3%

+ WATSON LABS INC 3%

N202513 001 Dec 07, 2011 Jun CTNA

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

@ APOTEX INC
@ MIKART5MG/5ML
5MG/5MLA074997 001 Oct 15, 1997 Apr DISC
A075039 001 Jan 29, 1999 Jun DISC

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB	TEVA PHARMS USA	5MG	A071655	001	Nov 14, 1988	Mar CAHN
----	-----------------	-----	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Jul NEWA
AA		100MG/5ML	A203208	001	Jul 12, 2013	Jul NEWA
AA	+ VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jul CTEC

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Jun CMFD
	@	5MG	A077290	001	Dec 08, 2005	Mar DISC
AB		10MG	A077290	002	Dec 08, 2005	Jun CMFD
	@	10MG	A077290	002	Dec 08, 2005	Mar DISC
AB		15MG	A077290	003	Dec 08, 2005	Jun CMFD
	@	15MG	A077290	003	Dec 08, 2005	Mar DISC
AB		20MG	A077290	004	Dec 08, 2005	Jun CMFD
	@	20MG	A077290	004	Dec 08, 2005	Mar DISC
AB		30MG	A077290	005	Dec 08, 2005	Jun CMFD
	@	30MG	A077290	005	Dec 08, 2005	Mar DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A203601	001	Jan 30, 2013	Jan NEWA
AB		10MG	A203601	002	Jan 30, 2013	Jan NEWA
AB	MALLINCKRODT INC	5MG	A202321	001	Apr 25, 2013	Apr NEWA
AB		10MG	A202321	002	Apr 25, 2013	Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Jul NEWA
AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
AB		10MG	A079046	004	Jul 11, 2013	Jul NEWA
AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		20MG	A079046	005	Jul 11, 2013	Jul NEWA
AB		30MG	A079046	006	Jul 11, 2013	Jul NEWA
AB		40MG	A079046	007	Jul 11, 2013	Jul NEWA
AB	IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Jul CTEC
AB		10MG	A079087	003	Jun 14, 2010	Jul CTEC
AB		20MG	A079087	005	Jun 14, 2010	Jul CTEC
AB		30MG	A079087	006	Jul 22, 2010	Jul CTEC
AB		40MG	A079087	007	Jun 14, 2010	Jul CTEC
AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Jul NEWA
AB		7.5MG	A200822	003	Jul 15, 2013	Jul NEWA
AB		10MG	A200822	004	Jul 15, 2013	Jul NEWA
AB		15MG	A200822	005	Jul 15, 2013	Jul NEWA
AB		20MG	A200822	006	Jul 15, 2013	Jul NEWA
AB		30MG	A200822	007	Jul 15, 2013	Jul NEWA
AB		40MG	A200822	001	Jul 15, 2013	Jul NEWA

OXYTOCIN

INJECTABLE;INJECTION
OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219	001	Feb 13, 2013	Jan NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May CAHN

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

	@ ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004	Apr DISC
	@ TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002	May CAHN
	TAXOL					
AP	HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Apr CMFD
	@	6MG/ML	N020262	001	Dec 29, 1992	Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar CAHN
AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL
CREON

	ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013	Mar NEWA
--	--------	---	---------	-----	--------------	----------

PANCURONIUM BROMIDE

INJECTABLE;INJECTION
PANCURONIUM BROMIDE

AP	+	TEVA PHARMS USA	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
AP	+		2MG/ML	A072760	001	Jul 31, 1990	Mar CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

>A>	AB	TEVA PHARMS USA	1MCG	A090829	001	Sep 27, 2013	Sep NEWA
>A>	AB		2MCG	A090829	002	Sep 27, 2013	Sep NEWA
>A>	AB		4MCG	A090829	003	Sep 27, 2013	Sep NEWA
		ZEMPLAR					
>D>		ABBVIE	1MCG	N021606	001	May 26, 2005	Sep CFTG
>A>	AB		1MCG	N021606	001	May 26, 2005	Sep CFTG
>D>			2MCG	N021606	002	May 26, 2005	Sep CFTG
>A>	AB		2MCG	N021606	002	May 26, 2005	Sep CFTG
>D>	+		4MCG	N021606	003	May 26, 2005	Sep CFTG
>A>	AB	+	4MCG	N021606	003	May 26, 2005	Sep CFTG

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL
PAROXETINE HYDROCHLORIDE

	@ APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006	Apr DISC
--	--------------	------------------	---------	-----	--------------	----------

PAROXETINE MESYLATECAPSULE;ORAL
BRISDELLE

+ NOVEN THERAP EQ 7.5MG BASE N204516 001 Jun 28, 2013 Jun NEWA

PEGINESATIDE ACETATESOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS

@ TAKEDA PHARMS USA EQ 10MG BASE/ML (EQ 10MG BASE/ML) N202799 007 Mar 27, 2012 May DISC

+ EQ 10MG BASE/ML (EQ 10MG BASE/ML) N202799 007 Mar 27, 2012 Apr CAHN

@ EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N202799 008 Mar 27, 2012 May DISC

+ EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N202799 008 Mar 27, 2012 Apr CAHN

OMONTYS PRESERVATIVE FREE

@ TAKEDA PHARMS USA EQ 1MG BASE/0.5ML (EQ 1MG N202799 001 Mar 27, 2012 May DISC

+ EQ 1MG BASE/0.5ML (EQ 1MG N202799 001 Mar 27, 2012 Apr CAHN

@ EQ 2MG BASE/0.5ML (EQ 2MG N202799 002 Mar 27, 2012 May DISC

+ EQ 2MG BASE/0.5ML (EQ 2MG N202799 002 Mar 27, 2012 Apr CAHN

@ EQ 3MG BASE/0.5ML (EQ 3MG N202799 003 Mar 27, 2012 May DISC

+ EQ 3MG BASE/0.5ML (EQ 3MG N202799 003 Mar 27, 2012 Apr CAHN

@ EQ 4MG BASE/0.5ML (EQ 4MG N202799 004 Mar 27, 2012 May DISC

+ EQ 4MG BASE/0.5ML (EQ 4MG N202799 004 Mar 27, 2012 Apr CAHN

@ EQ 5MG BASE/0.5ML (EQ 5MG N202799 005 Mar 27, 2012 May DISC

+ EQ 5MG BASE/0.5ML (EQ 5MG N202799 005 Mar 27, 2012 Apr CAHN

@ EQ 6MG BASE/0.5ML (EQ 6MG N202799 006 Mar 27, 2012 May DISC

+ EQ 6MG BASE/0.5ML (EQ 6MG N202799 006 Mar 27, 2012 Apr CAHN

PENICILLIN V POTASSIUM

TABLET;ORAL

PENICILLIN V POTASSIUM

>A> AB HIKMA PHARMS EQ 250MG BASE A090549 001 Oct 11, 2013 Sep NEWA

>A> AB EQ 500MG BASE A090549 002 Oct 11, 2013 Sep NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

PARAGON BIOTECK 2.5% N203510 001 Mar 21, 2013 Mar NEWA

+ 10% N203510 002 Mar 21, 2013 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

@ HOSPIRA 50MG/ML A089744 001 Dec 18, 1987 Mar DISC

PHYTONADIONE

TABLET;ORAL

MEPHYTON

+ VALEANT PHARMS 5MG N010104 003 Jun CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

MYLAN PHARMS INC 5MG A074019 001 Sep 03, 1992 Jun CTEC

+ 10MG A074019 002 Sep 03, 1992 Jun CTEC

@ WATSON LABS 5MG A074437 001 Feb 27, 1995 Jun DISC

@ 10MG A074437 002 Feb 27, 1995 Jun DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB ACCORD HLTHCARE EQ 15MG BASE A200044 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A200044 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A200044 003 Feb 13, 2013 Jan NEWA

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200268	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200268	003	Feb 13, 2013	Jan NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383	001	Mar 12, 2013	Mar NEWA
AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Mar NEWA
AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Mar NEWA
AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467	001	Feb 06, 2013	Jan NEWA
AB		EQ 30MG BASE	A202467	002	Feb 06, 2013	Jan NEWA
AB		EQ 45MG BASE	A202467	003	Feb 06, 2013	Jan NEWA
AB	SANDOZ	EQ 15MG BASE	A078670	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078670	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078670	003	Feb 13, 2013	Jan NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Jan NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A091298	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A091298	003	Feb 13, 2013	Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A202456	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A202456	003	Feb 13, 2013	Jan NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CTEC
@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul DISC

COLYTE WITH FLAVOR PACKS

MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
-------------	--	---------	-----	--------------	----------

COLYTE-FLAVORED

@ MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul DISC
@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul DISC

POLYMYXIN B SULFATE

POWDER;FOR RX COMPOUNDING

POLY-RX

@ X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001		Mar DISC
----------------	-----------------------	---------	-----	--	----------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A065006	001	Dec 17, 1998	Jul CAHN
----	-----------	--------------------------------	---------	-----	--------------	----------

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

CELGENE	1MG	N204026	001	Feb 08, 2013	Feb NEWA
	2MG	N204026	002	Feb 08, 2013	Feb NEWA
	3MG	N204026	003	Feb 08, 2013	Feb NEWA
+	4MG	N204026	004	Feb 08, 2013	Feb NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128	001	Feb 22, 2013	Feb NEWA
----	---------------	-------	---------	-----	--------------	----------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Mar CAHN
AB		0.25MG	A091254	002	Nov 30, 2010	Mar CAHN
AB		0.5MG	A091254	003	Nov 30, 2010	Mar CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	Mar CAHN
AB		1MG	A091254	005	Nov 30, 2010	Mar CAHN
AB		1.5MG	A091254	006	Nov 30, 2010	Mar CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Mar NEWA

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		0.25MG	A091683	002	Mar 27, 2013	Mar NEWA
AB		0.5MG	A091683	003	Mar 27, 2013	Mar NEWA
AB		0.75MG	A091683	004	Mar 27, 2013	Mar NEWA
AB		1MG	A091683	005	Mar 27, 2013	Mar NEWA
AB		1.5MG	A091683	006	Mar 27, 2013	Mar NEWA

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMMLIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Jan CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan CAHN
+	AMYLIN PHARMS LLC	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun CRLD
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun DISC

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	CIPLA LTD	10MG	A077904	001	Oct 23, 2006	Aug CAHN
AB		20MG	A077904	002	Oct 23, 2006	Aug CAHN
AB		40MG	A077904	003	Oct 23, 2006	Aug CAHN

PRAZQUANTEL

TABLET;ORAL

BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr DISC
@		15MG/5ML	A040571	001	Aug 25, 2005	Apr DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May CAHN
			PREDNISOLONE SODIUM PHOSPHATE				
	@	NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May DISC
	@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar DISC
	@	WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar CFTG
			PREDNISOLONE SODIUM PHOSPHATE				
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar NEWA

PREDNISONE

TABLET;ORAL

PREDNISONE

AB		HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	May CAHN
AB			2.5MG	A040538	001	Jan 08, 2004	May CAHN
AB			5MG	A080292	001		May CAHN
AB			10MG	A088832	001	Dec 04, 1985	May CAHN
AB			20MG	A083677	001		May CAHN
AB			50MG	A088465	001	Jun 01, 1984	May CAHN

PRIMIDONE

TABLET;ORAL

TABLET;ORAL

PRIMIDONE

@ DR REDDYS LABS LTD 50MG
 @ 250MG
 @ WEST WARD 50MG

A040862 001 Oct 03, 2008 Apr DISC
 A040862 002 Oct 03, 2008 Apr DISC
 A040667 001 Jul 27, 2006 Jul DISC

PROBENECID

TABLET;ORAL

PROBENECID

@ IVAX SUB TEVA PHARMS 500MG

A083740 001 May 09, 1984 May DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

>A> AP EMCURE PHARMS LTD EQ 5MG BASE/ML

A204147 001 Oct 15, 2013 Sep NEWA

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB BANNER PHARMACAPS 100MG
 AB 200MG

A200900 001 Aug 16, 2013 Jul NEWA
 A200900 002 Aug 16, 2013 Jul NEWA

PROMETRIUM

AB ABBVIE INC 100MG
 AB + 200MG
 @ 300MG

N019781 001 May 14, 1998 May CAHN
 N019781 002 Oct 15, 1999 May CAHN
 N019781 003 Oct 15, 1999 May CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP + TEVA PHARMS USA 25MG/ML
 AP + 50MG/ML

A040454 001 Aug 22, 2002 Mar CAHN
 A040454 002 Aug 22, 2002 Mar CAHN

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA CARACO 6.25MG/5ML

A040891 001 Mar 13, 2009 May CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB CARACO 12.5MG
 AB 25MG
 AB 50MG

A040863 001 Dec 30, 2008 May CAHN
 A040863 002 Dec 30, 2008 May CAHN
 A040863 003 Dec 30, 2008 May CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PROPARACAINE HYDROCHLORIDE

AT AKORN INC 0.5%

A040277 001 Mar 16, 2000 Jul CAHN

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

AB TEVA PHARMS USA 10MG/ML

A075102 001 Jan 04, 1999 Mar CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

AB GLATT AIR 60MG
 AB 80MG
 AB 120MG
 AB 160MG

A078065 001 Jan 26, 2007 Feb CAHN
 A078065 002 Jan 26, 2007 Feb CAHN
 A078065 003 Jan 26, 2007 Feb CAHN
 A078065 004 Jan 26, 2007 Feb CAHN

TABLET;ORAL

INDERAL

@ WYETH PHARMS INC 10MG
 @ 20MG
 AB 40MG
 AB 60MG
 AB + 80MG
 @ 90MG

N016418 001 Jul CAHN
 N016418 003 Jul CAHN
 N016418 002 Jul CAHN
 N016418 009 Oct 18, 1982 Jul CAHN
 N016418 004 Jul CAHN
 N016418 010 Oct 18, 1982 Jul CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

VIVACTIL

@ TEVA WOMENS 5MG
 @ 10MG

N016012 001 Mar CAHN
 N016012 002 Mar CAHN

PYRIMETHAMINETABLET; ORAL
DARAPRIM

+	AMEDRA PHARMS	25MG	N008578	001		Apr	CAHN
---	---------------	------	---------	-----	--	-----	------

QUAZEPAMTABLET; ORAL
DORAL

@	SCIENCURE PHARMA INC	7.5MG	N018708	003	Feb 26, 1987	Jun	CAHN
+		15MG	N018708	001	Dec 27, 1985	Jun	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152	001	Mar 27, 2012	Apr	CAHN
AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Apr	CAHN
AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Apr	CAHN
AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Apr	CAHN
AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Apr	CAHN
AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Apr	CAHN
AB	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	May	CAHN
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	May	CAHN
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	May	CAHN
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	May	CAHN
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	May	CAHN
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	May	CAHN
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	May	CAHN
AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762	001	Feb 27, 2013	Feb	NEWA
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	Feb	NEWA
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	Feb	NEWA
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	Feb	NEWA
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	Feb	NEWA
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	Feb	NEWA
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	Feb	NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504	001	Feb 12, 2013	Jan	NEWA
AB		EQ 50MG BASE	A201504	002	Feb 12, 2013	Jan	NEWA
AB		EQ 100MG BASE	A201504	003	Feb 12, 2013	Jan	NEWA
AB		EQ 150MG BASE	A201504	004	Feb 12, 2013	Jan	NEWA
AB		EQ 200MG BASE	A201504	005	Feb 12, 2013	Jan	NEWA
AB		EQ 300MG BASE	A201504	006	Feb 12, 2013	Jan	NEWA
AB		EQ 400MG BASE	A201504	007	Feb 12, 2013	Jan	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006	Mar	DISC
@		EQ 10MG BASE	A076240	002	Jan 26, 2006	Mar	DISC
@		EQ 20MG BASE	A076240	003	Jan 26, 2006	Mar	DISC
@		EQ 40MG BASE	A076240	004	Jan 26, 2006	Mar	DISC
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725	001	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202725	002	Apr 29, 2013	Apr	NEWA
AB		EQ 20MG BASE	A202725	003	Apr 29, 2013	Apr	NEWA
AB		EQ 40MG BASE	A202725	004	Apr 29, 2013	Apr	NEWA
@	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Aug	DISC
@		EQ 10MG BASE	A076036	002	Jan 28, 2005	Aug	DISC
@		EQ 20MG BASE	A076036	003	Jan 28, 2005	Aug	DISC
@		EQ 40MG BASE	A076036	004	Jan 28, 2005	Aug	DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

	EISAI INC	5MG	N204736	001	Mar 26, 2013	Mar	NEWA
+		10MG	N204736	002	Mar 26, 2013	Mar	NEWA

RADIUM RA-223 DICHLORIDESOLUTION; INTRAVENOUS
XOFIGO

+	BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971	001	May 15, 2013	May	NEWA
---	----------------	-----------------------	---------	-----	--------------	-----	------

RAMELTEON

TABLET; ORAL

RAMELTEON

TABLET;ORAL

RAMELTEON						
AB	TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Jul NEWA
ROZEREM						
AB	+ TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul CFTG

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL						
	@ CIPLA	1.25MG	A077004	001	Aug 07, 2008	Jul DISC
	@	2.5MG	A077004	002	Aug 07, 2008	Jul DISC
	@	5MG	A077004	003	Aug 07, 2008	Jul DISC
	@	10MG	A077004	004	Aug 07, 2008	Jul DISC

RANITIDINE HYDROCHLORIDE

GRANULE, EFFERVESCENT;ORAL

ZANTAC 150						
	@ GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994	Jun CAHN

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE						
AP	ZYDUS PHARMS USA INC	25MG/ML	A091534	001	Feb 22, 2013	Feb NEWA
ZANTAC IN PLASTIC CONTAINER						
	@ COVIS PHARMA SARL	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jun DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	@ APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007	Apr DISC
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Apr CAHN
>A> AA	BRECKENRIDGE PHARM	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Sep CAHN
AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Apr CAHN
>D> AA	CYPRESS PHARM	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Sep CAHN

ZANTAC

AA	+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988	Jun CAHN
----	-----------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@ WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997	Jan DISC
	@	EQ 300MG BASE	A074864	002	Oct 20, 1997	Jan DISC
	@ WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005	Mar DISC
	@	EQ 300MG BASE	A077426	002	Dec 19, 2005	Mar DISC

ZANTAC 150

AB	GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Jun CAHN
ZANTAC 300						

AB	+ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jun CAHN
----	-----------------	---------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT;ORAL

ZANTAC 150

	@ GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994	Jun CAHN
--	-----------------	---------------	---------	-----	--------------	----------

ZANTAC 25

	+ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Jun CAHN
--	-----------------	--------------	---------	-----	--------------	----------

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA						
AB	+ GILEAD	1GM	N021526	001	Feb 12, 2007	Jul CFTG
AB		500MG	N021526	002	Jan 27, 2006	Jul CFTG
RANOLAZINE						
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Jul NEWA
AB		1GM	A201046	002	Jul 29, 2013	Jul NEWA

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT						
AB	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006	Jun CFTG
AB	+ RASAGILINE MESYLATE	EQ 1MG BASE	N021641	002	May 16, 2006	Jun CFTG
AB	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Aug NEWA
AB		EQ 1MG BASE	A201950	002	Sep 12, 2013	Aug NEWA
AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Jun NEWA
AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Jun NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN						
---------	--	--	--	--	--	--

TABLET;ORAL							
PRANDIN							
AB	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997	Jul	CTEC
AB		1MG	N020741	002	Dec 22, 1997	Jul	CFTG
AB	+	2MG	N020741	003	Dec 22, 1997	Jul	CFTG
REPAGLINIDE							
AB	CARACO	1MG	A077571	002	Jul 11, 2013	Jul	NEWA
AB		2MG	A077571	003	Jul 11, 2013	Jul	NEWA
AB	MYLAN PHARMS INC	0.5MG	A090252	001	Aug 23, 2013	Aug	NEWA
AB	PADDOCK LLC	0.5MG	A201189	001	Jul 17, 2013	Jul	NEWA
<u>RESERPINE</u>							
TABLET;ORAL							
SERPALAN							
	@ LANNETT	0.1MG	N010124	001		May	DISC
	@	0.25MG	N010124	002		May	DISC
<u>RIFAMPIN</u>							
CAPSULE;ORAL							
RIFAMPIN							
AB	LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013	Jul	NEWA
AB		300MG	A090034	002	Aug 21, 2013	Jul	NEWA
<u>RILUZOLE</u>							
TABLET;ORAL							
RILUTEK							
AB	+ COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995	Apr	CAHN
RILUZOLE							
AB	APOTEX CORP	50MG	A091300	001	Jun 18, 2013	Jun	NEWA
AB	GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013	Jun	NEWA
AB	MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013	Jun	NEWA
AB	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Jun	NEWA
<u>RIMANTADINE HYDROCHLORIDE</u>							
TABLET;ORAL							
RIMANTADINE HYDROCHLORIDE							
	@ COREPHARMA	100MG	A075916	001	Nov 02, 2001	Feb	DISC
<u>RISPERIDONE</u>							
SOLUTION;ORAL							
RISPERIDONE							
AA	BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009	May	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
RISPERIDONE							
AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb	NEWA
AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Feb	CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Mar	NEWA
AB		1MG	A078464	002	Apr 08, 2013	Mar	NEWA
AB		2MG	A078464	003	Apr 08, 2013	Mar	NEWA
AB		3MG	A078464	004	Apr 08, 2013	Mar	NEWA
AB		4MG	A078464	005	Apr 08, 2013	Mar	NEWA
<u>RIVASTIGMINE TARTRATE</u>							
CAPSULE;ORAL							
RIVASTIGMINE TARTRATE							
AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	Apr	NEWA
AB		EQ 3MG BASE	A091072	002	May 16, 2013	Apr	NEWA
AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr	NEWA
AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr	NEWA
<u>RIZATRIPTAN BENZOATE</u>							
TABLET;ORAL							
RIZATRIPTAN BENZOATE							
AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar	NEWA
AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A204339	002	Jul 01, 2013	Jun	NEWA
TABLET, ORALLY DISINTEGRATING;ORAL							
RIZATRIPTAN BENZOATE							
AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Jun	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013	Jun	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

AB		EQ 10MG BASE	A203062	002	Jul 01, 2013	Jun NEWA
AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	Jun NEWA
AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun NEWA
AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Jun NEWA
AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Jun NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ZEMURON

AP	+	ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan CAHN
		@	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan CAHN
AP	+		100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
REQUIP

AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar CAHN
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar CAHN
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar CAHN
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar CAHN
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar CAHN
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar CAHN
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar CAHN

ROPINIROLE HYDROCHLORIDE

@	COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul DISC
@		EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul DISC
@		EQ 1MG BASE	A078230	003	May 20, 2008	Jul DISC
@		EQ 2MG BASE	A078230	004	May 20, 2008	Jul DISC
@		EQ 3MG BASE	A078230	005	May 20, 2008	Jul DISC
@		EQ 4MG BASE	A078230	006	May 20, 2008	Jul DISC
@		EQ 5MG BASE	A078230	007	May 20, 2008	Jul DISC

TABLET, EXTENDED RELEASE;ORAL
REQUIP XL

AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar CAHN
		@	EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar CAHN
AB			EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar CAHN
AB			EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar CAHN
AB			EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar CAHN
AB			EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar CAHN

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr CAHN
AB			EQ 4MG BASE	A090869	002	May 17, 2012	Apr CAHN
AB			EQ 6MG BASE	A090869	003	May 17, 2012	Apr CAHN
AB			EQ 8MG BASE	A090869	004	May 17, 2012	Apr CAHN
AB			EQ 12MG BASE	A090869	005	May 17, 2012	Apr CAHN
AB		ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr NEWA
AB			EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr NEWA
AB			EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr NEWA
AB			EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr NEWA
AB			EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr NEWA

ROSIGLITAZONE MALEATE

TABLET;ORAL
AVANDIA

AB		SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jan CFTG
AB			EQ 4MG BASE	N021071	003	May 25, 1999	Jan CFTG
AB	+		EQ 8MG BASE	N021071	004	May 25, 1999	Jan CFTG

ROSIGLITAZONE MALEATE

AB		TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan NEWA
AB			EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan NEWA
AB			EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO

+	UCB INC	2MG/24HR	N021829	001	May 09, 2007	May CRLD
		8MG/24HR	N021829	006	Apr 02, 2012	May CRLD

SAQUINAVIR MESYLATETABLET; ORAL
INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004	Feb CAHN
---	------------------	---------------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDETABLET; ORAL
SELEGILINE HYDROCHLORIDE

@	DAVA PHARMS INC	5MG	A074641	001	Aug 02, 1996	Jan DISC
---	-----------------	-----	---------	-----	--------------	----------

SERTACONAZOLE NITRATECREAM; TOPICAL
ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003	Jun CAHN
---	--------------------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDETABLET; ORAL
SERTRALINE HYDROCHLORIDE

@	CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007	Aug CAHN
@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Aug CAHN
@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Aug CAHN
@	DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr DISC
@		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr DISC
@		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr DISC

SILDENAFIL CITRATETABLET; ORAL
SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb NEWA

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

>D>	JUVISYNC					
>D>	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343	004	Sep 18, 2012	Sep DISC
>A>	@	10MG;EQ 50MG BASE	N202343	004	Sep 18, 2012	Sep DISC
>D>		10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011	Sep DISC
>A>	@	10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011	Sep DISC
>D>		20MG;EQ 50MG BASE	N202343	005	Sep 18, 2012	Sep DISC
>A>	@	20MG;EQ 50MG BASE	N202343	005	Sep 18, 2012	Sep DISC
>D>		20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011	Sep DISC
>A>	@	20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011	Sep DISC
>D>		40MG;EQ 50MG BASE	N202343	006	Sep 18, 2012	Sep DISC
>A>	@	40MG;EQ 50MG BASE	N202343	006	Sep 18, 2012	Sep DISC
>D>	+	40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011	Sep DISC
>A>	@	40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011	Sep DISC

SIROLIMUSSOLUTION; ORAL
RAPAMUNE

>A>	+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Sep CAHN
>D>	+	WYETH PHARMS INC	1MG/ML	N021083	001	Sep 15, 1999	Sep CAHN

TABLET; ORAL

RAPAMUNE

>A>	PF PRISM CV	0.5MG	N021110	004	Jan 25, 2010	Sep CAHN
>A>		1MG	N021110	001	Aug 25, 2000	Sep CAHN
>A>	+	2MG	N021110	002	Aug 22, 2002	Sep CAHN
>A>	@	5MG	N021110	003	Feb 23, 2004	Sep CAHN
>D>	WYETH PHARMS INC	0.5MG	N021110	004	Jan 25, 2010	Sep CAHN
>D>		1MG	N021110	001	Aug 25, 2000	Sep CAHN
>D>	+	2MG	N021110	002	Aug 22, 2002	Sep CAHN
>D>	@	5MG	N021110	003	Feb 23, 2004	Sep CAHN

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Mar NEWA
	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Mar NEWA
	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Mar NEWA
	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Mar NEWA

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

		90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Mar	NEWA
	SODIUM CHLORIDE 0.9%						
>A>	HIKMA MAPLE	9MG/ML	A201833	001	Sep 24, 2013	Sep	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Mar	CPOT
	SOLUTION;IRRIGATION						
	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	450MG/100ML	N017864	001		Jan	DISC

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

+	MCPRF	10-91.5MCI/ML	A203605	001	Jun 28, 2013	Jun	NEWA
---	-------	---------------	---------	-----	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE;ORAL
SODIUM IODIDE I 123

>D>	+	CARDINAL HLTH 414	400uCi	N018671	003	May 27, 1982	Sep	DISC
>A>	@		400uCi	N018671	003	May 27, 1982	Sep	DISC

SODIUM PHENYL BUTYRATE

POWDER;ORAL
BUPHENYL

AB	+	MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar	CFTG
		SODIUM PHENYL BUTYRATE						
AB		SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Mar	NEWA

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL
VISICOL

@	SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Jul	DISC
---	--------------	-----------------	---------	-----	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE
@ NOVEL LABS INC
OSMOPREP

@	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Aug	DISC
+	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Aug	CTEC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER

+	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Jun	CRLD
---	---------	-------------------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL
KAYEXALATE

AA	+	COVIS PHARMA SARL	453.6GM/BOT	N011287	001		Apr	CAHN
		SUSPENSION;ORAL, RECTAL						
		SODIUM POLYSTYRENE SULFONATE						
	@	ROXANE	15GM/60ML	A089049	001	Nov 17, 1986	Mar	DISC

STAVUDINE

CAPSULE;ORAL
STAVUDINE

AB		HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008	Apr	CAHN
AB			20MG	A078957	002	Dec 29, 2008	Apr	CAHN
AB			30MG	A078957	003	Dec 29, 2008	Apr	CAHN
AB			40MG	A078957	004	Dec 29, 2008	Apr	CAHN

STREPTOZOCIN

INJECTABLE;INJECTION
ZANOSAR

+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Apr	CAHN
---	-----------------	----------	---------	-----	--------------	-----	------

SUCCIMER

CAPSULE;ORAL
CHEMET

+	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991	May	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL							
KLARON							
AB	+ VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996	Feb	CAHN
OINTMENT; OPHTHALMIC							
SULFACETAMIDE SODIUM							
AT	PERRIGO CO TENNESSEE	10%	A080029	001		Jun	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION							
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
	+ TEVA PHARMS USA	80MG/ML; 16MG/ML	A073303	001	Oct 31, 1991	Mar	CAHN
TABLET; ORAL							
SULFAMETHOPRIM							
	@ NOVEL LABS INC	400MG; 80MG	A070022	001	Feb 15, 1985	Mar	DISC
SULFAMETHOPRIM-DS							
	@ NOVEL LABS INC	800MG; 160MG	A070032	001	Feb 15, 1985	Mar	DISC
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH							
	@ SANDOZ	800MG; 160MG	N018598	004	May 19, 1982	Jun	DISC

SULINDAC

TABLET; ORAL							
SULINDAC							
AB	HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991	Apr	CMFD
AB		200MG	A073262	001	Sep 06, 1991	Apr	CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS							
SUMATRIPTAN SUCCINATE							
AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Apr	NEWA
AP	HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A200183	001	Sep 16, 2013	Aug	NEWA
AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb	CAHN
AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009	Mar	CAHN
SYSTEM; IONTOPHORESIS							
ZECUITY							
	+ NUPATHE	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan	NEWA
TABLET; ORAL							
SUMATRIPTAN SUCCINATE							
AB	HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013	May	NEWA
AB		EQ 50MG BASE	A078298	002	May 21, 2013	May	NEWA
AB		EQ 100MG BASE	A078298	003	May 21, 2013	May	NEWA
	@ MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009	Aug	DISC
	@	EQ 50MG BASE	A077163	002	Nov 02, 2009	Aug	DISC
	@	EQ 100MG BASE	A077163	003	Nov 02, 2009	Aug	DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE; ORAL							
ASTAGRAF XL							
	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jul	NEWA
		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jul	NEWA
	+	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jul	NEWA
OINTMENT; TOPICAL							
PROTOPIC							
	+ ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Jun	CRLD

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL							
TAMSULOSIN HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	0.4MG	A202433	001	Apr 30, 2013	Apr	NEWA

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION							
LYMPHOSEEK KIT							
	+ NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013	Mar	NEWA

TENIPOSIDE

INJECTABLE; INJECTION

INJECTABLE; INJECTION							
VUMON							
	+ CORDEN PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Apr	CAHN
	+ HQ SPECTL PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Jul	CAHN
<u>TERBINAFINE HYDROCHLORIDE</u>							
TABLET; ORAL							
TERBINAFINE HYDROCHLORIDE							
AB	CIPLA LTD	EQ 250MG BASE	A077137	001	Jul 02, 2007	Jul	CAHN
	@ MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Aug	DISC
<u>TERBUTALINE SULFATE</u>							
INJECTABLE; INJECTION							
TERBUTALINE SULFATE							
	@ TEVA PHARMS USA	1MG/ML	A076853	001	Jul 20, 2004	Mar	CAHN
<u>TESTOSTERONE</u>							
GEL; TRANSDERMAL							
TESTOSTERONE							
	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	NEWA
		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	NEWA
GEL, METERED; TRANSDERMAL							
TESTOSTERONE							
	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jan	NEWA
<u>TESTOSTERONE CYPIONATE</u>							
INJECTABLE; INJECTION							
TESTOSTERONE CYPIONATE							
AO	SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013	May	NEWA
AO		200MG/ML	A201720	002	Jun 03, 2013	May	NEWA
<u>TESTOSTERONE ENANTHATE</u>							
INJECTABLE; INJECTION							
DELATESTRYL							
	@ ENDO PHARMS	200MG/ML	N009165	001		Jan	CAHN
AO	+	200MG/ML	N009165	003		Jan	CAHN
<u>THALLOUS CHLORIDE TL-201</u>							
INJECTABLE; INTRAVENOUS							
THALLOUS CHLORIDE TL 201							
	@ MALLINCKRODT	2mCi/ML	A077698	001	Nov 09, 2006	Aug	DISC
<u>THEOPHYLLINE</u>							
TABLET, EXTENDED RELEASE; ORAL							
THEOPHYLLINE							
AB	+ TEVA PHARMS	450MG	A081236	001	Nov 09, 1992	Mar	CAHN
<u>THIABENDAZOLE</u>							
SUSPENSION; ORAL							
MINTEZOL							
	@ MERCK SHARP DOHME	500MG/5ML	N016097	001		May	CAHN
TABLET, CHEWABLE; ORAL							
MINTEZOL							
	@ MERCK SHARP DOHME	500MG	N016096	001		May	CAHN
<u>THIOGUANINE</u>							
TABLET; ORAL							
THIOGUANINE							
	+ ASPEN GLOBAL INC	40MG	N012429	001		Mar	CAHN
<u>TICLOPIDINE HYDROCHLORIDE</u>							
TABLET; ORAL							
TICLOPIDINE HYDROCHLORIDE							
	@ MYLAN	250MG	A075161	001	Sep 13, 1999	Aug	DISC
<u>TIGECYCLINE</u>							
INJECTABLE; IV (INFUSION)							
TYGACIL							
	+ PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Aug	CAHN

TILUDRONATE DISODIUMTABLET;ORAL
SKELID

@	SANOFI AVENTIS US	EQ 200MG BASE	N020707	001	Mar 07, 1997	Jun	DISC
---	-------------------	---------------	---------	-----	--------------	-----	------

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOPTIC-XE

AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Jan	CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Jan	CAHN

SOLUTION/DROPS;OPHTHALMIC
ISTALOL

BT	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	May	CAHN
		TIMOLOL MALEATE						
	@	AKORN	EQ 0.25% BASE	A074515	001	Mar 25, 1997	Jun	DISC
	@	APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Apr	DISC
	@		EQ 0.5% BASE	A075412	001	Sep 08, 2000	Apr	DISC

TINIDAZOLETABLET;ORAL
TINIDAZOLE

>A>	AB	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Sep	NEWA
>A>	AB		500MG	A202489	002	Oct 09, 2013	Sep	NEWA

TIOPRONINTABLET;ORAL
THIOLA

+	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	Aug	CTNA
---	----------------	-------	---------	-----	--------------	-----	------

TIZANIDINE HYDROCHLORIDECAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 2MG BASE	A091502	001	Nov 09, 2012	May	CAHN
AB			EQ 4MG BASE	A091502	002	Nov 09, 2012	May	CAHN
AB			EQ 6MG BASE	A091502	003	Nov 09, 2012	May	CAHN

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 2MG BASE	A076282	001	Dec 16, 2003	Feb	DISC
@		EQ 4MG BASE	A076282	002	Dec 16, 2003	Feb	DISC

TOBRAMYCINPOWDER;INHALATION
TOBI PODHALER

+	NOVARTIS	28MG	N201688	001	Mar 22, 2013	Mar	NEWA
---	----------	------	---------	-----	--------------	-----	------

SOLUTION;INHALATION
TOBI

>D>	+	NOVARTIS PHARMS	300MG/5ML	N050753	001	Dec 22, 1997	Sep	CFTG
>A>	AN	+	300MG/5ML	N050753	001	Dec 22, 1997	Sep	CFTG

>A>		TOBRAMYCIN						
>A>	AN	TEVA PHARMS USA	300MG/5ML	A091589	001	Oct 10, 2013	Sep	NEWA

SOLUTION/DROPS;OPHTHALMIC
TOBRAMYCIN

@	APOTEX INC	0.3%	A065087	001	Feb 25, 2002	Apr	DISC
---	------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATEINJECTABLE;INJECTION
TOBRAMYCIN SULFATE

>D>	AP	TEVA PARENTERAL	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992	Sep	CAHN
>A>	AP	TEVA PHARMS USA	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992	Sep	CAHN

TOFACITINIB CITRATETABLET;ORAL
XELJANZ

>A>	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Sep	CAHN
>D>	+	PFIZER	EQ 5MG BASE	N203214	001	Nov 06, 2012	Sep	CAHN

TOLAZAMIDETABLET;ORAL
TOLAZAMIDE

		MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar	CTEC
--	--	------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL
TOLAZAMIDE

+		500MG	A070259	003	Mar 17, 1986	Mar CTEC
@	WATSON LABS	250MG	A070514	001	Jan 09, 1986	Mar DISC
@		500MG	A070515	001	Jan 09, 1986	Mar DISC

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL
TROKENDI XR

	SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Aug NEWA
		50MG	N201635	002	Aug 16, 2013	Aug NEWA
		100MG	N201635	003	Aug 16, 2013	Aug NEWA
+		200MG	N201635	004	Aug 16, 2013	Aug NEWA

TABLET;ORAL

TOPAMAX

AB	JANSSEN PHARMS	25MG	N020505	004	Dec 24, 1996	Apr CRLD
AB	+	100MG	N020505	001	Dec 24, 1996	Apr CRLD

TOPIRAMATE

AB	ACTIVIS TOTOWA LLC	25MG	A078637	001	Feb 27, 2013	Feb NEWA
AB		50MG	A078637	002	Feb 27, 2013	Feb NEWA
AB		100MG	A078637	003	Feb 27, 2013	Feb NEWA
AB		200MG	A078637	004	Feb 27, 2013	Feb NEWA
AB	LUPIN	25MG	A078410	001	Sep 11, 2013	Aug NEWA
AB		50MG	A078410	002	Sep 11, 2013	Aug NEWA
AB		100MG	A078410	003	Sep 11, 2013	Aug NEWA
AB		200MG	A078410	004	Sep 11, 2013	Aug NEWA
AB	UNICHEM LABS LTD	200MG	A090162	004	Feb 19, 2013	Feb NEWA
@	UPSHER SMITH	25MG	A078499	001	Jan 07, 2010	Jun DISC
@		50MG	A078499	002	Jan 07, 2010	Jun DISC
@		100MG	A078499	003	Jan 07, 2010	Jun DISC
@		200MG	A078499	004	Jan 07, 2010	Jun DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

>A>	GLAXO WELLCOME	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Sep CAHN
>A>	+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Sep CAHN
>D>	SMITHKLINE BEECHAM	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Sep CAHN
>D>	+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Sep CAHN

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 4MG BASE/VIAL	A202351	001	Jun 26, 2013	Jun NEWA
AP	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Aug NEWA

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

+	PROSTRAKAN INC	EQ 60MG BASE	N020497	001	May 29, 1997	May CAHN
---	----------------	--------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB	HETERO LABS LTD III	5MG	A079234	001	Jan 27, 2009	Apr CAHN
AB		10MG	A079234	002	Jan 27, 2009	Apr CAHN
AB		20MG	A079234	003	Jan 27, 2009	Apr CAHN
AB		100MG	A079234	004	Jan 27, 2009	Apr CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE INC	50MG	A202390	001	May 16, 2013	Apr NEWA
AB	CSPC OUYI PHARM CO	50MG	A091498	001	Mar 29, 2013	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

RYZOLT

@ PURDUE PHARMA

@

@

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012	Apr CAHN
AB2		200MG	A091609	002	Jun 27, 2012	Apr CAHN
AB2		300MG	A091609	003	Jun 27, 2012	Apr CAHN
AB1	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Feb CRLD

TABLET, EXTENDED RELEASE;ORAL									
TRAMADOL HYDROCHLORIDE									
AB2	+	SUN PHARMA GLOBAL	100MG	A091607	001	Dec 30, 2011	Feb	CRLD	
TABLET, ORALLY DISINTEGRATING;ORAL									
RYBIX ODT									
	@	SHIONOGI INC	50MG	N021693	001	May 05, 2005	Aug	DISC	
<u>TRAMETINIB DIMETHYL SULFOXIDE</u>									
TABLET;ORAL									
MEKINIST									
		GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	May	NEWA	
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	May	NEWA	
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	May	NEWA	
<u>TRANDOLAPRIL</u>									
TABLET;ORAL									
TRANDOLAPRIL									
	@	CIPLA	1MG	A077307	002	Jun 12, 2007	Jul	DISC	
	@		2MG	A077307	001	Jun 12, 2007	Jul	DISC	
	@		4MG	A077307	003	Jun 12, 2007	Jul	DISC	
	@	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008	Apr	DISC	
	@		2MG	A078493	002	Aug 25, 2008	Apr	DISC	
	@		4MG	A078493	003	Aug 25, 2008	Apr	DISC	
<u>TRANEXAMIC ACID</u>									
INJECTABLE;INJECTION									
TRANEXAMIC ACID									
AP		CUSTOPHARM INC	100MG/ML	A201580	001	Jun 14, 2013	Jun	NEWA	
<u>TRAVOPROST</u>									
SOLUTION/DROPS;OPHTHALMIC									
TRAVOPROST									
		PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb	NEWA	
<u>TRAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
TRAZODONE HYDROCHLORIDE									
AB		TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar	CAHN	
AB			100MG	A071524	001	Dec 11, 1987	Mar	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
OLEPTRO									
	@	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	May	DISC	
	@		300MG	N022411	002	Feb 02, 2010	May	DISC	
	+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Jun	CMFD	
			300MG	N022411	002	Feb 02, 2010	Jun	CMFD	
<u>TREPROSTINIL</u>									
INJECTABLE;IV (INFUSION)-SC									
REMODULIN									
		UNITED THERAP	1MG/ML	N021272	001	May 21, 2002	May	CAIN	
			2.5MG/ML	N021272	002	May 21, 2002	May	CAIN	
			5MG/ML	N021272	003	May 21, 2002	May	CAIN	
	+		10MG/ML	N021272	004	May 21, 2002	Jun	CAIN	
SOLUTION;INHALATION									
TYVASO									
	+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	May	CAIN	
<u>TRETINOIN</u>									
CREAM;TOPICAL									
RETIN-A									
AB	+	VALEANT BERMUDA	0.025%	N019049	001	Sep 16, 1988	Jun	CAHN	
AB1	+		0.05%	N017522	001		Jun	CAHN	
AB	+		0.1%	N017340	001		Jun	CAHN	
GEL;TOPICAL									
ATRALIN									
	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr	CAHN	
RETIN-A MICRO									
AB	+	VALEANT INTL	0.04%	N020475	002	May 10, 2002	Jul	CTEC	
AB	+		0.1%	N020475	001	Feb 07, 1997	Jul	CTEC	
TRETINOIN									
AB		SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jul	NEWA	

GEL; TOPICAL							
TRETINOIN							
AB		0.1%	A202026	001	Jul 17, 2013	Jul	NEWA
<u>TRIAMCINOLONE ACETONIDE</u>							
CREAM; TOPICAL							
KENALOG							
	@ APOTHECON	0.025%	N011601	003		Apr	DISC
	@	0.1%	N011601	006		Apr	DISC
TRIACET							
	@ TEVA	0.025%	A084908	001		Apr	DISC
	@	0.5%	A084908	003		Apr	DISC
TRIAMCINOLONE ACETONIDE							
AT	+ FOUGERA PHARMS	0.025%	A085692	001		Apr	CRLD
AT	+	0.1%	A085692	003		Apr	CRLD
	@ G AND W LABS	0.025%	A089797	001	May 31, 1991	May	DISC
	@ TARO	0.025%	A086277	001		Apr	DISC
	@	0.1%	A086276	001		Apr	DISC
	@	0.5%	A086275	001		Apr	DISC
INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL							
TRIVARIS							
	@ ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008	May	DISC
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	VERSAPHARM INC	0.025%	A202374	001	May 08, 2013	Apr	NEWA
AT		0.1%	A202374	002	May 08, 2013	Apr	NEWA
AT	+ WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN
OINTMENT; TOPICAL							
KENALOG							
	@ APOTHECON	0.025%	N011600	003		Apr	DISC
	@	0.1%	N011600	001		Apr	DISC
TRIAMCINOLONE ACETONIDE							
	@ TARO	0.025%	A040040	001	Sep 30, 1994	May	DISC
	@	0.025%	A040374	001	Jun 05, 2001	May	DISC
	@	0.1%	A087902	001	Dec 27, 1982	May	DISC
	@	0.5%	A040386	001	Jun 05, 2001	May	DISC
<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>							
TABLET; ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
	@ WEST WARD	2MG	A040337	002	Feb 16, 2000	Jul	DISC
	@	5MG	A040337	001	Feb 16, 2000	Jul	DISC
<u>TRIMETHOPRIM</u>							
TABLET; ORAL							
TRIMETHOPRIM							
AB	+ TEVA	100MG	N018679	001	Jul 30, 1982	Jul	CRLD
	@	200MG	A071259	001	Jun 18, 1987	Jun	DISC
<u>TROSPIMUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
TROSPIMUM CHLORIDE							
AB	PADDOCK LLC	60MG	A201291	001	May 24, 2013	May	NEWA
<u>URSODIOL</u>							
TABLET; ORAL							
URSODIOL							
AB	PAR PHARM	250MG	A202540	001	Feb 14, 2013	Feb	NEWA
AB		500MG	A202540	002	Feb 14, 2013	Feb	NEWA
	@ TEVA PHARMS USA	250MG	A079184	001	May 13, 2009	Apr	DISC
	@	500MG	A079184	002	May 13, 2009	Apr	DISC
<u>VALACYCLOVIR HYDROCHLORIDE</u>							
TABLET; ORAL							
VALACYCLOVIR HYDROCHLORIDE							
AB	ACTAVIS GRP PTC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Mar	CAHN
AB		EQ 500MG BASE	A090370	001	Mar 16, 2011	Mar	CAHN
<u>VALPROIC ACID</u>							
CAPSULE; ORAL							
VALPROIC ACID							
AB	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	Feb	NEWA

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

@ BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008	Jun DISC
@	250MG	N022152	002	Jul 29, 2008	Jun DISC
@	500MG	N022152	003	Jul 29, 2008	Jun DISC

VANCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

>A> AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Sep CAHN
>A> AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	Sep CAHN
>A> AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Sep CAHN
>A> AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Sep CAHN
>A> AP	EMCURE PHARMS LTD	EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013	Sep NEWA
>D> AP	PFIZER	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Sep CAHN
>D> AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	Sep CAHN
>D> AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Sep CAHN
>D> AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Sep CAHN

VECURONIUM BROMIDEINJECTABLE;INJECTION
VECURONIUM BROMIDE

AP	TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999	Apr CAHN
AP		20MG/VIAL	A074688	002	Aug 25, 1999	Apr CAHN

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	VALEANT BERMUDA	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Jul CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Jul CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Jul CAHN

VERAPAMIL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VERELAN PM

>A> AB	ALKERMES GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Sep CAHN
>A> AB		200MG	N020943	002	Nov 25, 1998	Sep CAHN
>A> AB	+	300MG	N020943	003	Nov 25, 1998	Sep CAHN
>D> AB	ELAN DRUG	100MG	N020943	001	Nov 25, 1998	Sep CAHN
>D> AB		200MG	N020943	002	Nov 25, 1998	Sep CAHN
>D> AB	+	300MG	N020943	003	Nov 25, 1998	Sep CAHN

INJECTABLE;INJECTION
VERAPAMIL HYDROCHLORIDE

@ INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985	Mar DISC
-------------------	----------	---------	-----	--------------	----------

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB	HERITAGE PHARMS INC	80MG	A071880	001	Apr 05, 1988	Aug CMFD
AB		120MG	A071881	001	Apr 05, 1988	Aug CMFD

TABLET, EXTENDED RELEASE;ORAL
VERAPAMIL HYDROCHLORIDE

AB	CARACO	120MG	A090529	001	Dec 30, 2011	May CAHN
AB		180MG	A090529	002	Dec 30, 2011	May CAHN
AB		240MG	A090529	003	Dec 30, 2011	May CAHN

VERTEPORFININJECTABLE;INJECTION
VISUDYNE

+	VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Jan CAHN
---	--------------------	-----------	---------	-----	--------------	----------

VINCRISTINE SULFATEINJECTABLE;INJECTION
VINCRISTINE SULFATE PFS

AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Apr CAHN
----	-----------------	--------	---------	-----	--------------	----------

VINORELBINE TARTRATEINJECTABLE;INJECTION
VINORELBINE TARTRATE

AP	DR REDDYS LABS LTD	EQ 10MG BASE/ML	A202017	001	Sep 12, 2013	Aug NEWA
AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Apr CAHN

VORICONAZOLE

FOR SUSPENSION;ORAL

FOR SUSPENSION;ORAL
VFEND

AB	+	PFIZER	200MG/5ML	N021630	001	Dec 19, 2003	May CFTG
AB		VORICONAZOLE					
AB		MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013	May NEWA

>A> VORTIOXETINE HYDROBROMIDE

>A> TABLET;ORAL

>A> BRINTELLIX

>A>		TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Sep NEWA
>A>			EQ 10MG BASE	N204447	002	Sep 30, 2013	Sep NEWA
>A>			EQ 15MG BASE	N204447	003	Sep 30, 2013	Sep NEWA
>A>	+		EQ 20MG BASE	N204447	004	Sep 30, 2013	Sep NEWA

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

AB		AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013	Feb NEWA
AB			2MG	A202202	002	Mar 04, 2013	Feb NEWA
AB			2.5MG	A202202	003	Mar 04, 2013	Feb NEWA
AB			3MG	A202202	004	Mar 04, 2013	Feb NEWA
AB			4MG	A202202	005	Mar 04, 2013	Feb NEWA
AB			5MG	A202202	006	Mar 04, 2013	Feb NEWA
AB			6MG	A202202	007	Mar 04, 2013	Feb NEWA
AB			7.5MG	A202202	008	Mar 04, 2013	Feb NEWA
AB			10MG	A202202	009	Mar 04, 2013	Feb NEWA
AB		IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013	Jun NEWA
AB			2MG	A200104	002	Jun 27, 2013	Jun NEWA
AB			2.5MG	A200104	003	Jun 27, 2013	Jun NEWA
AB			3MG	A200104	004	Jun 27, 2013	Jun NEWA
AB			4MG	A200104	005	Jun 27, 2013	Jun NEWA
AB			5MG	A200104	006	Jun 27, 2013	Jun NEWA
AB			6MG	A200104	007	Jun 27, 2013	Jun NEWA
AB			7.5MG	A200104	008	Jun 27, 2013	Jun NEWA
AB			10MG	A200104	009	Jun 27, 2013	Jun NEWA

ZALEPLON

CAPSULE;ORAL

SONATA

AB		PFIZER	5MG	N020859	001	Aug 13, 1999	Apr CAHN
AB	+		10MG	N020859	002	Aug 13, 1999	Apr CAHN

ZIDOVUDINE

TABLET;ORAL

RETROVIR

@ VIIIV HLTHCARE

ZIDOVUDINE

AB		HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Feb CMFD
AB		@	300MG	A202058	001	Oct 07, 2011	Jan DISC
AB	+	HETERO LABS LTD III	300MG	A090092	001	Apr 25, 2008	Apr CRLD

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Sep NEWA
>A>	AB		EQ 40MG BASE	A202395	002	Oct 10, 2013	Sep NEWA
>A>	AB		EQ 60MG BASE	A202395	003	Oct 10, 2013	Sep NEWA
>A>	AB		EQ 80MG BASE	A202395	004	Oct 10, 2013	Sep NEWA

ZOLEDRONIC ACID

INJECTABLE;INJECTION

ZOLEDRONIC ACID

AP		DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar NEWA
AP		EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar NEWA

INJECTABLE;IV (INFUSION)

RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CTEC
----	---	----------	-------------------	---------	-----	--------------	----------

ZOLEDRONIC ACID

AP		ACS DOBFAR INFO SA	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Aug NEWA
>A>	AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Sep NEWA
AP		ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Feb NEWA
AP		AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Feb NEWA

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Feb NEWA
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Jul CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar NEWA
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Jul CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	May NEWA
AP	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar NEWA
AP	PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Feb NEWA
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul NEWA
AP	PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Apr NEWA
+	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb NEWA
AP		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb NEWA
	ZOMETA					
AP	+ NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Feb CFTG
AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Aug CTEC

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

>A>	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Sep NEWA
-----	-------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr NEWA
AB		5MG	A202078	002	May 14, 2013	Apr NEWA
AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr NEWA
AB		5MG	A201779	002	May 14, 2013	Apr NEWA
AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr NEWA
AB		5MG	A203186	002	May 14, 2013	Apr NEWA

ZOMIG

AB	IPR	2.5MG	N020768	001	Nov 25, 1997	Apr CFTG
AB	+	5MG	N020768	002	Nov 25, 1997	Apr CFTG

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr NEWA
AB		5MG	A202476	002	May 14, 2013	Apr NEWA
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr NEWA
AB		5MG	A202560	002	May 14, 2013	Apr NEWA
AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013	Apr NEWA
AB		5MG	A202890	002	May 15, 2013	Apr NEWA

ZOMIG-ZMT

AB	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Apr CFTG
AB	+	5MG	N021231	002	Sep 17, 2001	Apr CFTG

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

@	DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007	Apr DISC
@		10MG	A077985	002	Apr 23, 2007	Apr DISC

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Apr CAHN
AB		12.5MG	A078179	001	Jun 06, 2011	Apr CAHN
AB	APOTEX INC	6.25MG	A200266	001	Sep 10, 2013	Aug NEWA
AB		12.5MG	A200266	002	Sep 10, 2013	Aug NEWA
AB	LUPIN LTD	6.25MG	A078970	001	Sep 11, 2013	Aug NEWA
AB		12.5MG	A078970	002	Sep 11, 2013	Aug NEWA
AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar NEWA
AB		12.5MG	A090153	002	Mar 25, 2013	Mar NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@	COREPHARMA	25MG	A077876	001	Feb 21, 2007	Feb DISC
@		50MG	A077876	002	Feb 21, 2007	Feb DISC
@		100MG	A077876	003	Feb 21, 2007	Feb DISC
@	DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Mar DISC
@		50MG	A077645	003	Sep 29, 2006	Mar DISC
@		100MG	A077645	001	Dec 22, 2005	Mar DISC

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
 TYLENOL

+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul CTNA
+		650MG	N019872	002	Jan 11, 2001	Jul CTNA

ASPIRIN

CAPSULE;ORAL
 ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan NEWA
---	------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May CAHN
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Aug NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	CIPLA LTD	5MG	A077318	001	Jul 25, 2013	Jul NEWA
		10MG	A077318	002	Jul 25, 2013	Jul NEWA

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr CRLD
---	--------	------	---------	-----	--------------	----------

CHILDREN'S ZYRTEC ALLERGY

@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr DISC
+		5MG	N021621	003	Nov 16, 2007	Feb CRLD
@		10MG	N021621	004	Nov 16, 2007	Feb DISC

CHILDREN'S ZYRTEC HIVES RELIEF

@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr DISC
+		5MG	N021621	005	Nov 16, 2007	Feb CRLD
@		10MG	N021621	006	Nov 16, 2007	Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL
 DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr CAHN
--	-------------------	-------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB;TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar CTNA
---	------------	-----------------	---------	-----	--------------	----------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

TAGAMET HB

@	MEDTECH PRODS	100MG	N020238	001	Jun 19, 1995	Aug CAHN
+		200MG	N020238	002	Aug 21, 1996	Aug CAHN

CLOTRIMAZOLE

CREAM;VAGINAL
 MYCELEX-7

>A>	BAYER	1%	N018230	002	Dec 26, 1991	Sep CAHN
>D>	BAYER PHARMS	1%	N018230	002	Dec 26, 1991	Sep CAHN

CREAM, TABLET;TOPICAL, VAGINAL
 MYCELEX-7 COMBINATION PACK

>A>	BAYER	1%,100MG	N020389	002	Jun 23, 1994	Sep CAHN
>D>	BAYER PHARMS	1%,100MG	N020389	002	Jun 23, 1994	Sep CAHN

TABLET;VAGINAL
 MYCELEX-7

TABLET;VAGINAL									
MYCELEX-7									
>A>	BAYER	100MG	N018182	002	Dec 26, 1991	Sep	CAHN		
>D>	BAYER PHARMS	100MG	N018182	002	Dec 26, 1991	Sep	CAHN		
<u>DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE									
	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Feb	NEWA		
<u>FAMOTIDINE</u>									
TABLET;ORAL									
PEPCID AC									
	MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Jul	CTNA		
<u>FEXOFENADINE HYDROCHLORIDE</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY									
	DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013	Jan	NEWA		
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES									
	DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013	Jan	NEWA		
<u>KETOTIFEN FUMARATE</u>									
SOLUTION/DROPS;OPHTHALMIC									
KETOTIFEN FUMARATE									
	@ APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Apr	DISC		
<u>LEVONORGESTREL</u>									
TABLET;ORAL									
LEVONORGESTREL									
	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan	NEWA		
	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb	NEWA		
<u>LORATADINE</u>									
SYRUP;ORAL									
LORATADINE									
	@ APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004	Apr	DISC		
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
LORATADINE AND PSEUDOEPHEDRINE SULFATE									
	@ WATSON LABS INC FL	5MG;120MG	A076208	001	Jan 28, 2004	Feb	DISC		
<u>MICONAZOLE NITRATE</u>									
CREAM;VAGINAL									
MICONAZOLE NITRATE									
>D>	APHENA PHARMA MD	2%	A074366	001	Feb 22, 1996	Sep	CAHN		
		2%	A074366	001	Feb 22, 1996	Jan	CAHN		
>A>	G AND W LABS INC	2%	A074366	001	Feb 22, 1996	Sep	CAHN		
<u>MINOXIDIL</u>									
SOLUTION;TOPICAL									
MINOXIDIL (FOR MEN)									
	@ APOTEX INC	2%	A074924	001	Apr 29, 1998	Apr	DISC		
MINOXIDIL (FOR WOMEN)									
	@ APOTEX INC	2%	A074924	002	Apr 29, 1998	Apr	DISC		
MINOXIDIL EXTRA STRENGTH (FOR MEN)									
	@ APOTEX INC	5%	A075839	001	Oct 01, 2001	Apr	DISC		
<u>NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE</u>									
SOLUTION/DROPS;OPHTHALMIC									
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE									
	AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013	Jan	NEWA		
<u>OMEPRazole; SODIUM BICARBONATE</u>									
FOR SUSPENSION;ORAL									
ZEGERID OTC									
+	MSD CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Jun	NEWA		
<u>OXYBUTYNIN</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+	MSD CONSUMER	3.9MG/24HR	N202211	001	Jan 25, 2013	Jan NEWA
---	--------------	------------	---------	-----	--------------	----------

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL;TOPICAL

RID MOUSSE

>A>	+	BAYER	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000	Sep CAHN
-----	---	-------	------------------	---------	-----	--------------	----------

>D>	+	BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000	Sep CAHN
-----	---	----------------	------------------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

	PAR PHARM	17GM/SCOOPFUL	A079214	001	Jan 31, 2013	Jan NEWA
--	-----------	---------------	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	WATSON LABS	EQ 75MG BASE	A075212	001	Jan 14, 2000	Mar DISC
---	-------------	--------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2013

NO SEPTEMBER 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2013 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001					NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8435502	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8445543	Jul 12, 2027	U-1078		NPP	Feb 01, 2016
<u>ADEFOVIR DIPIVOXIL - ADEFOVIR DIPIVOXIL</u>						
A 202051 001					PC	Mar 02, 2014
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001 >A>	5468743	Apr 20, 2016	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 001	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 002	8168616	Jul 03, 2026	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6589508	Apr 03, 2014	U-793			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001 >A>	8518919	Nov 22, 2025	U-1430		M-129 NPP	Aug 30, 2016 Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001 >A>	8518919	Nov 22, 2025	U-1430			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002					NC NCE	Dec 20, 2014 Feb 25, 2016
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	8497256	Jun 23, 2031	U-1229			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	>A> 8344006	Sep 23, 2029	DP U-1402		>A> ODE	Mar 20, 2015
	>A> 8344006*PED	Mar 23, 2030			>A> PED	Sep 20, 2015
	>A> 8445524	Mar 26, 2029	DS			
	>A> 8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	>A> 8344006	Sep 23, 2029	DP U-1402		>A> ODE	Mar 20, 2015
	>A> 8344006*PED	Mar 23, 2030			>A> PED	Sep 20, 2015
	>A> 8445524	Mar 26, 2029	DS			
	>A> 8445524*PED	Sep 26, 2029				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	>A> 8524777	Mar 16, 2025	U-1235			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	>A> 7323463	Jan 19, 2023	DP	Y		
	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 7888310	Jul 25, 2023	U-1433			
	>A> 8137992	Jul 25, 2023	U-1433			
	>A> 8137993	Jul 25, 2023	U-1433			
	>A> 8137994	Jul 25, 2023	U-1433			
	>A> 8431155	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Nov 10, 2024	DP			
	>A> 8528545	Oct 16, 2028	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	>A> 8528545	Oct 16, 2028	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	RE43580	Feb 02, 2021	DP U-227			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A 090704 003					PC	Jun 02, 2013
<u>CAPECITABINE - XELODA</u>						
N 020896 001	5472949	Dec 14, 2013	U-271			
	5472949*PED	Jun 14, 2014				
<u>CAPECITABINE - XELODA</u>						
N 020896 002	5472949	Dec 14, 2013	U-271			
	5472949*PED	Jun 14, 2014				
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N 203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001 >A>	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	>A> 8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					I-665	Jan 23, 2016
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8506987	Jan 09, 2023	U-1204			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	>A> 8546450	Aug 09, 2030	U-1435			
	>A> 8546450	Aug 09, 2030	U-1436			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Dec 13, 2019
					PED	Sep 22, 2016
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	>A> 8524773	Apr 01, 2018	U-1384			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
>A>	8524773	Apr 01, 2018	U-1384			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202542 001					>A> PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202723 001					>A> PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001 >A>	8513299	Apr 14, 2030	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002 >A>	8513299	Apr 14, 2030	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	8481078	Oct 01, 2024	DP U-1416			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	>A> 7754702	Feb 13, 2027	DP U-1432			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	8501158	Mar 08, 2020	U-1422			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	>A> 5980867	Dec 20, 2013	DP		M-128	Aug 28, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					NPP	Jul 26, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8347879	Apr 01, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Nov 11, 2025	DP U-1424			
>A>	8534281	Aug 10, 2029	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUVOXAMINE MALEATE - FLUVOXAMINE MALEATE</u>						
A 091476 002					PC	Sep 09, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7566705	May 21, 2020	DP U-1068			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - GATIFLOXACIN</u>						
A 202653 001					>A> PC	Mar 30, 2014
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	8367605	May 24, 2014	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	>A> RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	>A> RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	>A> RE44459	Mar 26, 2019	U-1431			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
>A>	8546372	Apr 29, 2030	U-1287			
>A>	8551521	Apr 29, 2030	U-1287			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8067437	Jun 02, 2020		U-1168		
	8479730	Oct 11, 2028	DP			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	6123916	Sep 26, 2017		U-1125		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6844013	Dec 13, 2018	DS DP	U-1221		
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	>A> 8536163	Dec 18, 2026		U-1440		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6844013	Dec 13, 2018	DS DP	U-1221		
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	>A> 8536163	Dec 18, 2026		U-1440		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8512297	Sep 15, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	8486456	Oct 03, 2028	DP	U-1054		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8377982	May 28, 2024		U-1363		
	8377982*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8512717	Mar 07, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	>A> 6391874	Jul 11, 2017	DS DP U-800			
	>A> 6391874	Jul 11, 2017	DS DP U-1429			
	>A> 6713485	Sep 29, 2020	DS DP U-800			
	>A> 6713485	Sep 29, 2020	DS DP U-1429			
	>A> 6727256	Jan 08, 2019	DS DP U-800			
	>A> 6727256	Jan 08, 2019	DS DP U-1429			
	>A> 6828320	Jul 11, 2017	U-800			
	>A> 6828320	Jul 11, 2017	U-1429			
	>A> 8513262	Jan 08, 2019	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	>A> 8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	>A> 8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	>A> 8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	>A> 8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	>A> 8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		NS	Jun 05, 2016
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	>A> 8530498	May 15, 2023	U-1216			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 001					PC	Feb 16, 2013

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO* RTO**	Apr 30, 2016 Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	>A> 8540665	Oct 22, 2029	U-1438			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005					D-134	Apr 26, 2015
					I-674	Jun 28, 2016
					NCE	Oct 28, 2015
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029		U-1427		
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026		U-1427		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8496965	Apr 20, 2018	DP			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	5541170	Jul 30, 2013	DP	U-141		
	5541171	Jul 30, 2013	DP	U-141		
	6649180	Apr 13, 2020	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	8475841	Mar 20, 2018		U-604		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	8475841	Mar 20, 2018		U-604		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8420663	Sep 30, 2029	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					PC	Dec 28, 2013
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001 >A>	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625	002				NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428	001	8450311	May 29, 2029	DP		
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050703	001	5569672	Oct 29, 2013	U-1358		
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746	001	5569672	Oct 29, 2013	U-1358		
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791	001	6306900	Feb 27, 2018	DP		
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791	002	6306900	Feb 27, 2018	DP		
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286	001				NP	Jun 27, 2016
<u>NEPAFENAC - ILEVRO</u>						
N 203491	001	5475034	Jun 06, 2014	U-100		
		6403609	Jul 17, 2018	DP		
		7947295	Jun 08, 2024	DP		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152	001	8460704	Mar 12, 2029	U-1409		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	8455524	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	8455524	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	8455524	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	005	8455524	Apr 18, 2027	U-1029		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001	8501164	Jun 14, 2029	DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002	8501164	Jun 14, 2029	DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	001	8389537	Jul 18, 2026	DS DP U-1374		
		8415363	Jul 18, 2026	DS DP U-1407		
		8501760	Jul 18, 2026	DS DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	002	8389537	Jul 18, 2026	DS DP U-1374		
		8415363	Jul 18, 2026	DS DP U-1407		
		8501760	Jul 18, 2026	DS DP		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002	8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003	8431163	Jun 30, 2029	U-1286		
		8431163*PED	Dec 30, 2029			
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	001				NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	002				NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	003				NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	004				NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	005				NPP	Jul 26, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004					NPP	Jul 26, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6489346	Jul 16, 2016	DS DP U-588	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-588	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	6489346	Jul 16, 2016	DS DP U-623	Y		
	6489346	Jul 16, 2016	DS DP U-624	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-623	Y		
	6699885	Jul 16, 2016	U-624	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016	U-1025			
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016	U-1025			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					NPP	Dec 21, 2015
<u>OSPHEMIFENE - OSPHENA</u>						
N 023505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 022211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 020280 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 020280 002	8409616	Nov 26, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087	006				PC	Jul 07, 2013
<u>PACLITAXEL - ABRAXANE</u>						
N 021660	001	>A> 7758891	Feb 21, 2026	U-1434	I-676	Sep 06, 2016
		>A> 7820788	Mar 03, 2024	DP U-1092	ODE	Sep 06, 2020
		>A> 7820788	Mar 03, 2024	DP U-1290		
		>A> 7820788	Mar 03, 2024	DP U-1434		
		>A> 7923536	Dec 09, 2023	U-1117		
		>A> 7923536	Dec 09, 2023	U-1290		
		>A> 7923536	Dec 09, 2023	U-1434		
		>A> 8138229	Dec 09, 2023	DP U-1092		
		>A> 8138229	Dec 09, 2023	DP U-1290		
		>A> 8138229	Dec 09, 2023	DP U-1434		
		>A> 8314156	Dec 09, 2023	U-1290		
		>A> 8314156	Dec 09, 2023	U-1434		
		>A> RE41884	Aug 14, 2016	U-1117		
		>A> RE41884	Aug 14, 2016	U-1290		
		>A> RE41884	Aug 14, 2016	U-1434		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	001	8518981	Jan 30, 2024	DP		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	8518981	Jan 30, 2024	DP		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	005				M-93	Jul 29, 2019
					NCE	Apr 30, 2014
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829	001				>A> PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829	002				>A> PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829	003				>A> PC	Dec 24, 2013
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	5874447	Jun 10, 2017	DS	NP	Jun 28, 2016
		7598271	Feb 12, 2023	DS		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	8440170	Mar 14, 2029	DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	001	5856336	Dec 25, 2020	DS	U-998	
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	002	5856336	Dec 25, 2020	DS	U-998	
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363	003	5856336	Dec 25, 2020	DS	U-998	
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311	001	RE42152	Dec 10, 2018	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	8404703	Mar 02, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	8404703	Mar 02, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N 022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	8470801	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 002					PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 003					PC	Jan 20, 2014
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 002	6677358	Jun 12, 2018	DS DP U-1265	Y		
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 003	6677358	Jun 12, 2018	DP U-1265	Y		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Mar 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8518949	Mar 27, 2026	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005					NPP	Jun 27, 2016
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8431154	Feb 19, 2023	DP			
	>A> 8536206	Mar 08, 2024	U-1115			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8457988	Dec 17, 2022	U-1110			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
>A>	8536130	Sep 22, 2028	U-1276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	>A> 8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	>A> 8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	>A> 8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	>A> 8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	8431615	May 30, 2028	U-1398			
	>A> 8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001					M-124	Jan 28, 2016
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001					M-128	Jul 24, 2016
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Apr 15, 2022	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Apr 15, 2022	U-1285			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8372995	Oct 08, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 02, 2018	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5258510	Nov 02, 2013	DS DP			
>A>	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5258510	Nov 02, 2013	DS DP			
>A>	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5258510	Nov 02, 2013	DS DP			
>A>	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	>A> 7999007	Mar 29, 2029	DP U-1413			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	>A> 7999007	Mar 29, 2029	DP U-1413			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	>A> 7999007	Mar 29, 2029	DP U-1413			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	>A> 7999007	Mar 29, 2029	DP U-1413			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS			
<u>TROSPIMUM CHLORIDE - TROSPIMUM CHLORIDE</u>						
A 091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389			
	8512745	Feb 14, 2030	DP			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6770675	Nov 24, 2018	DP U-1322			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026	U-1418			
<u>VIGABATRIN - SABRIL</u>						
N 020427 001					>A> NCE >A> PED	Aug 21, 2014 Feb 21, 2015
<u>VIGABATRIN - SABRIL</u>						
N 022006 001					>A> NCE >A> ODE >A> PED >A> PED	Aug 21, 2014 Aug 21, 2016 Feb 21, 2017 Feb 21, 2015
<u>VORICONAZOLE - VORICONAZOLE</u>						
A 202361 001					>A> PC	Mar 24, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	>A> 7144884	Jan 09, 2023	DS DP U-1439		>A> NCE	Sep 30, 2018
	>A> 8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	>A> 7144884	Jan 09, 2023	DS DP U-1439		>A> NCE	Sep 30, 2018
	>A> 8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	>A> 7144884	Jan 09, 2023	DS DP U-1439		>A> NCE	Sep 30, 2018
	>A> 8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	>A> 7144884	Jan 09, 2023	DS DP U-1439		>A> NCE	Sep 30, 2018
	>A> 8476279	Oct 02, 2022	DP U-1439			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	8052987	Oct 27, 2023	U-1199			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	>A> 8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	>A> 8512747	Sep 24, 2019	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>